Towards An HTA Ecosystem: From Local Needs To Global Opportunities Thank You to All Our Sponsors
PLATINUM
UNIVERSITÀ CATTOLICA del Sacro Cuore
ALTA SCUOLA DI ECONOMIA E MANAGEMENT DEI SISTEMI SANITARI
GOLD
SILVER Contents Welcome 4 President’s Welcome 5 Minister of Health’s Welcome 6 Greetings From the Rome 2017 Local Organising Committee 8 International Scientific Programme Committee (ISPC) Co-Chairs’ Message 9 Rome 2017 Local Organizing Committee 10 International Scientific Program Committee (ISPC) 11 About HTAi 13 HTAi Board of Directors 2016-2017 15 Interest Groups 16 Policy Forums 18 Partnerships 19 HTAi Secretariat 20 General Information 21 General Information 23 Program 35 Pre-Meeting Workshops 40 Feature Sessions 52 Panels 72 Oral Presentations 93 Vignettes 117 HTAi Interest Group Meetings 150 HTAi and Associated Meetings 152 Sponsor Events and Symposia 155 Posters 163 Posters 165 Sponsors / Exhibitors 205 Platinum Sponsors 207 Gold Sponsors 213 Silver Sponsors 215 Symposia Sponsors 216 Exhibitors 217 Other Contributions 220 Exhibit Floor Plans 221 Notes 224 WELCOME
Welcome
Benvenuti a Roma! Welcome HTA is now evolving towards an to Rome, and to HTAi 2017 — integrated network or “ecosystem” Towards an HTA Ecosystem: where local needs can be addressed. This new ecosystem is shaped by both From Local Needs to Global old and new forms of cooperation, Opportunities and builds on the groundbreaking We are pleased to be hosting our global global collaboration proposed by the members in what promises to be a International Network of Agencies stimulating and very current meeting for Health Technology Assessment that focuses on the production and (INAHTA) in 1993. For example, by implementation of HTA and how best to 2019, the European Network for Health impact health care decision-making at Technology Assessment (EUnetHTA) the global level. We encourage you to is expected to sustain its own HTA enjoy the ambience of Rome and take system that is fully integrated within advantage of everything this historical the European regulatory framework city has to offer, while being an active for drugs and medical devices. In the participant in this annual gathering of the Americas, the Regional Network of global HTA community. Health Technology Assessments for the Americas (RedETSA) is proposing a new THE THEME OF OUR CONFERENCE model for collaboration and, similarly, Asian countries have started a new HTA is considered an effective approach network through HTAsiaLink. Many other to governing health systems, managing examples have been reported worldwide. innovation, and informing decision- making at national and regional levels. We hope the HTAi 2017 Annual Meeting International collaborations, national and will contribute to generating many regional HTA bodies, and hospital-based discussions on this ecosystem approach HTA units or functions all contribute to and propelling it beyond national borders a sustainable health care network — one towards a more inclusive, international that requires coordination to improve model that helps facilitate health care clinical and organisational processes and decision-making at the global level. patient outcomes.
4 PRESIDENT’S WELCOME
President’s Welcome meeting over the past two years, in particular On behalf of the HTAi Board of the International Directors, I would like to extend a Scientific Programme hearty “Buongiorno e benvenuti!” to Committee Chairs the HTAi Annual Meeting 2017. Rabia Kahveci and Americo Cicchetti, all of We are delighted that this year’s the Committee members, as representatives — who hail from more well as the Local Organising Committee. than 59 countries — have joined us in Without their support, and that of others Rome, Italy, a country well-established in the HTA community, HTAi would cease in HTA. to function. The dedication of our many members is a wonderful testament to These next five days provide a unique our community and to the collaborative opportunity in which to contribute to global effort to improve health care. the development of our field. While Rome is enchanting, and we encourage One example of this dedication is the you to enjoy the many facets of the work of our 10 Interest Groups, which are city, we also hope you maximize your holding their own annual meetings here time here and attend the progressive in Rome. I encourage you to attend their plenary sessions and diverse array of meetings, connect with other members, panels and workshops, oral and poster or visit the HTAi booth for more details. presentations, and this year’s new introduction of vignettes. Make sure to Rome is an energetic, vibrant city, and we also seize the opportunity to network hope that HTAi 2017 reflects this vibrancy by seeking out members with similar in lively and energetic discussions. It’s interests or divergent opinions. You your opportunity to make it happen, so never know what might lead to future “Andiamo!” Let’s go! collaborations or have a positive impact on your own work. Professor Guy Maddern, Australia President, HTAi I would like to thank the volunteers who contributed to the planning of this
5 MINISTER OF HEALTH’S WELCOME
the Regional Health Minister of Health’s Authorities under a Welcome unique framework that was developed Message From the Minister of thanks to the joint Health, the Honourable participation of major Beatrice Lorenzin stakeholders. Health care systems worldwide are But this is just the first step. In 2016, the facing major challenges as they try Italian government created, in the Fiscal to guarantee timely patient access to Law for 2016, a national commission valuable technological innovations tasked with reviewing and updating while, at the same time, ensuring the “LEAs” (Livelli Essenziali di Assistenza) sustainability of economic and social — the core health benefits and services systems. These challenges are shaping provided by the Italian National Health the future of health care systems Service — to ensure they are appropriate internationally, and it is becoming more and current. and more evident that the best way to approach them is to rely on HTA. Indeed, this review process will make good use of HTA methods and tools to The Government of Italy and my Ministry, inform decision-making and make HTA in particular, are making substantial affordable, accepted, and sustainable. investments in the implementation of a Our final objective is to define a formal National Programme for HTA (NaPHTA). process for introducing services within LEAs and for making selective Recent legislation established a National disinvestments, if needed, based on the Coordinating Office for HTA (NCOHTA) at founding principles of HTA. the Ministry of Health, which collaborates with the Agenzia per i Servizi Sanitari Hosting HTAi’s 14th Annual Meeting Regionali (AGENAS, the National provides an opportunity to present the Agency for Regional Health Services), new NaPHTA that is currently being the Agenzia Italiana del Farmaco (AIFA, implemented – the first concrete the Italian Medicines Agency), and result in a journey that began with the
6 MINISTER OF HEALTH’S WELCOME
achievements of the NaPHTA Working Group. The NaPHTA is built into the new EU HTA Network, which, I am proud to say, was guided by our Italian team.
Indeed, I am very proud of what has already been achieved. I hope this important meeting will foster international collaboration between Italy and other countries — European and non-European alike — aimed at achieving the challenging objective identified recently in Malta: to make drug innovation sustainable and accessible through pricing negotiation for innovative drugs, and with the active cooperation of the HTA community.
We are committed to maintaining our universal health care system while ensuring a sustainable future, and we strongly believe the right way forward will depend on the development of genuine global collaboration among open-minded stakeholders.
The Honourable Beatrice Lorenzin, Minister of Health, Italy
7 GREETINGS FROM THE ROME 2017 LOCAL ORGANISING COMMITTEE
Greetings From the Rome 2017 Local Organising Committee
Cari amici, dear friends, has made with the help of the scientific community and the support of the On behalf of the Local Organising National Health Service’s national and Committee, it is my great honour and regional institutions and hospitals, pleasure to welcome you to Rome patients’ and citizens’ groups, and for the 14th Annual Meeting of Health industry. Technology Assessment international (HTAi). Thanks to the initiative of the We are convinced that the 2017 HTAi Società Italiana di Health Technology Annual Meeting will be a unique Assessment (SIHTA), the “Eternal City” is opportunity to foster discussion and hosting for the second time since 2005. collaboration among different scientific domains, stakeholders, and institutional Italy, and Rome in particular, have levels. Such collaboration is vital for provided a fruitful environment for creating an effective HTA ecosystem establishing a dynamic HTAi scientific needed to meet the challenge of network, culminating in this annual providing timely and comprehensive meeting thanks to a very broad and health care for all that is both sustainable representative Local Organising and respectful of human dignity. Committee. Since 2005, Italy has pioneered hospital-based HTA, and HTA Enjoy your stay with us in Roma! is now at the forefront of the country’s health policy agenda, as evidenced by Professor Americo Cicchetti, Italy the endorsement of SIHTA by Italian President and Founder, Società Italiana Minister of Health Beatrice Lorenzin. di Health Technology Assessment We are grateful for Minister Lorenzin’s (SIHTA); Secretary, HTAi Board of Directors; recognition of the contributions SIHTA and Chair, Local Organising Committee
8 INTERNATIONAL SCIENTIFIC PROGRAMME COMMITTEE (ISPC) CO-CHAIRS’ MESSAGE
International Scientific Programme Committee (ISPC) Co-Chairs’ Message
Dear friends and colleagues,
As Co-Chairs of the International We will try to define, through discussion, Scientific Programme Committee (ISPC), the role of HTA, how we can engage we extend a warm welcome to all you professionals in the HTA process, stakeholders and users of HTA, and look and how we can acquire and benefit forward to exploring, together, how we from the analysis of big data in both can work toward developing an HTA experimental and real-world settings. ecosystem and to bringing about positive The ethical dilemmas related to these change in health care globally. interactions and the role of multi- stakeholder involvement in facing them Our committee has worked hard to will also be explored. refine plenary themes and topics, and select outstanding speakers. Our We hope the 14th HTAi Annual Meeting intention with HTAi 2017 is to develop will inspire new collaborations and a deeper understanding of the benefits facilitate interaction between you and and challenges of HTA worldwide, and your colleagues from other countries. to foster collaboration within the HTA Please take this opportunity to exchange community. We will also explore, on ideas, share expertise, and develop new a macro level, the integration of HTA relationships and partnerships. decision-making and regulatory systems, and challenge these interactions and And now, let us get to work! the impact they have at the meso and micro levels. Dr. Rabia Kahveci, Ankara, Turkey Professor Americo Cicchetti, Rome, Italy
9 ROME 2017 LOCAL ORGANIZING COMMITTEE
• Dr. Andrea Messori, Tuscany Region Rome 2017 Local and SIHTA Board Member Organizing • Dr. Sandro Franco, SIHTA Committee Board Member • Dr. Francesca Patarnello, Amgen and Chair SIHTA Board Member • Prof. Walter Ricciardi, President of Professor Americo Cicchetti, Italy the National Institute of Health President and founder of the Società • Dr. Francesco Bevere, Director Italiana di Health Technology of AGENAS Assessment (SIHTA) • Dr. Marcella Marletta, Director General of Drugs and Medical Co-Chair Devices, Ministry of Health Dr. Marco Marchetti, Italy • Prof. Mario Melazzini, Director of the Gemelli University Hospital Italian Medicines Agency (AIFA) • Prof. Luca Pani, Manager, EU Network Pharmacovigilance Members Oversight Group • Dr. Pietro Derrico, President of SIHTA • Dr. Renato Botti, Director General of • Dr. Carlo Favaretti, Past-President of Health Planning, Ministry of Health SIHTA • Dr. Marina Cerbo, AGENAS • Dr. Ottavio Davini, Torino Hospital • Prof. Giovanni Apolone, Milan Trust and SIHTA Board Member Cancer Institute • Dr. Giandomenico Nollo, University • Dr. Elisabetta Graps, Head of HTA of Trento and SIHTA Board Member Unit, Puglia Region • Prof. Francesco Mennini, University • Dr. Giovanna Scroccaro, Veneto of Tor Vergata and SIHTA Board Region Health Directorate Member
10 ROME 2017 LOCAL ORGANIZING COMMITTEE
• Dr. Luciana Ballini, Emilia Romagna Region International • Dr. Antonio Gaudioso, Scientific Program Cittadinanzattiva Committee (ISPC) • Prof. Rosanna Tarricone, Bocconi University, Milan Co-Chairs • Dr. Dario Sacchini, Institute of Bioethics, Catholic University of the Professor Americo Cicchetti Sacred Heart Rome, Italy • Dr. Lorenzo Leogrande, Associazione Italiana Ingegneri Clinici (AIIC) President and founder of the Società President Italiana di Health Technology Assessment (SIHTA), Americo Cicchetti is Professor • Prof. Claudio Jommi, Associazione of Healthcare Management and the Italiana di Economia Sanitaria (AIES) Director of the Graduate School of President Health Economics and Management • Prof. Carlo Signorelli, Società Italiana at the Catholic University of the Sacred di Igiene (SITI) President Heart, Faculty of Economics, in Rome. • Prof. Marcello Pani, Società Italiana Professor Cicchetti is Chief of Research, di Farmacia Ospedaliera (SIFO) HTA Unit, at Gemelli University Hospital. President He is also a member of the Scientific Committee of Italy’s National Agency for Regional Health Services (AGENAS) and has been a member of the Pricing and Reimbursement Committee of the Italian Medicines Agency for six years. He is also a member of the Executive Committee of HTAi.
11 INTERNATIONAL SCIENTIFIC PROGRAM COMMITTEE (ISPC)
ISPC Committee Members • Prof. Andrés Pichon-Riviere, Dr. Rabia Kahveci, Associate Professor Argentina Ankara, Turkey • Dr. Wendy Babidge, Australia • Prof. Guy Maddern, Australia Dr. Kahveci is an Associate Professor at the Ankara Numune Training and • Dr. Franz Pichler, Australia Research Hospital and Chair of the • Dr. Clarice Petramale, Brazil hospital’s HTA Unit (ANHTA). She is also • Dagmara Chojecki, Canada the Director of the International Affairs • Dr. Tammy Clifford, Canada Office and the Deputy Clinical Director • Dr. Luigi Lepanto, Canada of the Family Medicine Department for • Dr. Brian O’Rourke, Canada the hospital. • Prof. Yingyao Chen, China • Andrea Rappagliosi, France Prior to joining ANHTA, Rabia worked in • Dr. Neil Bertelsen, Germany the Government of Turkey’s Ministry of • Dr. Alric Rüther, Germany Health and was a member of the Social • Dr. Marco Marchetti, Italy Security Institution’s Reimbursement Commission (pharmaceuticals • Prof. Walter Ricciardi, Italy and medical devices). Rabia is the • Dr. Temirkhan Kulkhan, Kazakhstan founding and past President of the • Dr. Jeonghoon Ahn, Korea Turkish Evidence-Based Medicine • Dr. Sungkyu Lee, Korea Association, where she still leads the HTA • Dr. Irene Lenoir-Wijnkoop, National Forum and HTA Stakeholder Netherlands Roundtables. She is a Director of HTAi • Prof. Gert Jan van der Wilt, and Chair of the HTAi Interest Group, Netherlands HTA in Developing Countries. Since • Dr. Keng Ho Pwee, Singapore 2015, she has been leading the Eurasian • Jani Mueller, South Africa HTA Initiative, which comprises nine • Dr. Alicia Granados, Spain member countries from Southeastern • Dr. Iñaki Gutiérrez-Ibarluzea, Spain Europe and Central Asia. • Dr. Laura Sampietro-Colom, Spain • Dr. Karen Facey, UK
12 ABOUT HTAI
About HTAi We are currently at the mid-point of implementing our 2015–2020 Strategic Health Technology Assessment Plan, with preparations underway to hear international (HTAi) is the global more from you, the members, as we scientific and professional society work towards the goals of the direction for everyone who produces, uses, or for 2020–2025. More information can be encounters HTA to support optimal found online: www.htai.org/htai/strategic- policy- and decision-making. HTAi direction.html has members from approximately 60 countries and provides a neutral To support the implementation of the forum for discussion by welcoming all Strategic Plan, HTAi relies on seven Board stakeholders, including researchers, Advisory Committees, which are chaired agencies, policy-makers, industry, by Board Directors and comprised of academia, health service providers, HTAi members. The focus of these patients, and patient representatives. Committees aligns with our Strategic Objectives, which aim to: Our mission is to support and promote • optimise the relevance, consistency the development, communication, of content, and impact of the Annual understanding and use of HTA around Meetings the world as a scientifically based and • support the continued growth, multi-disciplinary means of informing scope, output dissemination, and decision-making on the use of effective influence of the Policy Forums technologies and the efficient use of resources in health care. • continue to evaluate and add value for our members HTAi is governed by an elected and • support the international hubs of internationally renowned Board of content discussion and resource Directors spanning members from development within the HTAi’s 11 countries. The Board of Directors is Interest Groups responsible for working with the HTAi • strengthen our partnership relations community to devise, implement, to support further member and evaluate the Society’s strategic collaborations direction on behalf of the members.
13 ABOUT HTAI
• identify gaps in resources and tools for HTA producers and users and support the Society’s membership to build capacity • build sustainability within the Society by reviewing our approach to operations and business development to allow direct and staggered reinvestment into activities of value to members.
In addition to the Annual Meeting, Policy Forums, Interest Groups, and partnership and capacity activities, HTAi strives to support initiatives that are of importance to the HTAi community, such as the HTAi Glossary, the HTAi Vortal, and AdhopHTA. An HTAi membership also provides access to the International Journal of Technology Assessment in Health Care (IJTAHC). Launched in 1984, IJTAHC has a rich history and is the official scientific journal of the Society.
HTAi also supports national and regional initiatives for countries embarking on implementing HTA programmes, and works to connect members with common interests.
If you would like more information or to get involved, please contact the HTAi Secretariat at [email protected]
14 HTAI BOARD OF DIRECTORS 2016-2017
HTAi Board of Non-Voting Ex-Officio Directors Members • Professor Carole Longson, United 2016-2017 Kingdom (Past-President) • Laura Sampietro-Colom, Spain Executive Committee (HTAi Policy Forum Chair) • President, Guy Maddern, Australia • Wendy Babidge, Australia (Editor-in- (2015–2017) Chief, International • Vice-President, Sean Tunis, US Journal of Technology Assessment (2015–2017) in Health Care) • Treasurer, Don Juzwishin, Canada • Sophie Söderholm Werkö, Sweden (2015–2018) (INAHTA Board of Directors) • Secretary, Americo Cicchetti, Italy • Allison Hagen, Canada (Director of (2015–2018) Finance and Administration, Institute of Health Economics) Directors • Christa Harstall, Canada (Institute of Health Economics) • Jeonghoon Ahn, South Korea (2014–2017) • Kalipso Chalkidou, UK (2016–2019) • Yingyao Chen, China (2016–2019) • David Grainger, Australia (2015–2018) • Rabia Kahveci, Turkey (2014–2017) • François Meyer, France (2014–2017) • Alric Rüther, Germany (2016–2019)
15 INTEREST GROUPS
Ethical Issues in HTA Interest Groups (Election Underway) HTAi’s Interest Groups serve as hubs Current: for sharing international experiences and expertise among HTA users and • Professor Gert Jan van der Wilt, producers worldwide. Netherlands • Dr. Wija Oortwijn, Netherlands Assessment of Vaccination Programs Candidates: • Professor Mondher Toumi, France • Ken Bond • Christelle Saint Sardos, France • Dario Sacchini • Silvie Jerabkova, Czech Republic Hospital-Based HTA Disinvestment and Early Awareness • Professor Americo Cicchetti, Italy (Election Underway) • Professor Marco Marchetti, Italy Current: HTA in Developing Countries • Dr. Hans-Peter Dauben, Germany • Dr. Brian Godman, United Kingdom/ • Dr. Rabia Kahveci, Turkey Sweden • Professor Paulo Picon, Brazil • Dr. Iñaki Gutiérrez-Ibarluzea, Spain Impact of Public Health Candidates: Interventions Nutrition • Dr. Vigdis Laurvak • Dr. Irene Lenoir-Wijnkoop, Netherlands • Dr. Julie Polisena • Dr. Iñaki Gutiérrez-Ibarluzea, Spain • Rosmin Esmail Information Retrieval Early Career Network (Election Underway) • Denny John, India • Ingrid Harboe, Norway* • Associate Professor Maoling • Dr. Siw Waffenschmidt, Germany Wei, China *Candidate TBD
16 INTEREST GROUPS
Patient and Citizen Involvement and useful materials, conduct meetings, workshops, training sessions, and more. • Neil Bertelsen, UK • Dr. Janet Wale, Australia Interest Groups are hubs of active HTA producers or users, ranging from 50 to Regulatory Interactions and 300 Society members per group and Conditional Coverage comprise approximately 60 per cent of (Election Underway) the Society’s membership. Involvement Current: in Interest Groups is open to all Society members across different nations, fields • Dr. Franz Pichler, Australia of interest, and expertise, allowing the • Professor Urs Brügger, Switzerland HTA community to share information and collaborate on projects of mutual Candidates: interest. • Dr. Massoud Toussi The only stipulation is that you must hold • Dr. Michelle Mujoomdar an up-to-date Society membership. Each • Richard Charter member in good standing can join up to three different Interest Groups of their Over time, HTAi members have choosing. established and strengthened our Interest Groups (IGs) as a way of achieving a For more information, please visit the thriving international society serving as a Society website at www.htai.org or email primary professional and scientific forum [email protected] for all those who undertake and use HTA in health care, business, government, academic institutions and consultancies.
The Interest Groups provide a unique environment for the members of HTAi to network and share information throughout the year. Interest Group members share topic updates, participate in the development of new research
17 POLICY FORUMS
Policy Forums HTAi Policy Forums HTAi hosts three policy forums annually: recent Global Policy Forum will be The HTAi Global Policy Forum, the Latin presented at this HTAi annual meeting. America Policy Forum, and the Asia Reports from all of the Policy Forum Policy Forum. These events are meeting meetings are published in the HTAi’s places for senior leaders from HTA, official journal, The International Journal coverage bodies, and industry to discuss of Technology Assessment in Health key issues with global and regional policy Care. The background papers informing relevance. The meetings are convened the discussions at the meetings are also by expert organising committees available on the HTAi website at www. comprising key HTAi members and htai.org/policy-forum/global-policy- representatives from stakeholders in the forum.html. relevant regions. This year saw the 13th Global Policy Forum held in Barcelona, For more information or if you have Spain in January and the second questions regarding any Policy Forum Latin American Policy Forum held in issues, please contact the Policy Lima, Peru in April. The fifth Asia Policy Forum Manager, Rebecca Trowman, at Forum will be held in Beijing, China this [email protected]. November.
Topics discussed at the meetings of the Forums are diverse and complex, and consider the pressing methodological and conceptual issues for HTA. Past Policy Forum meetings have tackled topics such as Value Frameworks, Changing HTA Paradigms, Improving Evidence Production, HTA and Value, Adaptive Approaches to Licensing, and Disinvestment. Findings from the most
18 PARTNERSHIPS
Partnerships
HTAi is actively committed to international important emerging new, emerging, or collaboration. In addition to official relations obsolete health technologies including status with the World Health Organization, drugs, devices, procedures, programmes, HTAi has signed formal memoranda of and settings in health care. understanding with INAHTA, ISQua, and EuroScan. HTAi also collaborates with about INAHTA 82 organisational members and regularly The International Network works with other like-minded organisations. of Agencies for Health Technology Assessment World Health is a network of 52 publicly Organization funded HTA agencies that support health In January 2015, system decision-making that affects more HTAi became a non- than one billion people in 33 countries governmental organisation around the globe. INAHTA brings HTA in official relations with the agencies together to share knowledge and World Health Organization. tools to strengthen their roles as essential The HTAi leadership is constantly working contributors to health outcomes and health together with WHO on meetings and system sustainability. events and is currently renewing the collaboration agreement for the next ISQua three years. The International Society for Quality in Health Care EuroScan is a global organisation International with origins dating back Network to 1985. Its mission is to inspire and drive The International improvement in the quality and safety of Information Network on New, Emerging health care worldwide through education, and Obsolete Health Technologies is a knowledge sharing, and external evaluation, collaborative network of agencies and supporting health systems and connecting scientific association of individuals and people through a global network that spans institutions that exchange information on 100 countries and five continents.
19 HTAI SECRETARIAT
Daniel Lalonde HTAi Secretariat Incoming Executive Director The HTAi Secretariat is located at [email protected] the Institute of Health Economics in Edmonton, Alberta. The Secretariat Lucy Turner provides professional strategic and Outgoing Managing Director administrative support to the Board [email protected] of Directors and its committees, and oversees all HTAi activities. Marlene Hanke Annual Meetings Health Technology Assessment [email protected] international (HTAi) 1200, 10405 Jasper Avenue Kris Schindel Edmonton, Alberta, Canada T5J 3N4 Registration [email protected] [email protected] HTAi.org Rebecca Trowman Policy Forums [email protected] Laura Varga Events Administration [email protected] Anna Williams Administration/Memberships [email protected] JoAnne Zaborowski Interest Groups [email protected]
20 General Information
GENERAL INFORMATION
General Information Guide to Rome Western Civilization, and many consider it to be the first-ever metropolis. About Rome The Roman poet Tibullus was the first “All roads lead to Rome” is an expression to call Rome the Eternal City (La Città that refers to Rome’s prolific number of Eterna) in the 1st century BC, with Ovid roads that literally do all lead to Rome, and Virgil following his lead. Rome, and which has led the international HTA which is also known as the “Caput community to its doorstep. Mundi” or Capital of the World, was not built in a day and it would take you many Rome is the capital of Italy, its largest city. days to see all of it. But it is worth taking Located on the Tiber River, in the central- whatever time you have here to explore west portion of the Italian Peninsula, it is this most fascinating of cities. From the also the fourth-most populous city in the Pantheon, you are probably 20 or 30 European Union, with almost 4.3 million minutes by foot from most of the places residents living in its environs. that deserve to be seen: the Colosseum, Roman Forum, Piazza Navona, Piazza Vatican City, the seat of the Roman Catholic di Spagna, Campo de’ Fiori, St. Peter’s Church and the home of the Pope, is Basilica, the Trevi Fountain, Castel Sant’ an independent country geographically Angelo, Villa Borghese, and Trastevere. located within Rome’s boundaries. It is the only existing example of a country within Rome is so filled with art and architecture, a city, which is why Rome has often been wonderful sights, cultural exhibits, and so described as a capital of two states. much more that the city will astound and fascinate you. Divertiti! Enjoy! Rome’s history spans almost 2,800 years. During that time, it has been known by Climate many names: the Roman Republic, the Roman Empire, the Papal States, the Rome has a warm, temperate, Kingdom of Italy, and the Italian Republic. subtropical climate, with cool winters It is regarded as one of the birthplaces of and warm-to-hot summers. The city also
23 GENERAL INFORMATION
enjoys the highest number of daylight Electricity hours in Europe. Electricity in Italy conforms to the June is the best time to visit Italy in European standard of 220 V to 230 V, terms of weather. At the beginning of with a frequency of 50 Hz. Wall outlets the month, the weather is much like typically accommodate plugs with it is in May: pleasantly warm but not two or three round pins. Adapters may very hot. However, toward the end be required for appliances from other of the month, temperatures can rise countries. very steeply. In Rome, the temperature averages between 16 and 27 degrees Insurance Celsius (61 to 80 degree Fahrenheit). In It is strongly recommended that those June, wet days in cities like Rome are attending and participating in HTAi uncommon; however, if they occur the 2017 purchase adequate coverage temperature can plunge significantly. for health, travel, and private liability insurance before departing their home Banks and Currency countries. The organisers will not accept In Italy, as in most of Western Europe, responsibility for personal injury, or the official currency is the euro (€). personal property loss or damage, for Foreign currencies are readily exchanged conference attendees/participants or at airports and banks. their guests.
Bank debit or credit cards are the most Restaurants and Gratuities convenient means of getting cash at Tipping in Italy is not mandatory the automated teller machines (ATMs, but welcomed. known in Italy as Bancomat). Major hotels, department stores, and some Taxes restaurants accept major credit cards (Visa, MasterCard, American Express), but In Italy, the consumption tax (known cash (euros) is the preferred method of in other countries as VAT, GST, or sales payment. tax) is 10% in restaurants and hotels, and 22% on all other goods and services.
24 GENERAL INFORMATION
Annual Meeting Details Local HTAi Annual Meeting Management: Meeting Dates and Venue MCO International Group June 17 to 21, 2017 Via Luigi Carlo Farini, 11 50121 Firenze (Florence), Italy The Ergife Palace Hotel Tel.: 39 055 26 39 073 Via Aurelia, 619-00165 Fax: 39 055 24 5849 Rome, Italy Tel.: 39 06 66441 [email protected] Fax: 39 06 6632689 www.mcointernationalgroup.com www.ergifepalacehotel.com Access and Security Check-in time: 11:00 Check-out time: 10:00 Name badges will be provided to all delegates and participants at the Meeting Language Registration/Check-in Desk. The badge is your admission pass to all Annual The official language of the HTAi 2017 Meeting sessions, the exhibit area, and Conference is English. All sessions will be social events. Delegates are required conducted in English. to wear their name badges at all times and will not be granted access to the Meeting Secretariat conference without them. This is to International HTAi Annual Meeting ensure that access to the conference is Management: properly managed.
HTAi Secretariat 10405 Jasper Avenue Edmonton, Alberta, Canada, T5J 3N4 Tel.: 1 780 448 4881 Fax: 1 780 448 0018 [email protected] www.htai.org
25 GENERAL INFORMATION
Registration / Check-In Desk Exhibit Area The Annual Meeting Registration / The exhibit tables are located on Check-in Desk is located at the main Lower Level -1 (Expo Gallery 1) and entrance to the hotel in the reception Lower Level -2 (Expo Gallery 2). (See the area on the ground floor, and will be exhibit floor plans in this programme open during the following times: for details). They will be open at the following times: Saturday, June 17: 07:30 – 18:00 Sunday, June 18: 07:30 – 19:30 Sunday, June 18: 08:30 – 17:00 Monday, June 19: 06:30 – 20:00 Monday, June 19: 11:00 – 19:00 Tuesday, June 20: 07:30 – 20:00 Tuesday, June 20: 10:00 – 19:00 Wednesday, June 21: 7:30 – 11:00 Wednesday, June 21: 08:30 – 10:30
Timetable Poster Viewings All HTAi 2017 Annual Meeting sessions Posters are displayed throughout the will be held at the Ergife Palace Hotel. Annual Meeting venue on digital poster Please consult the Schedule-At-A-Glance columns and are available for viewing at section in the programme (or the app) the following times: for detailed timing for sessions and refreshment breaks. All time references Monday, June 19: 07:00 – 20:00 within the programme are noted in Tuesday, June 20: 07:00 – 20:00 Central European Summer Time (CEST) Wednesday, June 21: 07:00 – 10:30 in 24-hour format.
Meeting App Note: Please refer to the Posters section for scheduled presentations. Download the “HTAi 2017” app for the full Annual Meeting experience! The app is a free download available from the App Store (Apple) and Google Play. More details at http://m.xcdsystem.com/ htai2017
26 GENERAL INFORMATION
Speakers’ Ready-Room / Slides WiFi Centre / Slide Preview Room Complimentary WiFi service, courtesy The Slides Centre is located in the of the HTAi Annual Meeting, is available GERASA room on Lower Level -2, next to throughout the common areas and the LEPTIS MAGNA (plenary room). meeting spaces of the Ergife Palace Hotel. Speakers are asked to load their slides in the Slides Centre at least two hours before Lost Property their presentation (or by no later than 18:00 the previous day if their session starts Please report any lost or unattended at 08:00). It is strongly recommended that items immediately to conference staff. presenters use only the laptops provided in Should you lose anything while at the the conference rooms. Ergife Palace Hotel, please inquire about it at the Annual Meeting Registration/ The Slides Centre opens one hour before Check-in Desk, where any recovered the start of the meeting day and closes lost property will be held. one hour after the end of the meeting day. Please make sure to be on time to Photographer have your presentation uploaded. The schedule is as follows: An official photographer/videographer is present during the Annual Meeting. Saturday, June 17: 06:30 – 17:30 By registering for the HTAi 2017 Annual Sunday, June 18: 07:30 – 17:30 Meeting, you agree to have your picture Monday, June 19: 07:30 – 20:00 taken and your presence recorded. Tuesday, June 20: 07:30 – 20:00 Wednesday, June 21: 07:30 – 13:00 Smoking Policy Conference Rooms At the Ergife Palace Hotel, smoking is After a session ends, please vacate the strictly prohibited. There are designated meeting rooms promptly so that the next smoking rooms on the lobby level sessions and presentations can begin on and smoking sections in some of the time. restaurants.
27 GENERAL INFORMATION
Refreshment Breaks and Lunch Lunch and refreshments will be served in the exhibit areas during the following times:
Saturday, June 17 (Workshop attendees only) 10:00 – 10:30 Morning Break Lower Level -2, Exhibition Area Lower Level -1, Exhibition Area Lower Level -1, Massalia Foyer 12:00 – 13:00 Lunch Restaurant Le Quattro Stagioni, Ground Floor 14:30 – 15:00 Afternoon Break Lower Level -2, Exhibition Area Lower Level -1, Exhibition Area Lower Level -1, Massalia Foyer Sunday, June 18 (Workshop attendees only) 10:00 – 10:30 Morning Break Lower Level -2, Exhibition Area Lower Level -1, Exhibition Area Lower Level -1, Massalia Foyer Ground Floor, Bar and Shops Area 12:00 – 13:00 Lunch Restaurant Le Quattro Stagioni, Ground Floor 14:30 – 15:00 Afternoon Break Lower Level -2, Exhibition Area Lower Level -1, Exhibition Area Lower Level -1, Massalia Foyer Ground Floor, Bar and Shops Area
28 GENERAL INFORMATION
Monday, June 19 11:00 – 11:30 Morning Break Lower Level -2, Exhibition Area Lower Level -1, Exhibition Area Lower Level -1, Massalia Foyer Ground Floor, Bar and Shops Area 13:00 – 14:30 Lunch Restaurant Le Quattro Stagioni, Ground Floor 16:00 – 16:30 Afternoon Break Lower Level -2, Exhibition Area Lower Level -1, Exhibition Area Lower Level -1, Massalia Foyer Ground Floor, Bar and Shops Area Tuesday, June 20 10:00 – 10:30 Morning Break Lower Level -2, Exhibition Area Lower Level -1, Exhibition Area Lower Level -1, Massalia Foyer Ground Floor, Bar and Shops Area 13:00 – 14:30 Lunch Restaurant Le Quattro Stagioni, Ground Floor 16:00 - 16:30 Afternoon Break Lower Level -2, Exhibition Area Lower Level -1, Exhibition Area Lower Level -1, Massalia Foyer Ground Floor, Bar and Shops Area Wednesday, June 21 10:00 – 10:30 Morning Break Lower Level -2, Exhibition Area Lower Level -1, Exhibition Area Lower Level -1, Massalia Foyer Ground Floor, Bar and Shops Area
29 HTAi 2017 App Download the HTAi 2017 App for the Full Annual Meeting Experience
Review the programme, plan your schedule and find out more about HTAi Download the “HTAi 2017” app for the full Annual Meeting experience! The app is a free download available from the App Store (Apple) and Google Play. More details at http://m.xcdsystem.com/htai2017 SIRMIUM
RIEZ
MELILLA
MASUT
LYSTRA
Ground Floor EDESSA
AUZIA
RESTAURANT FOYER STAIRS TO LOWER LEVEL -1 (TO ORANGE 1, ORANGE 2, ALCANTARA, ARLES MERIDA, SPALATO, TREVIRI)
FOYER RESTAURANT FOYER
STAIRS TO LOWER LEVEL -1 (TO MASSALIA 1, MASSALIA 2, RECEPTION MYLASA, NIMES)
MAIN REGISTRATION ENTRANCE DESK FOYER
ELEVATORS BAR FOYER
BAR STAIRS TO LOWER LEVELS -1 AND -2 (TO LEPTIS MAGNA, THUGGA, GERASA) BAR SHOP COFFEE BREAK AREAS
BAR ROOM NIMES ROOM ROOM ORANGE 2 MASSALIA II
ROOM ORANGE 1
ROOM MYLASA
ROOM MASSALIA I ROOM ALCANTARA
Lower Level -1 ROOM TREVIRI
ROOM STAIRS FROM THE POLA GROUND FLOOR COFFEE BREAK AREAS STAIRS FROM THE GROUND
FLOOR ROOM EXHIBITION AREA SPALATO
ROOM MERIDA ROOM 19 20 21 EFESO
ROOM TARRAGONA ELEVATORS 10 11 12 13 14 15 16 17 18
HOSPITALITY ROOM
COFFEE BREAK AREA ROOM CESAREA ROOM ROOM STAIRS FROM HAMA THE GROUND SABRATHA FLOOR AND TO LOWER LEVEL -2 Lower Level -2
COFFEE BREAK POSTERS AREA
ELEVATORS
9 1 8 2 7 3 6 4
5 ROOM GERASA I IV LEPTIS MAGNA
STAIRS FROM II THE GROUND FLOOR AND LOWER LEVEL -1
SPEAKERS’ READY-ROOM
Program
Schedule-At-A-Glance
17th June, 18th June, 19th June, HTAi Business Meetings Saturday Sunday Monday Social Events 7.00-7.30 IG Steering committee IJTAHC Editors Pre-conference Workshops (Invite Only) Meeting 7.30-8.00 (Invite Only) Breaks/Networking 8.00-8.30 Global Poster Sessions Policy Forum: 8.30-9.00 HTAi Pre-conference The Business Pre-conference Opening and Keynote Plenary Sessions Board of Workshops Workshops 9.00-9.30 and Topic Scop- IG Meetings Directors ing Meeting 9.30-10.00 Meeting (Invite Only) Plenary Session 1 Panel Sessions (Invite Only) 10.00-10.30 Break / Networking Break / Networking Oral Sessions 10.30-11.00 Pre-conference Pre-conference Vignette Sessions Workshops Workshops 11.00-11.30 Break / Networking Symposia Sessions Poster Session 1/Exhibits Invite only Sessions 11.30-12.00 Panel Session 1 12.00-12.30 Lunch Break / Lunch Break / Networking Networking 12.30-13.00 Global Policy Forum: 13.00-13.30 Pre-conference Committee Pre-conference Lunch Break /Networking/ IG: IG: SY01: Resistance To SY02: ISPC Workshops Meeting Workshops Poster 2/Exhibits Assessment Impact Antimicrobials A Call Building HTA Processes 2018 (Invite Only) of Vaccination of Public For Multi-Disciplinary For Good HTA Decisions: Meeting Programs Health Action: How can HTA Findings Of A Research (Invite 13.30-14.00 Lunch Break /Networking/ Interven- help? Project And Implications Only) Poster Session 3/Exhibits tions For a Complex Area (AD) 14.00-14.30 Asia Lunch Break /Networking/ (INPHORM) Angelini Spa Policy Forum: Poster 4/Exhibits Eli Lilly and Company Committee 14.30-15.00 Break / Networking Meeting Break / Networking Panel Session 2 15.00-15.30 Pre-conference (Invite Only) Pre-conference Workshops Workshops 15.30-16.00 16.00-16.30 Break / Networking/ Poster Session 5/Exhibits 16.30-17.00 Oral Session 1 Vignette IG: IG: SY03: Using Re- SY04: Enlarging The Session 1 HTA in Patient and al-World Data To Make Value Framework In The 17.00-17.30 Policy Forum IG: Developing Citizen In- Flexible Payment Assessment Coordinating Early Career Countries volvement Models Work For of Immunization Plans 17.30-18.00 Committee Network Everyone: Learnings Meeting Meeting And Challenges MSD (Invite Only) F. Hoffmann-La Roche 18.00-18.30 Oral Session 2 Vignette Poster Session 2 Session 6 18.30-19.00 Poster Session 7 19.00-19.30 Annual General Meeting 19.30-20.00 Welcome Reception 20.00-20.30 20.30-21.30 Sponsor’s Reception Programme Free Evening (Invite Only) 21.30-22.30
20th June, 21st June, Tuesday Wednesday
7.00-7.30 IG: Regulatory Business Interactions & Development Committee 7.30-8.00 Conditional Meeting 8.00-8.30 Coverage (RICC) (Invite Only)
8.30-9.00 Plenary Session 2 Panel Session 5 9.00-9.30 9.30-10.00 10.00-10.30 Break / Networking Break / Networking/ Poster Session 8/Exhibits Poster Session 15/ Exhibits 10.30-11.00 Panel Session 3 Plenary Session 3 11.00-11.30 11.30-12.00 12.00-12.30 Oral Session 3 Closing and Awards 12.30-13.00 13.00-13.30 Lunch Break /Networking/ IG: IG: IG: SY05: Making Drug SY06: Global WHO IJTAHC Poster Session 9/Exhibits Ethical Issues Disinvestment and Early Awareness Information Development Work: Lessons On Business Editorial in HTA Retrieval How R&D can Provide Value Meeting Board 13.30-14.00 Lunch Break / Networking/ The Answers HTA Assessmenet (Invite Meeting Poster Session 10/Exhibits Assessment Bodies Frameworks Only) (Invite 14.00-14.30 Lunch Break / Networking/ Need Only) Poster Session 11/Exhibits PhRMA Mundipharma Inter- national Limited 14.30-15.00 Panel Session 4 15.00-15.30 15.30-16.00 16.00-16.30 Break / Networking/ Poster Session 12/Exhibits HTAi Business Meetings 16.30-17.00 Oral Vignette IG: SY07: Changing The HTA Paradigm: Social Events Session 4 Session 3 Hospital Based Beyond Clinical And Economic 17.00-17.30 HTA Evaluation For Innovative Drugs Pre-conference Workshops
Breaks/Networking 17.30-18.00 Takeda Pharmaceuticals International Poster Sessions 18.00-18.30 Oral Vignette Poster Session 13 Plenary Sessions Session 5 Session 4 18.30-19.00 Poster Session 14 IG Meetings 19.00-19.30 Panel Sessions 19.30-20.00 Oral Sessions 20.00-20.30 Vignette Sessions 20.30-21.30 Conference Dinner Symposia Sessions 21.30-22.30 Invite only Sessions
GENERAL INFORMATION
39 PRE-MEETING WORKSHOPS
Pre-Meeting Workshops Saturday, June 17, 2017
WS.02 Discretely Integrated Condition Event (DICE) Simulation for Integrated HTA
8:30 – 16:30, ORANGE II (-1)
Moderator: Jaime Caro, US
Speaker: Jorgen Moller, UK
WS.03 Towards a Reflective MCDA Ecosystem: From Theory to Implementation
8:30 – 16:30, ORANGE I (-1)
Moderator: Michele Tringali, Italy
Speakers: Rob Baltussen, Netherlands Mireille Goetghebeur, Canada Norman Daniels, US Irina Cleemput, Belgium Janine van Til, Netherlands Matteo Ritrovato, Italy Sitaporn Youngkong, Thailand Hector Castro Jaramillo, Colombia Adriana Velazquez Berumen, Switzerland Marcella Marletta, Italy Walter Ricciardi, Italy Salah Ghabri, France Antonio Sarria-Santamera, Spain
40 PRE-MEETING WORKSHOPS
WS.04 HTA 102: Introduction to Hospital-Based HTA (HB-HTA) for Managers and Health Care Professionals 8:30 – 16:30, MYLASA (-1)
Moderator: Marco Marchetti, Italy
Speakers: Americo Cicchetti, Italy Jani Mueller, South Africa Kristian Kidholm, Denmark Luciane Cruz, Brazil Rossella Di Bidino, Italy Carmen Furno, Italy
WS.05 Selecting Rapid Review Methods for HTA
8:30 – 12:00, MASSALIA II (-1)
Moderator: Eva Kaltenthaler, UK
Speakers: Katy Cooper, UK Marrissa Martyn-St James, UK Ruth Wong, UK
WS.06 Exploring the Usefulness of a Preliminary, Validated Quality-Appraisal Tool for Case Series Studies 8:30 – 12:00, POLA (-1)
Moderators: Bing Guo, Canada Carmen Moga, Canada
41 PRE-MEETING WORKSHOPS
WS.07 Introduction to Ethics in Health Technology Assessment
8:30 – 12:00, SPALATO (-1)
Moderator: Wija Oortwijn, Netherlands
Speakers: Gert Jan van der Wilt, Netherlands Ken Bond, Canada Dario Sacchini, Italy Anna Scott, Australia Bjørn Hofmann, Norway
WS.08 Adaptation of Checklists and the EUnetHTA Core Model 3.0 for Low-Resource Settings 8:30 – 12:00, CESAREA (-1)
Moderator: Jani Mueller, South Africa
Speakers: Davide Croce, Italy David Tivey, Australia
WS.09 The Relevance of Core Outcome Sets to HTA Organisations
8:30 – 12:00, MASSALIA I (-1)
Moderator: Paula Williamson, UK
Speakers: Jamie Kirkham, UK Sara Brookes, UK
42 PRE-MEETING WORKSHOPS
WS.10 Value of Information: Active Learning Through User-Friendly Computations and Application Discussions 13:00 – 16:30, POLA (-1)
Moderators: Jonathan Campbell, US Robert McQueen, US
WS.11 Trial-Based Economic Evaluations of Medical Devices in Multinational Studies: Beyond Transferability 13:00 – 16:30, MASSALIA II (-1)
Moderators: Corianne De Borgie, Netherlands Brent Opmeer, Netherlands
WS.12 A Network to Deal With the Challenges of Frailty: Sharing Evidence From IMI-SPRINT-T Project 13:00 – 16:30, SPALATO (-1)
Moderators: Americo Cicchetti, Italy Silvia Coretti, Italy Speakers: Matteo Ruggeri, Italy Thomas Rapp, France Marianne Klemp, Norway Don Juzwishin, Canada
43 PRE-MEETING WORKSHOPS
WS.13 Comparison of Immunization Group Policies and Impact on Vaccine Adoption 13:00 – 16:30, MASSALIA I (-1)
Moderators: Karen Facey, UK Mondher Toumi, France Speakers: James Harris, New Zealand Chiara de Waure, Italy Dávid Dankó, Hungary Nicolas Van de Velde, Belgium Christelle Saint Sardos, France Silvie Jerabkova, Czech Republic
WS.14 How to Get Your Manuscript Accepted
13:00 – 16:30, CESAREA (-1)
Moderators: Marjukka Mäkelä, Finland Catherine Meads, UK
44 PRE-MEETING WORKSHOPS
Sunday, June 18, 2017
WS.15 Hospital-Based HTA to Support Decision-Making in Low- and Middle-Income Countries 8:30 – 16:30, CESAREA (-1)
Moderators: Fernanda Rodrigues Rodrigues, Brazil Luciane Cruz, Brazil Speakers: Marco Marchetti, Italy Olga Andrea Alcaraz, Argentina Maria Angélica Ferreira, Brazil Carisi Polanczyk, Brazil
WS.16 Text Analysis Tools and Rapid Reviews: Practical Guidance for Advanced Information Retrieval 8:30 – 16:30, MYLASA (-1)
Moderators: Ingrid Harboe, Norway Siw Waffenschmidt, Germany Speakers: Julie Glanville, UK Carol Lefebvre, UK Sarah McGill, Canada Andrew Booth, UK Fiona Campbell, UK
45 PRE-MEETING WORKSHOPS
WS.17 From Evidence Generation to Guideline Development: Building an HTA-Based Decision-Making Ecosystem 8:30 – 16:30, POLA (-1)
Moderator: Joseph Mathew, India
Speakers: Rabia Kahveci, Turkey Paulo Picon, Brazil Andrés Pichon-Riviere, Argentina Sebastian Garcia Marti, Argentina Jani Mueller, South Africa Temirkhan Kulkhan, Kazakhstan Mouna Jameleddine, Tunisia Di Xue, China
46 PRE-MEETING WORKSHOPS
WS.18 Patient Involvement in HTA: Why, When, and How
8:30 – 16:30, MASSALIA I (-1)
Moderator: Karen Facey, UK
Speakers: Marie-Pierre Gagnon, Canada Ann Single, Australia Helle Hansen, Denmark Aline Silva, Brazil Camilla Nielsen, Denmark Maarten Wit, Netherlands David Grainger, Australia Marion Danner, Germany Lisbeth Ørtenblad, Denmark Lars Sandman, Sweden Heidi Livingstone, UK Sophie Staniszewska, UK Sophie Werkö, Sweden David Hailey, Australia Jaye Bea Smalley, US Durhane Wong-Rieger, Canada Alessandra Lo Scalzo, Italy Antje Tockhorn-Heidenreich, UK Neil Bertelsen, Germany Deborah Maskens, Canada Valentina Strammiello, Belgium Michelle Mujoomdar, Netherlands Lizzie Thomas, UK Naomi Fearns, UK Andrew Booth, UK Lindsay Lockhart, UK Neil McGregor-Paterson, UK
47 PRE-MEETING WORKSHOPS
WS.20 Building Consensus on Defining Core Competencies for High-Quality, Effective, and Efficient HTA 8:30 – 12:00, SIRMIUM (Main Floor)
Moderator: Iñaki Gutiérrez-Ibarluzea, Spain
Speakers: Jani Mueller, South Africa Marco Chiumente, Italy Inaki Imaz-Iglesia, Spain Mouna Jameleddine, Tunisia
WS.21 How to Use GRADEPro GDT for Health Technology Assessment
8:30 – 12:00, ARLES (Main Floor)
Moderators: Arindam Bose, New Zealand Ray Kirk, New Zealand
WS.22 HTA 101: Introduction to Health Technology Assessment
8:30 – 12:00, TARRAGONA (-1)
Moderator: Clifford Goodman, US
WS.23 Fostering Early Dialogue in Oncology HTAs via the PACE Continuous Innovation Indicators (CII) 13:00 – 16:30, SIRMIUM (Main Floor)
Moderator: Clifford Goodman, US
Speakers: Silvia Paddock, Germany
48 PRE-MEETING WORKSHOPS
WS.24 An Integrated Approach to the Assessment of Health Technologies
13:00 – 16:30, SPALATO (-1)
Moderator: Ansgar Gerhardus, Germany
Speakers: Wija Oortwijn, Netherlands Gert Jan van der Wilt, Netherlands Ken Bond, Canada Dario Sacchini, Italy Pietro Refolo, Italy
WS.25 HTA Impact: A Hands-On Workshop From INAHTA on the Theory and Practice of HTA Impact Assessment 13:00 - 16:30, TARRAGONA (-1)
Moderator: Sophie Werkö, Sweden
Speakers: David Hailey, Australia Susan Myles, UK Alicia Aleman, Uruguay Jaime Rodriguez, Colombia
49 PRE-MEETING WORKSHOPS
WS.26 International Experiences of Horizon Scanning: An Introduction to Early Awareness and Alert Systems 13:00 – 16:30, ARLES (Main Floor)
Moderator: Roberta Joppi, Italy
Speakers: Brendon Kearney, Australia Dmitry Meshkov, Russia Avila Vidal, Brazil Hanne Pedersen, Denmark Svetlana Palevskaya, Russia Pollyanna Gomes, Brazil Elisabeth Bermudez, France Dawn Craig, UK
50 PRE-MEETING WORKSHOPS
Patient care is what we care
51 FEATURE SESSIONS
Feature Sessions Sunday, June 18 Welcome Reception 19:30 - 21:30, Villa Medici Viale Trinità dei Monti, 1 00187 Rome Join us in welcoming delegates from around the world in the historic ambiance and lavishly landscaped gardens of Villa Medici. Connect and network with our international attendees and leave with memorable impressions of a sumptuous renaissance palace and incredible views over Rome.
52 FEATURE SESSIONS
Monday, June 19
Welcome Ceremony and Prof. Guido Rasi, Executive Director, Keynote Address European Medicines 8:30 – 9:30, LEPTIS MAGNA (-2) Agency, UK
• Welcome address by the President Professor Guido Rasi of HTAi, Prof. Guy Maddern is the Executive Director of the European Medicines • Welcome address by the Chair of Agency. He started his second term the Local Organising Committee, in November 2015, but has held the Prof. Americo Cicchetti position since 2011. • Opening address by Italy’s Minister of Health, The Honourable Professor Rasi was Director General Beatrice Lorenzin of the Italian Medicines Agency from • Keynote presentation by the 2008 to 2011, and a member of its Executive Director of the European Management Board from 2004 to 2008. Medicines Agency, Prof. Guido Rasi: From 2005 to 2008, he was Director of Aligning the Access Path to Patients the National Research Council (NRC) in the EU Institute of Molecular Medicine in Rome. Prior to this, he worked for 15 years for the NRC Institute for Experimental Medicine.
He holds a degree in medicine and surgery from the University of Rome, with specializations in internal medicine, allergology, and clinical immunology. He has authored more than 100 scientific publications.
53 FEATURE SESSIONS
Monday, June 19 Latin America. The discussions will be Plenary Session 1 challenged by representatives of hospital and clinical guideline networks to assess 9:30 – 11:00, LEPTIS MAGNA (-2) the vertical impact of HTA on hospitals and clinicians, as well as to discuss Towards an Integrated HTA whether this impact can be enhanced Framework for a More Sustainable by guidelines and hospital-based HTA at Health Care Ecosystem: Principles meso and micro levels. and the Way Forward CO-CHAIRS The 67th World Health Assembly in Dr. Rabia Kahveci, 2014 promoted systematic utilization Head of the HTA Unit at of independent health intervention and Ankara Numune Training technology assessment in support of and Research Hospital universal health coverage to inform (ANHTA), Turkey policy decisions. to reach this goal, integration between institutional Dr. Alric Ruether, levels and research is needed without Head, International Affairs, constraint in terms of geography Institute for Quality and or decision-making authority, along Efficiency in Health Care with a more dynamic collaborative (IQWiG), Germany environment. This plenary takes us on an HTA journey across regional networks around the world, describing the interactions between macro, meso, and micro decision-making levels. We simplify decision-making interactions and explore whether horizontal and vertical integrations are feasible. We welcome Dr. Wim Goettsch, Director, EUnetHTA JA3 Directorate, followed by a panel of experts representing regional networks in Europe, Asia, and
54 FEATURE SESSIONS
SPEAKER PANELLISTS Dr. Wim Goettsch, Dr. Erik Normann, Director, EUnetHTA JA3 President, International Directorate, National Hospital Federation, Health Care Institute (ZIN), Norway Netherlands Dr. Normann is President of the Wim Goettsch, PhD is the International Hospital Federation (IHF) current Director of the EUnetHTA JA3 and President of the Norwegian Hospital (2016–2020) Directorate. Between 2010 and Health Service Association (NSH). and 2015, he was the Project Leader He is a pediatrician, but has mostly for EUnetHTA Work Package 5 (WP5) held different management positions. Joint Action (JA) 1 and 2 on Relative These include CEO of several hospitals Effectiveness Assessments. Until the in or near Oslo, CEO of Oslo Municipal beginning of 2013, he was the Deputy Child and Family Services, Director of Secretary of the Medicinal Products the Department of Hospital Services Reimbursement Committee at the Dutch within Norway’s Directorate of Health, National Health Care Institute. He has a Secretary General of the Norwegian Air PhD in immunology and an advanced Ambulance Foundation, and CEO of education in pharmaco-epidemiology Curato Røntgen AS, the largest private and pharmaco-economics. He has diagnostic imaging company in Norway. published more than 70 articles in peer- reviewed international journals.
55 FEATURE SESSIONS
Dr. Brian O’Rourke, IMWi) at Philipps University in Marburg, President and CEO, Germany. AWMF-IMWi coordinates and CADTH, Canada supports the development of the clinical practice guidelines of the 174 societies Dr. Brian O’Rourke is organised under the umbrella of the the President and Chief AWMF, and is responsible for the quality Executive Officer of CADTH. He joined assurance of the AWMF guideline CADTH in January of 2009 following register, which currently contains more a distinguished career as a pharmacist than 700 guidelines. She is Vice-Chair of and health service executive with the the AWMF’s Standing Commission for Canadian military. With over 30 years of Clinical Practice Guidelines, represents experience in health care, Dr. O’Rourke AWMF in the National Programme for actively positions CADTH as the leading Disease Management Guidelines and the source of health technology information Programme for Guidelines in Oncology. in Canada. He has a Bachelor of Science She is involved in several quality initiatives in Pharmacy from Dalhousie University on the national level such as Cross- and a Doctor of Pharmacy from the Sectoral Quality in Health Care. She University of Toronto. Brian also serves trained in general surgery from 1995 to as the Board Chair for the International 2000, and has authored or co-authored Network of Agencies for Health more than 150 publications. Technology Assessment. Professor Kopp served as Chair of the Prof. Ina Kopp, Director, Guidelines International Network (G-I-N) Institute for Medical in 2014-2015 and 2015-2016, and has Knowledge Management, been a member of the G-I-N Board of Association of the Trustees since 2012. Scientific Medical Societies (AMWF), Germany
Professor Kopp is Director of the Association of the Scientific Medical Societies’ Institute for Medical Knowledge Management (AWMF-
56 FEATURE SESSIONS
Dr. Nguyen Khanh Phuong, Her computer skills including statistical Head, Health Economics packages such as STATA. Department, Health Strategy and Policy Dr. Nguyen Khanh Phuong is a member Institute, and President, of the Joint Learning Network Provider HTAsiaLink, Vietnam Payment Method and has been invited to lecture on health economics at Dr. Nguyen Khanh Phuong is a health the Hanoi School of Public Health in economist with more than 20 years Hanoi, Vietnam. of experience in the areas of health financing and pharmaceutical and health systems in Vietnam. She is currently the Head of the Department of Health Economics for the Health Strategy and Policy Institute. Her main focus is on providing evidence-based consultation for policy development on health financing, health insurance, and pharmaceutical-related issues.
She has extensive research experience as well as experience with the practical implementation of policies on health financing, health insurance, and pharmaceuticals. Her particular areas of expertise include policy evaluation and monitoring, research proposal design and development, costing of hospital services, and economic and project evaluation. She has served as the principal investigator on many studies in the above-mentioned areas.
57 FEATURE SESSIONS
Tuesday, June 20 data and to interpret results wisely. This plenary focuses on the contribution Plenary Session 2 and of the HTA ecosystem in the implementation of value-based health Presentation of the care systems. Speakers will be engaged H. David Banta Award in defining the role of HTA in this paradigm, the challenges in engaging 8:30 – 10:00, LEPTIS MAGNA (-2) professionals in HTA, and the potential contributions the analysis of big data Embracing a Value-Based could make to the HTA process. Paradigm in Health Care Systems: Engaging Professionals and CO-CHAIRS Mastering Big Data for Prof. Americo Cicchetti, Effective HTA Professor of Management, Faculty of Economics, Health care systems are more and more Catholic University of the engaged in maximizing value from the Sacred Heart, Italy relevant resources invested in health. HTA is key for the implementation of Dr. Wija Oortwijn, a value-based paradigm. But effective Manager Health Unit, HTA needs the enhancement of both Ecorys Nederland B.V., horizontal collaboration (among HTA Netherlands doers at the same institutional level) and vertical cooperation (among doers at micro, meso, and macro levels). HTA production should benefit from both the experimental data and real-world data produced at any level of the ecosystem and at any stage of the technology’s life cycle. The exploitation of this huge asset needs the development of new professional competencies and new technical capabilities to master big
58 FEATURE SESSIONS
SPEAKERS Prof. Christopher Chute, Bloomberg Distinguished Prof. Gualtiero Ricciardi, Professor, Department President, Istituto of Health Policy and Superiore di Sanità, Italy Management, Johns Hopkins Institute for Clinical Gualtiero (Walter) Ricciardi and Translational Research, US is a professor of Hygiene and Public Health at the Catholic University of the Dr. Chute received his undergraduate Sacred Heart (UCSC) in Rome. In August and medical training at Brown University, 2015, He was appointed President of his internal medicine residency at the Italian National Institute of Health Dartmouth, and doctoral training in (Istituto Superiore di Sanità) where he Epidemiology at Harvard. He is board- was Commissioner from July 2014 certified in Internal Medicine and to July 2015. In 2010, he was elected Clinical Informatics, and a Fellow of President of the European Public the American College of Physicians, Health Association (EUPHA). In 2011, the American College of Epidemiology, he was re-elected for a second term, and the American College of Medical and has served as the Past-President Informatics. His career has focused since 2014. He has been a member of on how we can represent clinical the Executive Board of the US National information to support analyses and Board of Medical Examiners and is inferencing, including comparative- currently a member of the WHO/Europe effectiveness analyses, decision European Advisory Committee on Health support, best evidence discovery, and Research, a member of the European translational research. He has had a Commission’s Expert Panel on effective deep interest in semantic consistency, ways of investing in health, Director harmonized information models, and of the WHO Collaborating Centre ontology. His current research focuses for Health Policy, Governance, and on translating basic science information Leadership at UCSC, and editor of the to clinical practice, and how we classify European Journal of Public Health and dysfunctional phenotypes (disease). He Oxford Handbook of Public Health. has been the principal investigator (PI) on a large portfolio of research, has
59 FEATURE SESSIONS
been active on many health information Australian Department of Health and technology standards efforts, and was in charge of the Department’s currently chairs the World Health Health Information Centre for more than Organization (WHO) ICD-11 Revision. 10 years. The Centre housed Western Australia’s major state-wide collections Dr. Merran Smith, of health data, including collections Chief Executive, on hospital morbidity, perinatal and Population Health mental health, and the cancer registry. Research Network, During this period, she was responsible Australia for establishing data linkage as a core Department of Health service. She also Dr. Smith commenced as the inaugural participated in a number of significant Chief Executive of Australia’s Population nationally funded population health Health Research Network (PHRN) in research projects. Dr. Smith has served April 2009. The Network supports as chair or a member of a number of the development and operations of Australia’s top national health information Australia’s population-based national committees. She continues to actively data-linkage infrastructure, which links contribute to national health information the statutory and administrative data policy and strategy, and is committed held by Australian, state, and territory to the ongoing development and use of governments. The main focus for Australia’s rich information resources for the PHRN is health data, but most health system improvement. jurisdictions also include other human- services data in their linkage systems, such as early-childhood and education data. The Network receives funding from the Australian government through the National Collaborative Research Infrastructure Strategy. Government agencies and academic partners also make cash and in-kind contributions to the Network. Prior to joining the PHRN, Dr. Smith was a Director in the Western
60 FEATURE SESSIONS
Dr. Michael Seewald, VP & Worldwide Head, Center of Excellence for Real World Evidence, Novartis Pharma, Switzerland
Michael Seewald is a biochemist by education. During his academic career, he has built deep skills in analytical disciplines (biophysics, bioinformatics, chemoinformatics) while addressing key questions around human biology and disease pathology. He has authored and co-authored articles in leading publications such as Nature and The EMBO Journal. When Michael began his career in the industry, he was leading cross-functional teams in research, heading Bayer Pharma’s bioinformatics efforts, and proposing new targets for pharmaceutical research. Subsequently, he transitioned through roles in finance, strategy, and marketing, building general management skills and deep knowledge of value generation across the life cycle of health care innovations. At Novartis, Michael has been heading the Center of Excellence for Real World Evidence since 2015.
61 FEATURE SESSIONS
H. David Banta A review of nominations was undertaken by a committee, and Distinguished Career Award candidates were reviewed on the basis of their fundamental contributions to Presented by Professor the field of HTA internationally, the Guy Maddern, Society lasting impact of these contributions, President the demonstration of their lifelong commitment to progress in HTA, and History of the Award their involvement in or impact on HTAi or its predecessor society. The H. David Banta Distinguished Career Award was established in 2012 to 2017 Recipient recognize and celebrate individuals, over their careers, who have made a lasting Christopher Henshall, impact on advancing the development Independent and use of HTA internationally as a Consultant, UK means of informing decision-making about the introduction and use of Dr. Henshall received health technologies. numerous nominations for this year’s award. As Founding President Recipients of this award are those of HTAi, founder and long-standing who have demonstrated a significant Chair of the HTAi Global and Asia Policy dedication to and impact on the Forums, and dedicated Society member field of HTA at the international level, and leader, Dr. Henshall has contributed including, but not limited to, outstanding boundlessly to the Society. contributions to the science and methodology of HTA and/or leadership In the course of his career in health in the advancement of the production research and innovation, Dr. Henshall and use of HTA to support evidence- has worked for the Health Promotion informed decision-making in health Research Trust and the UK Medical systems. Candidates should also have Research Council. He has also worked demonstrated significant involvement in for the Department of Health and the or an impact on the HTAi community. National Health Service (NHS) in England (where, as Under Secretary, he was
62 FEATURE SESSIONS
involved in establishing the NHS’s R&D Dr. Henshall now works as an budget, the NHS HTA Programme, and independent consultant, advising the National Institute for Health and governments and public- and private- Clinical Excellence [NICE]). He has also sector organisations on health, research, worked at the Department of Trade and and innovation policy. Industry (where he was responsible for UK science and innovation policy and funding), and the University of York (where, as Pro Vice Chancellor, he was responsible for promoting enterprise and innovation and links with the economy, government, and businesses at home and overseas).
Other recent positions include the Founding President of Health Technology Assessment International (HTAi), Chair of the HTAi Policy Forum from 2005–2007 and 2011–2016, and Chair of the HTAi Asia HTA Policy Forum from 2013-2016. Other recent positions include Board Director of Alberta Innovates (the public funder of research and innovation in the Province of Alberta, Canada), Associate Professor in the Health Economics Research Group at Brunel University London, and Honourary Fellow at the Centre for Health Economics at the University of York (UK).
63 FEATURE SESSIONS
Ministero della Salute Italy The new Italian National HTA Program for Health Technology As- sessment (for medical devices and diagnostics) has been established thanks to the Financial Law of 2015. The program is coordinated by the Ministry of Health with the collaboration of Regional Health Authorities, the National Agency of Drugs (AIFA) and the National Agency of Regional Healthcare Services (Age.Na.S.) and the National Institute of Health (ISS). The heart of the Program is the National Coordinating Office for HTA, directly responsible for setting pri- orities, for issuing national guidance and for monitoring the impact of the whole program. www.salute.gov.it
64 FEATURE SESSIONS
Tuesday, June 20 Conference Dinner 20:30 - 24:00 Villa Miani, Via Trionfale, 151
Experience “la dolce vita” with an evening at the beautiful Villa Miani. Engage in inspiring conversations over an Italian three-course dinner, and join attendees for a breathtaking view from the terrace or share your moves on the dance floor.
65 FEATURE SESSIONS
Wednesday, June 21 the question of how this might be incorporated in the current practice Plenary Session 3 of HTA. 10:30 – 12:00, LEPTIS MAGNA (-2) CO-CHAIRS Facing Ethical Dilemmas for a Eleanor Bradford, Head of Communications, Health System’s Sustainability: University of Aberdeen, UK The Role of Multi-Stakeholder Involvement in HTA Dr. Sean Tunis, Founder and Chief Executive An HTA ecosystem hosts a variety of Officer, Center for mutually dependent agents and agencies Medical Technology that function in ways that give rise to the Policy (CMTP), US emergence of system properties such as equity and sustainability. It is based SPEAKER on mutual recognition and a sufficient degree of agreement on what a properly Prof. Norman Daniels, functioning health care system looks like Mary B. Saltonstall and how it can best be achieved. Clearly, Professor of Population an HTA ecosystem entails different Ethics, and Professor of roles for the various stakeholders and Ethics and Population for how they should collaborate. In Health, Department this session, Norman Daniels, Mary B. of Global Health and Population, Saltonstall Professor of Population Ethics Harvard School of Public Health, US and Professor of Ethics and Population Health in the Department of Global Norman Daniels, PhD, is Mary B. Health and Population at the Harvard Saltonstall Professor and Professor School of Public Health, will argue of Ethics and Population Health in that accountability for reasonableness the Department of Global Health and could be an appropriate framework for Population at the Harvard School stakeholder involvement and deliberation of Public Health. Formerly chair of in HTA. A panel discussion will address the Philosophy Department at Tufts University, his most recent books
66 FEATURE SESSIONS
include Just Health: Meeting Health performed the function of European Union Needs Fairly (Cambridge, 2008); coordinator for Poland’s National Health Setting Limits Fairly: Learning to Share Fund in Łódź. Since 2005, she has been Resources for Health, 2nd edition, the champion leader for the World Alliance (Oxford, 2008); From Chance to for Patient Safety. In 2006, she established Choice: Genetics and Justice (2000); the Patient Safety Foundation, and has and Is Inequality Bad for Our Health? been an expert in public health since 2009. (2000). His research is on justice and Since 2015, she has been the Chair of the health policy, including priority setting Governing Board of the International Alliance in health systems, fairness and health of Patients’ Organizations (IAPO). systems reform, health inequalities, and intergenerational justice. Alexandre Lemgruber, Regional Advisor, Health Technologies, Pan American PANELLISTS Health Organization, Brazil Prof. Antonio Gasbarrini, Director of Internal Medicine, Gemelli Fondazione Policlinico, Italy
Jolanta Bilińska, Chair, International Alliance of Patients’ Organizations, Poland
Jolanta Bilińska has an MA in Clinical Psychology and previously worked to diagnose hospitalised children and teenagers with personal disorders. In the early 1990s, she began working for Dziennik Łódzki, a regional newspaper. She has published almost 2,000 articles on medical issues and politics. Since 2004, she has
67 FEATURE SESSIONS
Wednesday, June 21 INTERNATIONAL JOURNAL OF Closing Ceremony and TECHNOLOGY ASSESSMENT IN Presentation of Awards HEALTH CARE (IJTAHC) AWARDS 12:00 – 13:00, LEPTIS MAGNA (-2) • Egon Jonsson Award • Best Reviewer Presentation of Awards Award presenter: Professor Egon Jonsson, Executive HTAi ANNUAL MEETING Director and CEO, Institute of Health PRESENTATION AWARDS Economics, Canada • Best Oral Presentation • Best Student Oral Presentation BEST REVIEWER AWARD • Best Poster Award presenter: • Best Student Poster Wendy Babidge, Director, Research, Award presenters: Audit & Academic Surgery Division, Royal Australasian College of Surgeons, Editor- Prof. Americo Cicchetti, Professor of in-Chief of the IJTAHC, Australia Management, Faculty of Economics, Catholic University of the Sacred Heart, Italy This year, HTAi awarded a total Dr. Rabia Kahveci, Head of the HTA Unit of 22 Travel Grants to 13 patients at Ankara Numune Training and Research and patient representatives, Hospital (ANHTA), Turkey five residents of lower-income countries, and four students.
We would like to thank our Travel Grant Sponsors for their generous support.
68 FEATURE SESSIONS
JILL SANDERS MEMORIAL the clinical effectiveness and cost- SCHOLARSHIP AWARD effectiveness of the TB screening algorithm in active case finding among Award presenter: HIV/AIDS patients in low-resource Dr. Sean Tunis, Founder & Chief settings: A single centre study. Executive Officer, Center for Medical Technology Policy (CMTP), US He is passionate about evidence-based health care and plans on working to DR. EVIDENCE NYAMADZAWO, improve Africa’s capacity in HTA and JILL SANDERS MEMORIAL growing the HTA profession on the SCHOLARSHIP RECIPIENT continent. Evidence Nyamadzawo is a dentist and Chair of the Health Technology Welcome to the New Assessment Committee at Matsanjeni Health Centre, Swaziland. He has a HTAi President Bachelor of Dental Surgery degree from Dr. Sean Tunis, US (Incoming President) the University of Zimbabwe, and recently Prof. Guy Maddern, Australia (Outgoing completed an MBA in Finance from President) the University of St Mark and St John (UK). He is also an MSc HTA student at the University of Glasgow, and an MA Closing Remarks student in Applied and Professional Ethics at the University of Leeds. Dr. Sean Tunis, US Evidence has nine years of experience Introduction to HTAi at both clinical and policy-making levels in the private and public health sectors Annual Meeting Vancouver, in Zimbabwe and Swaziland. His current June 1 to 5, 2018 research projects include “An economic evaluation of mindfulness-based Dr. Tammy Clifford, Chief Scientist and cognitive therapy (MBCT) compared to Vice-President, Evidence Standards, routine practices for patients diagnosed CADTH, Canada with depression, employing a decision Dr. Brian O’Rourke, President and CEO, analytic model,” and “Evaluating CADTH, Canada
69 FEATURE SESSIONS
Patients. Our mission for life. Together, we can do even more than help patients. Join us on our mission to change lives. IT TAKES IMAGINATION TO MAKE SCIENCE MORE GROUNDBREAKING. That’s the difference between making devices and making progress. Edwards, Edwards Lifesciences and the An uncompromising pursuit of excellence. stylized E logo are trademarks of Edwards An unwavering focus on solutions that will make Lifesciences Corporation or its affiliates. the most difference for patients. Collaborating side-by-side with clinicians to understand their © 2017 Edwards most complex problems. It’s what we do every Lifesciences Corporation. day to advance science for patients, for life. All rights reserved. To learn more about what it takes to advance PP--US-1915 v1.0 science for life, visit www.bostonscientific.com. Edwards Lifesciences Irvine CA 92614 USA © 2017 Boston Scientific Corporation and its affiliates. edwards.com All rights reserved. CORP-421303-AA AUG2016
70 FEATURE SESSIONS
71 PANELS
Panels Monday, June 19, 2017
PN.01 HTA-Regulatory Dialogue: A Pivotal Element for Effective Evidence Generation Plans and Assessment? 11:30 – 13:00, TARRAGONA (-1)
Moderator: Alicia Granados, Spain
Panellists: Guido Rasi, UK Sarah Garner, UK Flora Giorgio, Belgium Andrea Rappagliosi, Belgium Agnès Buzyn, France
PN.02 HTA of Medical Devices: Are We Getting Closer to Solving the Puzzle?
11:30 – 13:00, POLA (-1)
Moderator: Rosanna Tarricone, Italy
Panellists: Claudius Griesinger, Italy Adriana Velazquez Berumen, Switzerland Marcella Marletta, Italy Richard Charter, Switzerland Leandro Pecchia, UK
72 PANELS
PN.03 Impact of Post-Genomic Technologies on Health Care
11:30 – 13:00, ORANGE I (-1)
Moderator: Marco Marchetti, Italy
Panellists: Andrea Urbani, Italy Albert Sickmann, Germany Paola Roncada, Italy Stephen Pennington, Ireland Zoltan Takats, UK Joshua LaBaer, US
PN.04 Methods for Assessing the Value of Telemedicine: What Have We Learned So Far? 11:30 – 13:00, MYLASA (-1)
Moderator: Kristian Kidholm, Denmark
Panellists: Jeremy Wyatt, UK Roberto Dandi, UK Anne Lee, Denmark
PN.06 Will the Patient-Centric Approach of Value-Based Health Care Drive Innovation in HTA? 11:30 – 13:00, MASSALIA I (-1)
Moderator: Liesl Strachan, Australia
Panellists: Tammy Clifford, Canada Paula Williamson, UK Mark Skinner, US
73 PANELS
PN.07 Incorporating Multiple Criteria Into Health Technology Assessment: Opportunities and Challenges 11:30 – 13:00, SIRMIUM (Main Floor)
Moderator: Praveen Thokala, UK
Panellists: Kalipso Chalkidou, UK Nancy Devlin, UK
PN.08 Genomics and Health Technology Assessment: Global Challenges and Responses 11:30 – 13:00, ARLES (Main Floor)
Moderator: Yingyao Chen, China
Panellists: Andrés Pichon-Riviere, Argentina Temirkhan Kulkhan, Kazakhstan Arindam Bose, New Zealand Vivian Coates, US Bruno Dallapiccola, Italy
PN.09 Evolving HTA Practices to Address Health System Changes
11:30 – 13:00, MASSALIA II (-1)
Moderator: Brent Fraser, Canada
Panellists: Meindert Boysen, UK Andrew Wilson Anne D’Andon, France
74 PANELS
PN.10 Patient Involvement in HTA: Experiences From the Front Line of HTA Production 11:30 – 13:00, SPALATO (-1)
Moderator: Irina Cleemput, Belgium
Panellists: Sophie Werkö, Sweden Grace Li Ying Huang, Chinese Taipei Hervé Nabarette, France Ken Bond, Canada Carlos Pinzón
PN.11 RWD and MEA: Tools for Overcoming Methodological and Sustainability Challenges of Adaptive Pathways 11:30 – 13:00, CESAREA (-1)
Moderator: Simona Montilla, Italy
Panellists: Panos Kanavos Americo Cicchetti, Italy Hans-Georg Eichler, UK Mario Melazzini, Italy Carole Longson, UK Ad Schuurman, Netherlands Rui Santos Ivo, Portugal Anne-Sophie Lapointe
75 PANELS
PN.12 Health Technology Assessment and Aging: Responding to Challenges and Opportunities in the Ecosystem 14:30 – 16:00, MERIDA (-1)
Moderator: Don Juzwishin, Canada
Panellists: Heather McNeil, Canada Jeonghoon Ahn, Korea, Republic of Yingyao Chen, China Americo Cicchetti, Italy Naoto Kume, Japan Paul Stolee, Canada
PN.13 What Journal Reviewers Look for: Tips From Editors/Publisher
14:30 – 16:00, POLA (-1)
Moderator: Wendy Babidge, Australia
Panellists: Anna Hofvander, UK Catherine Meads, UK Anna Zawada Gert Jan van der Wilt, Netherlands
PN.14 Open Innovation and Low-Cost Health Technologies: A New Paradigm to Improve Global Health Equity 14:30 – 16:00, SIRMIUM (Main Floor)
Moderator: Marco Marchetti, Italy
Panellists: Andrea Urbani, Italy Bruno Lenzi Giuseppe Vetrugno, Italy Adriana Velazquez Berumen, Switzerland Jani Mueller, South Africa
76 PANELS
PN.15 Design of HTA Systems: How to Address Decision-Makers’ Needs and Recognize Resource Constraints? 14:30 – 16:00, MYLASA (-1)
Moderator: Dávid Dankó, Hungary
Panellists: James Raftery, UK Dixon Thomas, India Ansgar Hebborn, Switzerland Valentina Strammiello, Belgium
PN.16 Allocating Scarce Health Care Resources: How Do Value Frameworks Add Value?
14:30 – 16:00, ORANGE I (-1)
Moderator: Laura Sampietro-Colom, Spain
Panellists: Wija Oortwijn, Netherlands Meindert Boysen, UK Dell Kingsford Smith, US Neil Bertelsen, Germany Armando Genazzani, Italy Fay Habens, UK
PN.17 Rules of Engagement: Motivations for Engaging Patients in HTA Decisions
14:30 – 16:00, MASSALIA II (-1)
Moderator: Alaa Hamed, US
Panellists: Jaime Caro, US Lars Sandman, Sweden Peter Kolominsky-Rabas, Germany Raf Mertens, Belgium
77 PANELS
PN.18 HTA for Public Health Interventions: Addressing the Challenges of Complexity and Uncertainty 14:30 – 16:00, SPALATO (-1)
Moderators: Carlo Favaretti, Italy Irene Lenoir-Wijnkoop, France Panellists: Iñaki Gutiérrez-Ibarluzea, Spain Chiara de Waure, Italy Ansgar Gerhardus, Germany Beth Shaw, UK Claudia Wild, Austria
PN.19 Supporting Global and Local Decision-Making to Achieve UHC
14:30 – 16:00, MASSALIA I (-1)
Moderator: Melanie Bertram, Switzerland
PN.20 Are HTA Agencies and Immunization Groups Duplicating or Complementing Efforts in Vaccines Review? 14:30 – 16:00, ARLES (Main Floor)
Moderator: Mondher Toumi, France
Panellists: Marianne Klemp, Norway Christelle Saint Sardos, France Oliver Damm Ken Eng, Canada
78 PANELS
PN.21 Integrating HTA and Procurement for Cost-Effective and Cost-Saving Technologies 14:30 – 16:00, ORANGE II (-1)
Moderator: Pietro Calamea
Panellists: Tammy Clifford, Canada Mirella Marlow, UK François Meyer, France Sebastian Gaiser, Germany Marina Cerbo, Italy Gian Franco Gensini Americo Cicchetti, Italy Marcella Marletta, Italy
PN.22 Working on Clinical Practice Guidelines (CPGs) and HTAs in Resource- Limited Settings: Experience From Eurasian Countries 14:30 – 16:00, CESAREA (-1)
Moderator: Elizabeta Zisovska, Macedonia
Panellists: Sinisa Stevic Ahmed Novo, Bosnia and Herzegovina Mirela Cela Sanja Simovic, Montenegro Khaled Zghal Nabil Seyidov Temirkhan Kulkhan, Kazakhstan Rabia Kahveci, Turkey Bermet Baryktabasova
79 PANELS
PN.55 Better Decisions for Better Health in India: HTA Towards UHC for One-Sixth of the Global Population 14:30 – 16:00, TARRAGONA (-1)
Moderator: Laura Downey, UK
Panellists: Vijay Gauba Shankar Prinja, India
Tuesday, June 20, 2017 PN.24 HTA of Orphan Drugs: Latest Approaches and Principles for Assessment
10:30 – 12:00, MASSALIA I (-1)
Moderator: Karen Facey, UK
Panellists: Elena Nicod, Italy Owen Mosely Sheela Upadhyaya, UK Alastair Kent
PN.25 E-Health Evidence Generation in HTA and Adjoining Traditions: Current State and Future Perspectives 10:30 – 12:00, ARLES (Main Floor)
Moderator: Anne Ekeland, Norway
Panellists: Persephone Doupi Hannele Hyppönen Kristian Lampe, Finland
80 PANELS
PN.26 Perspectives on the Assessment of Medical Devices, With a Focus on a Life Cycle Approach 10:30 – 12:00, ORANGE I (-1)
Moderator: Tammy Clifford, Canada
Panellists: Leandro Pecchia, UK Danica Marinac-Dabic Art Sedrakyan Petra Schnell-Inderst, Austria Sebastian Gaiser, Germany
PN.27 HTA, Patient Safety and Value-Based Purchasing: Really Different Tracks? Challenging Stakeholders 10:30 – 12:00, TARRAGONA (-1)
Moderator: Arnold van Halteren, Netherlands
Panellists: Rabia Kahveci, Turkey William Padula, US Jolanta Bilińska, Poland Elizabeta Zisovska, Macedonia
PN.28 Zen and the Art of Evidence Synthesis
10:30 – 12:00, MYLASA (-1)
Moderator: Alric Rüther, Germany
Panellists: Guy Maddern, Australia Carole Longson, UK Wim Goettsch, Netherlands Americo Cicchetti, Italy Flora Giorgio, Belgium
81 PANELS
PN.29 Legitimacy of HTA Decisions for Health System Governance: What Accountability for Reasonableness (A4R) Combined With Multi-Criteria Decision Analyses (MCDA) Can Bring 10:30 – 12:00, MASSALIA II (-1)
Moderator: Mireille Goetghebeur, Canada
Panellists: Norman Daniels, US Rob Baltussen, Netherlands
PN.30 Improving Processes Involving HTAs and Regulators for Better Access to Medicines 10:30 – 12:00, CESAREA (-1)
Moderator: Ricardo Baptista Leite Richard Bergström Panellists: Andrea Rappagliosi, Belgium François Meyer, France Hannah Brühl, Germany Michael Berntgen, UK
PN.31 How to Measure Patient Preferences and Engage Patients in Value and Access Processes 10:30 – 12:00, POLA (-1)
Moderator: Isabelle Moulon, UK
Panellists: Durhane Wong-Rieger, Canada Steven Pearson, US Lizzie Thomas, UK Matt Reaney, UK Cat Ahmed, US
82 PANELS
PN.32 Approaches for Priority Setting: Which Is the Best Way?
10:30 – 12:00, MERIDA (-1)
Moderator: Praveen Thokala, UK
Panellists: Sitaporn Youngkong, Thailand Simon Walker, UK Kalipso Chalkidou, UK
PN.33 Acquisition of Topics and Dissemination of Results in Hospital HTA Centres
10:30 – 12:00, SPALATO (-1)
Moderator: Matthew Mitchell, US
Panellists: Luigi Lepanto, Canada Marco Marchetti, Italy Anne Ølholm, Denmark
PN.34 No Innovation Without Evaluation: The IDEAL Approach for Surgical Innovations 10:30 – 12:00, ORANGE II (-1)
Moderators: Janet Martin, Canada Peter McCulloch, UK Panellist: Maroeska Rovers, Netherlands
83 PANELS
PN.35 European Collaboration on Drug Policy: Horizon Scanning for Big Impact Pharmaceuticals 10:30 – 12:00, SIRMIUM (Main Floor)
Moderator: Karla Douw, Denmark
Panellists: Isabelle Nefkens, Netherlands Irina Cleemput, Belgium
PN.36 The State of Alzheimer’s Disease in Europe: Innovation, Value, and Challenges for HTA 14:30 – 16:00, CESAREA (-1)
Moderator: Martin Knapp, UK
Panellists: Ron Handels, Netherlands Jean Georges, Luxembourg Jacoline Bouvy, UK Catherine Reed, UK
PN.37 Evolving Information Retrieval Methods Will Change Our Way of Working: Are We Up to the Challenge? 14:30 – 16:00, SIRMIUM (Main Floor)
Moderator: Siw Waffenschmidt, Germany
Panellists: Carol Lefebvre, UK James Thomas Sarah McGill, Canada Tom Jefferson, Italy
84 PANELS
PN.38 Employing HTA to Achieve Universal Health Coverage and Support Sustainable Development Goals 14:30 – 16:00, SPALATO (-1)
Moderator: Louis Niessen, UK Tarang Sharma, Denmark Panellists: Joice Valentim, Brazil Denny John, India Xiaohua Ying, China Kim MacQuilkan, South Africa
PN.39 Synergistic Scientific Requirements Across Regulatory and HTA Agencies: An Achievable End Point? 14:30 – 16:00, MERIDA (-1)
Moderator: Tina Wang, UK
Panellists: Sean Tunis, US Lars Brüning, Germany Michael Berntgen, UK Michelle Mujoomdar, Netherlands Nick Crabb, UK
PN.40 Why Pharmaceuticals Should be Evaluated at the Hospital Level in an Integrated HTA Framework 14:30 – 16:00, POLA (-1)
Moderator: Marco Marchetti, Italy
Panellists: Rossella Di Bidino, Italy Rabia Kahveci, Turkey Risto Roine Brent Fraser, Canada
85 PANELS
PN.41 HTA Methods for Medical Technologies: Development, Applications, and Future Advancements 14:30 – 16:00, ARLES (Main Floor)
Moderator: Chris Kamel, Canada
Panellists: Rosanna Tarricone, Italy Claudia Wild, Austria Mark Campbell, UK Kristian Kidholm, Denmark
PN.42 Patient Involvement in HTA: Unique Needs of Developing Countries
14:30 – 16:00, MYLASA (-1)
Moderator: Neil Bertelsen, Germany
Panellists: Antonio Ciaglia, UK Yen-Huei (Tony) Tarn Stanimir Hasardzhiev, Bulgaria Aline Silva, Brazil Joice Valentim, Brazil
PN.43 Collaboration on HTA in Europe for Medical Devices: A Reality or a Dream?
14:30 – 16:00, MASSALIA I (-1)
Moderator: Brigitte Casteels, Switzerland
Panellists: Flora Giorgio, Belgium Sophie Cros, Belgium Rod Taylor, UK Alric Rüther, Germany Rosanna Tarricone, Italy
86 PANELS
PN.44 The Value of a Cure: Is HTA Ready for Breakthroughs?
14:30 – 16:00, MASSALIA II (-1)
Moderator: Dima Samaha, UK
Panellists: Charles Petrie, US François Houyez, France Zachary Fitzpatrick, UK Chantal Belorgey, France
PN.45 Challenges of Universal Health Coverage (UHC) in Developing Countries: Focus on Equity 14:30 – 16:00, ORANGE II (-1)
Moderator: Paulo Picon, Brazil
Panellists: Joseph Mathew, India Andrés Pichon-Riviere, Argentina Jani Mueller, South Africa Ida Shwartz Adriana Velazquez Berumen, Switzerland Mouna Jameleddine, Tunisia Temirkhan Kulkhan, Kazakhstan Di Xue, China
87 PANELS
PN.46 Health Economic Guidelines: Hot Topics in Economic Methods From INAHTA Member Agencies 14:30 – 16:00, TARRAGONA (-1)
Moderator: Tara Schuller, Canada
Panellists: Karen Lee, Canada Camille Schubert, Australia Saskia Knies, Netherlands Andreas Gerber-Grote, Switzerland Owen Moseley, UK
PN.47 Health Technologies and Environmental Sustainability: What Role for HTA?
14:30 – 16:00, ORANGE I (-1)
Moderator: Americo Cicchetti, Italy
Panellists: Iñaki Gutiérrez-Ibarluzea, Spain Americo Cicchetti, Italy Lorenzo Leogrande Maurizio Pernice
PN.52 Using HTA to Inform Country-Specific Reimbursement Mechanisms
14:30 – 16:00, LEPTIS MAGNA I (-2)
Moderator: Tessa Tan-Torres Edejer, Switzerland
Panellists: lse Krajenbrink, UK Shankar Prinja, India John Wong, Philippines Yot Teerawattananon
88 PANELS
Wednesday, June 21, 2017
PN.05 Joint HTA Assessment: Is It Worth the Effort? An Outlook to 2020 and Beyond From Various Perspectives 8:30 – 10:00, ORANGE II (-1)
Moderator: Elvira Müller, Germany
Panellists: Alric Rüther, Germany Ansgar Hebborn, Switzerland Gilly Spurrier Karen Facey, UK
PN.48 Rescuing the HTA Database: Future Options and Challenges
8:30 – 10:00, TARRAGONA (-1)
Moderator: Siw Waffenschmidt, Germany
Panellists: Elke Hausner, Germany Tracy Merlin, Australia Brian O’Rourke, Canada Patrice Chalon, Belgium Carlos Pinzón
PN.49 Just the Beginning: A Collaborative Effort Between HTA Activists in Africa
8:30 – 10:00, SIRMIUM (Main Floor)
Moderator: Jani Mueller, South Africa
Panellists: Adham Ismail, Egypt Benoit Mathivet , Tunisia Asma Ben Brahem, Tunisia Samir Ahid Joshua Wamboga
89 PANELS
PN.50 Ethical Values: Just a Matter of Social Preferences?
8:30 – 10:00, CESAREA (-1)
Moderator: Lars Sandman, Sweden
Panellists: Rob Baltussen, Netherlands Mireille Goetghebeur, Canada Bjørn Hofmann, Norway
PN.51 Patient Involvement in HTA: Methods, Experiences, and What Can We Learn From LMIC? 8:30 – 10:00, MASSALIA I (-1)
Moderator: Neil Bertelsen, Germany Antonio Gaudioso Panellists: Adriana Velazquez Berumen, Switzerland Edgardo Iozia, Italy Francesca Moccia Simone Borsci Melody Ni Ernesto Iadanza Leandro Pecchia, UK
PN.53 HTA Rapid Reviews: Methods, Production, and Utilization in Real Settings
8:30 – 10:00, MASSALIA II (-1)
Moderator: Sebastian Garcia Marti, Argentina
Panellists: Rhona Mijumbi-Deve, Uganda Cristian Herrera Chris Kamel, Canada
90 PANELS
PN.54 Value Assessment of Multi-Indication Products: Practical Solutions and Steps to Move Forward 8:30 – 10:00, MYLASA (-1)
Moderator: Adrian Towse, UK
Panellists: Ad Schuurman, Netherlands Carole Longson, UK Simona Montilla, Italy Katja Berg, UK Hannah Brühl, Germany
PN.56 Validation of Health Economic Models: Should We Promote a Pragmatic Approach? 8:30 – 10:00, POLA (-1)
Moderator: Jaime Caro, US
Panellists: Jorgen Moller, UK Salah Ghabri, France Matt Stevenson, UK Peter Kolominsky-Rabas, Germany
PN.57 Hospital-Based HTA: Experiences and Outcomes From 10 Countries Across the Globe 8:30 – 10:00, ORANGE I (-1)
Moderators: Janet Martin, Canada Laura Sampietro-Colom, Spain Panellists: Americo Cicchetti, Italy Marco Marchetti, Italy
91 PANELS
Free Executive Briefs from ECRI Institute at booth 11 level -1: Top 10 Hospital C-suite Watch List See which technology- related issues you should keep an eye on this year. rom li id iopsies to stem cell treatme t or roh s disease to a emotio al ro ot to dia etes acci es http://www.ecri.org.uk/ o r op 10 list co ers iss es that impact patie t sa ety capital expe dit res a d care deli ery.
92 ORAL PRESENTATIONS
Oral Presentations
OS.01 Country-Specific and Regional HTA: Country Focus (A) Monday, June 19, 16:30 - 18:00, MASSALIA II (-1)
OP01 Cross-Border Cooperation on High-Cost Capital Investments in Health Speaker: Ingrid Rosian-Schikuta, Austria
OP02 A Managed Access Approach to Appraising New Cancer Drugs in England Speaker: Linda Landells, UK
OP03 Trends in NICE Cancer Drugs Fund Reconsiderations Speaker: Judith Rubinstein, US
OP04 Lessons Learned When Implementing an HTA Institution in Costa Rica Speaker: Iñaki Gutiérrez-Ibarluzea, Spain
OP05 NIPT for Identification of Trisomy 21, 18, and 13 in Norway Speaker: Lene Juvet, Norway
93 ORAL PRESENTATIONS
OS.02 Developing Methods for HTA (A) Monday, June 19, 16:30 - 18:00, MERIDA (-1)
OP06 Past Speculations of Future Health Technologies: What Did They Predict? Speaker: Lucy Doos, UK
OP07 Towards Better Outcomes: New Standard for Placing a Value on Health Speaker: Paul Krabbe, Netherlands
OP08 NIHR HTA Programme Research Funding and UK Burden of Disease Speaker: James Raftery, UK
OP09 Quantifying Bias of Existing HIV Models Using Empirical Cascade Data Speaker: Angela Chang, US
OP10 Myeloma Patient Value Mapping Speaker: Simon Fifer, Australia
OS.03 Economic Evaluation and Decision-Making (A) Monday, June 19, 16:30 - 18:00, TARRAGONA (-1)
OP11 Structural Uncertainty in Economic Modelling for Smoking Cessation Speaker: Becky Pennington, UK
OP12 ABC and TDABC Methods: A Systematic Review of the Literature Speaker: Ana Etges, Brazil
94 ORAL PRESENTATIONS
OP13 Cost-Effectiveness Analysis of NIPT for Down Syndrome in China Speaker: Yan Xu, China
OP14 Health Utility Scores for Breast Cancer in China: A Multi-centre Survey Speaker: Le Wang, China
OP15 The Incremental Cost of Delirium Following Aortic Valve Replacement Speaker: Brian Potter, Canada
OS.04 Value-Based Health Policy and Management (A) Monday, June 19, 16:30 - 18:00, CESAREA (-1)
OP16 A Patient-Centred Value Framework for Health Care in Hemophilia Speaker: Brian O’Mahony, Ireland
OP17 HTA and Disinvestment in Australia Speaker: Mary Warner, Australia
OP18 Impact of Guidance on Biosimilar Use: A Study Involving All G-CSF Speaker: Antonio Addis, Italy
OP19 Unlocking the Potential of Established Products: Need for Incentives Speaker: Claudio Jommi, Italy
OP20 Innovations in Payment and Medical Care: How Do Poor and Mentally Ill Speaker: John Hsu, US
95 ORAL PRESENTATIONS
OS.05 Stakeholder Involvement (A) Monday, June 19, 16:30 - 18:00, LEPTIS MAGNA IV (-2)
OP21 Involving Clinical Experts in Prioritising Topics for HTA: RCT Speaker: Andrew Cook, UK
OP22 Societal Perspective on Cost Drivers for Health Technology Assessment Speaker: Asif Khowaja, Canada
OP23 MCDA to Elicit Stakeholders’ Preferences in Italy: Obinutuzumab Case Speaker: Martina Garau, UK
OP24 A Framework for Improved Systems of Care in Myocardial Infarction Speaker: Michèle de Guise, Canada
OP25 Evidence Gathering Across Key Stakeholders Involved in Early HTA Speaker: Stefania Manetti, Italy
OP26 Priority Setting: Being Accountable to the Adversely Affected Speaker: Maarten Jansen, Netherlands
96 ORAL PRESENTATIONS
OS.06 Clinical Practice Guidelines, Effectiveness and Safety (A) Monday, June 19, 18:00 - 19:00, SIRMIUM (Ground Floor)
OP27 Patient-Reported Outcome Measures in Carotid Artery Revascularisation Speaker: Munira Essat, UK
OP28 Health Apps: A Proposed Framework to Guide Clinical Risk Assessment Speaker: Michelle Helena van Velthoven, UK
OP29 Efficacy and Safety of RFA Combined With TACE for Primary Liver Cancer Speaker: Kun Xiong, China
OS.07 Country-Specific and Regional HTA: Regional Focus (A) Monday, June 19, 18:00 - 19:00, MYLASA (-1)
OP30 HTA and the Decision-Making Process for New Drug Listings in Hong Kong Speaker: Carlos Wong, China
OP31 Mapping of HTA in China: Preliminary Analysis and Comparison Speaker: Xunyouzhi Chi, China
OP32 The Political Economy of HTA Institutionalization: Historical Lessons Speaker: Nicole Salisbury, US
97 ORAL PRESENTATIONS
OS.08 Stakeholder Involvement: Public Focus (A) Monday, June 19, 18:00 - 19:00, TARRAGONA (1)
OP33 Developing a Public Version of an HTA Report Speaker: Naomi Fearns, UK
OP34 UK Stakeholders’ Preferences for Novel M-Health STI Testing and Treatment Speaker: Ala Szczepura, UK
OP35 Involving Members of the Public in a National Screening Programme HTA Speaker: Emma Cockcroft, UK
OS.09 Stakeholder Involvement: Patient Focus (A) Monday, June 19, 18:00 - 19:00, LEPTIS MAGNA II (-2)
OP36 The Mosaic of Patient Participation in HTA Speaker: Karen Facey, UK
OP37 Can Local Ultra-Orphan Patient Evidence Shape Global Understanding? Speaker: Heidi Livingstone, UK
OP38 Improving The Patient Centricity Of Value Assessments: A Rubric Speaker: Elisabeth Oehrlein, US
98 ORAL PRESENTATIONS
OS.10 Big Data for Better HTA (A) Tuesday, June 20, 12:00 - 13:00, POLA (-1)
OP39 Reporting Clinical Outcomes in TAVI Registries Speaker: Shixuan Zhang, Germany
OP40 First Case of Disinvestment Using Real-World Evidence in Brazil Speaker: Augusto Guerra, Brazil
OP41 Real-World Evidence Navigator to Support Evaluation of Relative Effect Speaker: Heather Stegenga, UK
OP42 Cost-Benefit of Computed Tomography in Secondary Hospitals in China Speaker: Hui Sun, China
OS.11 Clinical Practice Guidelines, Effectiveness and Safety (B) Tuesday, June 20, 12:00 - 13:00, ARLES (Ground Floor)
OP43 Unconventional HTA Use: Diagnosis of Likely Emerging Tropical Diseases Speaker: Jean-Charles Lafarge, France
OP44 Cost-Effectiveness of HCV Screening in Swiss Prisons Using Rapid Tests Speaker: François Girardin, Switzerland
OP45 Study on Effects of CAP Clinical Pathway on Antibiotics’ Utilization Speaker: Liping Zhu, China 99 ORAL PRESENTATIONS
OS.12 Country-Specific and Regional HTA: Country Focus (B) Tuesday, June 20, 12:00 - 13:00, MASSALIA I (-1)
OP46 Addressing NHS Priorities: Medtech Innovation Briefings Speaker: Naomi Herz, UK
OP47 National Drug Policy in Ukraine: Use of HTA in Decision-Making Speaker: Oresta Piniazhko, Ukraine
OP48 Allocation Equity as a Result of CON in China: An Impact Analysis Speaker: Luyang He, China
OS.13 Country-Specific and Regional HTA: Regional Focus (B) Tuesday, June 20, 12:00 - 13:00, MASSALIA II (-1)
OP49 Restrictive Versus Non-Restrictive Drug Reimbursement Systems Speaker: Laia Maynou, UK
OP50 European Assessments of Medical Devices: Avenues for Improvement Speaker: Katharina Hawlik, Austria
OP51 Thrombectomy in France: A National Use of EUnetHTA Joint Assessment Speaker: Huguette Lhuillier-Nkandjeu, France
100 ORAL PRESENTATIONS
OS.14 Country-Specific and Regional HTA: Regional Focus (C) Tuesday, June 20, 12:00 - 13:00, MYLASA (-1)
OP52 The HTA Cooperation Model in the Andalusian Public Health System Speaker: Teresa Molina-Lopez, Spain
OP53 Tuberculosis Treatment Adherence in Homeless: An Overview of Reviews Speaker: Flavia Elias, Brazil
OP54 HTA and Chronic Hepatitis C: Coverage Decisions in Eight Countries Speaker: Erica Visintin, UK
OS.15 Developing Methods for HTA (B) Tuesday, June 20, 12:00 - 13:00, MERIDA (-1)
OP55 HTA in Children and Adolescents: Adolescent Preferences for Child Health Utility 9D Health States Speaker: Julie Ratcliffe, Australia
OP56 Advancing Research in Hernia Repair: A Value of Information Analysis Speaker: Elisabet Jacobsen, UK
OP57 “Beyond the Mean” in Biomarker Modelling for Economic Evaluations Speaker: Georgios Nikolaidis, UK
OP58 Testing of an MCDA Value Framework With Decision-Makers Across Europe Speaker: Aris Angelis, UK
101 ORAL PRESENTATIONS
OS.16 Economic Evaluation: Devices, Drugs, Treatments (A) Tuesday, June 20, 12:00 - 13:00, ORANGE I (-1)
OP59 Decision Uncertainty and Incentives for Conducting Further Research Speaker: Oriana Ciani, Italy
OP60 Ramucirumab in Gastric Cancer Treatment: An Economic Evaluation Speaker: Marianna Mauro, Italy
OP61 Cost-Utility Analyses of Biologics for Refractory Ulcerative Colitis Speaker: Sophia Campbell Davies, Italy
OS.17 Economic Evaluation: Devices, Drugs, Treatments (B) Tuesday, June 20, 12:00 - 13:00, ORANGE II (-1)
OP62 Cost-Effectiveness of Mechanical Thrombectomy for Endovascular Therapy Speaker: Patricia Harrington, Ireland
OP63 Lights and Shadows of HTA Disinvestment in a Hospital Context Speaker: Carmen Furno, Italy
OP64 Economic Impact of Cardiac Device Remote Monitoring in South Korea Speaker: Jeonghoon Ahn, Korea, Republic of
102 ORAL PRESENTATIONS
OS.18 Economic Evaluation: Diagnostics Tuesday, June 20, 12:00 - 13:00, LEPTIS MAGNA IV (-2)
OP65 Lung Cancer Screening: Microsimulation Analysis Based on NLST and NELSON Speaker: Marina Treskova, Germany
OP66 Optical Coherence Tomography for Neovascular AMD: Economic Evaluation Speaker: Rodolfo Hernández, UK
OP67 Cost-Effectiveness of HPV-Based Primary Cervical Screening in Ireland Speaker: Michelle O’Neill, Ireland
OS.19 Hospital-Based HTA Tuesday, June 20, 12:00 - 13:00, SIRMIUM (Ground Floor)
OP68 An Evidence-Based Clinical Pathways Programme Reduces Low-Value Care Speaker: Matthew Mitchell, US
OP69 Hospital-Based HTA Is Applicable to the Investment Decision-Making Process Speaker: Tuija Ikonen, Finland
OP70 Economic Impact of Macular Edema Diseases, a Retrospective Study Speaker: Francesco Mennini, Italy
103 ORAL PRESENTATIONS
OS.20 Information Search and Knowledge Transfer (A) Tuesday, June 20, 12:00 - 13:00, TARRAGONA (-1)
OP71 Evidence-Based Searching for HTA: Keeping Up-to-Date With SuRe Info Speaker: Julie Glanville, UK
OP72 Adherence of Budget Impact Analyses to Principles of Good Practice Speaker: Giampiero Favato, UK
OP73 Using Visualisation in Scoping the Literature for a Prognostic HTA Speaker: Mark Clowes, UK
OS.21 Other Oral Presentations Tuesday, June 20, 12:00 - 13:00, CESAREA (-1)
OP74 Health care Inequity in Asia Despite High Universal Health Coverage Speaker: Jennifer Evans, UK
OP75 Implementing Risk Stratification in Primary Care: A Qualitative Study Speaker: Alison Porter, UK
OP76 Economic Contributions of Older Adults in Europe Speaker: Alexander Khoury, US
104 ORAL PRESENTATIONS
OS.22 Stakeholder Involvement: Patient Focus (A) Tuesday, June 20, 12:00 - 13:00, LEPTIS MAGNA I (-2)
OP77 Identifying Topics for HTA: The German “ThemenCheck Medizin” Speaker: Ulrich Siering, Germany
OP78 Patient Involvement in European HTA: Focus Group With Cardiac Patients Speaker: Michal Stanak, Austria
OP79 Experimenting With HTAi Patient Group Submission Template to Involve Patients Speaker: Alessandra Lo Scalzo, Italy
OS.23 Stakeholder Involvement: Public Focus (B) Tuesday, June 20, 12:00 - 13:00, LEPTIS MAGNA II (-2)
OP80 Public Involvement in HTA: Which Publics for Which Technologies? Speaker: Julia Abelson, Canada
OP81 Public Involvement in Modelling for Vaccination Evaluation Speaker: Sophie Staniszewska, UK
OP82 A National Citizens’ Perspective on Criteria for Resource Allocation Speaker: Véronique Déry, Canada
105 ORAL PRESENTATIONS
OS.24 Value-Based Health Policy and Management (B) Tuesday, June 20, 12:00 - 13:00, SPALATO (-1)
OP83 Value Assessment Framework: Evidence-Informed Deliberative Processes Speaker: Marcia Tummers, Netherlands
OP84 HTA Impact: Stories From the Front Lines of HTA Production and Use Speaker: Tara Schuller, Canada
OP85 Value to Society of a Nationwide Patient Blood–Management Program Speaker: Jorge Félix, Portugal
OS.25 Value-Based Health Policy and Management (C) Tuesday, June 20, 12:00 - 13:00, SABRATHA (-1)
OP86 Identifying Surgical Procedures of Low- or No-Added Value in Spain Speaker: Iñaki Gutiérrez-Ibarluzea, Spain
OP87 Value Assessment Criteria for Orphan Drugs in Eight European Countries Speaker: Victoria Tzouma, UK
OP88 Value-Based Approach for Medical Device Procurement Speaker: Andrea Messori, Italy
106 ORAL PRESENTATIONS
OS.26 Country-Specific and Regional HTA: Country Focus (C) Tuesday, June 20, 16:30 - 18:00, SABRATHA (-1)
OP89 Using Economic Evidence to Set Priorities in Ghana: The Case of Malaria Speaker: Rebecca Addo, Australia
OP90 Comprehensive Application of Health Technology Reassessment (HTR) Speaker: Ji Jeong Park, Korea, Republic of
OP91 Health Technology Assessment on the Da Vinci Surgical System Using Real-World Data in China Speaker: Yingpeng Qiu, China
OP92 Addressing Challenges of Implementing an HTA Framework in South Africa Speaker: Jani Mueller, South Africa
OP93 Conditional Financing in HTA Practice: The Dutch Experience Speaker: Amr Makady, Netherlands
OP94 Is NICE in the UK More Innovation-Friendly Than IQWiG/GBA in Germany? Speaker: Michael Schlander, Germany
107 ORAL PRESENTATIONS
OS.27 Economic Evaluation and Decision-Making (B) Tuesday, June 20, 16:30 - 18:00, MYLASA (-1)
OP95 An Update on the Economic Value of a Statistical Life-Year in Europe Speaker: Michael Schlander, Germany
OP96 A Framework to Develop the Structure of Public Health Economic Models Speaker: Hazel Squires, UK
OP97 Programme Budgeting Marginal Analysis for the Real World Speaker: Philippa Aanderson, UK
OP98 The Impact of Non-Divisibility and Diminishing Returns on the Threshold Speaker: Mike Paulden, Canada
OP99 Micro-Costing Study of Breast Cancer Intervention in China Speaker: Ju-Fang Shi, China
108 ORAL PRESENTATIONS
OS.28 Ethical, Social and Legal Issues in HTA Tuesday, June 20, 16:30 - 18:00, CESAREA (-1)
OP100 How HTA Is Adapting to Orphan Drugs in Canada — Not! Speaker: Durhane Wong-Rieger, Canada
OP101 Do We Need to Extend HTA to HEA (Health Enhancement Assessment)? Speaker: Bjørn Hofmann, Norway
OP102 High Media Coverage of HTA Reports: Lessons Learned Speaker: Anna Björklöf, Sweden
OP103 CONITEC’s Rapid Reports as Technical Support in Litigation Speaker: Carla Biella, Brazil
OP104 HTA’s Ethical Evaluation: Understanding the Diversity of Approaches Speaker: Georges-Auguste Legault, Canada
109 ORAL PRESENTATIONS
OS.29 Information Search and Knowledge Transfer (B) Tuesday, June 20, 16:30 - 18:00, MERIDA (-1)
OP105 Systematically Reconstructing Trial Context-Role for CLUSTER Searches? Speaker: Andrew Booth, UK
OP106 The Impact of Searching Fewer Databases in HTA Rapid Reviews Speaker: Ruth Wong, UK
OP107 Sources Used to Find Studies for SRs of Economic Evaluations Speaker: Julie Glanville, UK
OP108 Health Intervention Assessment Report Adaptation: The Tunisian Experience Speaker: Wafa Allouche, Tunisia
OP109 Making Best Use of Other’s HTAs by Both Adopting and Adapting Speaker: Katrine Frønsdal, Norway
OS.30 Stakeholder Involvement: Patient Focus (B) Tuesday, June 20, 16:30 - 18:00, LEPTIS MAGNA I (-2)
OP110 Survey of HTA Evaluation Strategies for Patent and Public Involvement Speaker: Anke-Peggy Holtorf, Switzerland
OP111 Patient Input: A Definition for Optimizing Use Speaker: Ann Single, Australia
110 ORAL PRESENTATIONS
OP112 Extending Consumer Engagement Opportunities in PBAC Processes Speaker: Jo Watson, Australia
OP113 Two Years of Consumer Hearings in Australian HTA Speaker: Sally Wortley, Australia
OP114 Shared Decision-Making and Adoption of Non-Invasive Prenatal Testing Speaker: Jian Ming, China
OS.31 Economic Evaluation: Devices, Drugs, Treatments (C) Tuesday, June 20, 16:30 - 18:00, MASSALIA I (-1)
OP115 Effect of MDR on Costs for Patients With Intra-Abdominal Infections in China Speaker: Xuemei Zhen, China
OP116 Cost-Effectiveness of Sacubitril/Valsartan in Heart Failure Speaker: Liang Lin, Singapore
OP117 Cost-Effectiveness Analysis of Policies Based on the DAA-IFN Regimens Speaker: Matteo Ruggeri, Italy
OP118 CEA of Molecular Profile Selection for Advanced Head and Neck Cancer Speaker: Carla Rognoni, Italy
OP119 Advanced Therapy Medicinal Products: Are Current HTA Methods Suitable? Speaker: Grace Hampson, UK
111 ORAL PRESENTATIONS
OP120 Recommendations From the Newly Developed HAS Guide on Budget Impact Speaker: Salah Ghabri, France
OS.32 Big Data for Better HTA (B) Tuesday, June 20, 18:00 - 19:00, POLA (-1)
OP121 Social Media to Collect Patient Perspectives on HRQoL in Melanoma Speaker: Rachel Kalf, Netherlands
OP122 The Financial Incentive to Market Secondary Patent of Ritonavir Speaker: Nathalie Vernaz, Switzerland
OP123 HTA in Digital Health: A Rapid Approach to Assess Health Apps Speaker: Mark Campbell, UK
OP124 Can Registry Failures Be Compensated by a Medico-Administrative Database? Speaker: Anne Lesquelen, France
OS.33 Capacity Building in HTA (Policy) Tuesday, June 20, 18:00 - 19:00, LEPTIS MAGNA IV (-2)
OP125 A New Collaborative Approach to Assess Innovative Health Technologies Speaker: Michèle de Guise, Canada
112 ORAL PRESENTATIONS
OP126 EUnetHTA Template to Aid Health Technology Assessment-Based Decisions Speaker: Luciana Ballini, Italy
OP127 Analysis of the Competencies to Be Acquired in HTA Speaker: Marco Chiumente, Italy
OP128 Knowledge and Attitudes of Health Care Management Students Among Health Speaker: Rabia Kahveci, Turkey
OS.34 Clinical Practice Guidelines, Effectiveness, and Safety (C) Tuesday, June 20, 18:00 - 19:00, MYLASA (-1)
OP129 Predictors of Effectiveness in Patients With Rheumatoid Arthritis Speaker: Juliana Alvares, Brazil
OP130 Emergency Ambulance Care of Older Adults Who Have Fallen: Cluster RCT Speaker: Helen Snooks, UK
OP131 Cost-Effectiveness of Dexamethasone and Adalimumab for Uveitis Speaker: Inigo Bermejo, UK
113 ORAL PRESENTATIONS
OS.35 Country-Specific and Regional HTA: Country Focus (D) Tuesday, June 20, 18:00 - 19:00, SIRMIUM (Ground Floor)
OP132 How a Shared Management of Home Infusion Can Control Expenditures Speaker: Cyril Olivier, France
OP133 HTA in Brazil: A Five-Year Review of CONITEC Activities Speaker: Roberta Rabelo, Brazil
OP134 Predictors of Public Health Outcomes: A Case Study From Turkey Speaker: Songul Cinaroglu, Turkey
OS.36 Integrating Regulation and HTA (Policy) Tuesday, June 20, 18:00 - 19:00, TARRAGONA (-1)
OP135 Confirmatory Versus Explorative End Points in Drug Approval Versus HTA Speaker: Charalabos-Markos Dintsios, Germany
OP136 Clinical Benefit of Oncological Therapies at the Time of Approval Speaker: Nicole Grössmann, Austria
OP137 Lawsuits to Receive Free Drugs: Expenditures for SUS Speaker: Erika Camargo, Brazil
OP138 Access to Orphan Drugs in the UK and Other European Countries Speaker: Bernarda Zamora, UK
114 ORAL PRESENTATIONS
OS.37 Stakeholder Involvement: Patient Focus (C) Tuesday, June 20, 18:00 - 19:00, LEPTIS MAGNA I (-2)
OP139 Measuring Patient Experiences With Medications: PESaM-Questionnaire Speaker: Merel Kimman, Netherlands
OP140 Pictures Speak Louder Than Words: Visuals to Explain NICE Guidance Speaker: Joost de Folter, UK
OP141 PROMS as Predictors of Health Care Use in Multiple Sclerosis Speaker: Michela Tinelli, UK
115 ORAL PRESENTATIONS
WHY WE INVENT AT MSD, WE ARE INVENTING FOR LIFE.
We are not inventing for invention’s sake – we are on a quest to cure – and to have an impact on countless people’s lives worldwide.
MSD is inventing because the world still needs cures for cancer, Alzheimer’s disease, HIV, and so many other causes of widespread suffering in people and animals.
We are taking on the world’s most challenging diseases to help people go on, unburdened, to experience, create and live their best lives.
MSD. Inventing for Life.
To explore our commitment to invention, visit www.msd.com and connect with us on Twitter.
Copyright © 2017 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. Kenilworth, NJ, USA. All rights reserved.
116 VIGNETTES
Vignettes
Vignette presentations are a new presentation format at this year’s Annual Meeting.
A vignette is a brief oral presentation designed to highlight a specific research finding. Each vignette will be 10 minutes in length, with five minutes dedicated to the presentation of up to three slides, and five minutes for discussion. Presentations will be held in a conference room and grouped by theme. Authors could not apply for vignettes directly; the vignettes were assigned by the International Scientific Programme Committee according to the score that each submission received.
VS.01 Big Data for Better HTA (A) Monday, June 19, 16:30 - 18:00, POLA (-1)
VP01 Effect of Early Life SES on Trajectories of Chinese Elders Health Speaker: Xiaoqian Hu, China
VP02 Are Journal Editors a Barrier to Publication of Real-World Evidence? Speaker: Elisabeth Oehrlein, US
VP03 Review of Patient-Powered Research Networks for Relative Effectiveness Speaker: Pall Jonsson, UK
VP04 Cost Analysis After Minimally Invasive Versus Open Lumbar Surgery Speaker: Hyung-Deuk Park, Korea, Republic of
VP05 Comprehensive Evaluation of an Evolving Transcatheter Technology
117 VIGNETTES
Speaker: Michèle de Guise, Canada
VP06 BRCA1/2-Related Ovarian Cancer Morbidity in Russia Speaker: Vasily Ryazhenov, Russia
VP07 Collaboratively Modelling the Impact of Interventions Retrospectively Speaker: Sukh Tatla, UK
VP08 Real-World Data Use in HTA Assessments: A Comparison of Five HTA Agencies Speaker: Amr Makady, Netherlands
VP09 Arthroplasty Registers as a Tool for Health Technology Assessment Speaker: Laia Domingo, Spain
VS.02 Clinical Practice Guidelines, Effectiveness, and Safety (A) Monday, June 19, 16:30 - 18:00, SIRMIUM (Ground Floor)
VP10 Optical Coherence Tomography to Guide PCI: A Rapid Assessment Speaker: Antonella Negro, Italy
VP11 Implantation of Magnetically Controlled Growing Rod: Systematic Review Speaker: Sunyoung Jo, Korea, Republic of
VP12 The Effectiveness and Safety of 3D Printing Technology in Orthopedics Speaker: Chenguang Ma, China
118 VIGNETTES
VP13 Relation Between MRI Use and Hip or Knee Replacements in the OECD Speaker: Robert Emprechtinger, Austria
VP14 Screening Recommendations for Socioeconomic Disadvantages In Pregnancy Speaker: Katharina Rosian, Austria
VP15 A Comparison of Reporting in UK HTA and Other Systematic Reviews Speaker: Eva Kaltenthaler, UK
VP16 Interventional Management of Hyperhidrosis: A Systematic Review Speaker: Ros Wade, UK
VP17 Physicians’ Perception of the Effects of Clinical Pathways in China Speaker: Jie Bai, China
VS.03 Country-Specific and Regional HTA (A) Monday, June 19, 16:30 - 18:00, MASSALIA I (-1)
VP18 Early Awareness and Alert System in Sweden: History and Current Status Speaker: Irene Eriksson, Sweden
VP19 Estimation of Melanoma Direct Costs According to a Clinical Pathway Speaker: Mirko Claus, Italy
VP20 A Data-Envelopment Analysis for Evaluating Peru’s Health System
119 VIGNETTES
Speaker: Lourdes Carrera, Peru
VP21 Telemedicine as a Tool for Public Health Planning Speaker: Pedro Galvan, Paraguay
VP22 Cancer Drugs Fund Allocation Under NICE: The First Six Months Speaker: Judith Rubinstein, US
VP23 Impact of Conditional Coverage on Medical Expenditures in Korea Speaker: Su-Jin Cho, Korea, Republic of
VP24 The Development of a Quality-Management Tool for HTA Agencies in Spain Speaker: Sergio Márquez-Peláez, Spain
VP25 African Countries Are Working Together to Enhance Medicine Use Speaker: Brian Godman, UK
VS.04 Developing Methods for HTA (A) Monday, June 19, 16:30 - 18:00, SPALATO (-1)
VP26 Comparing Statistical Methods for Meta-Analysis of Rare Event Data Speaker: Tarang Sharma, Denmark
VP27 Does HTA Methodology Affect the Decision to Fund Medical Tests? Speaker: Tracy Merlin, Australia
120 VIGNETTES
VP28 The Use of Ethnographic Fieldwork in HTA Speaker: Helle Hansen, Denmark
VP29 Organisational Aspects in HTA: A New Approach for Future Assessments Speaker: Gianfranco Damiani, Italy
VP30 Research and Analysis of European HTA Processes Speaker: Julia Sus, UK
VP31 HTA Evidence on E-Health/M-Health Technologies: Fields for Improvement Speaker: Vladimir Vukovic, Italy
VP32 Improving the Efficiency of Early Awareness for Non-Drugs in Spain Speaker: Iñaki Gutiérrez-Ibarluzea, Spain
VP33 Decision-Making Clinical Scenarios: A Support Method for HTA Speaker: Luiz Santoro Neto, Brazil
VS.05 Economic Evaluation: Diagnostics Monday, June 19, 16:30 - 18:00, SABRATHA (-1)
VP34 Economic Impact of Influenza-Like Illness in Vietnam Speaker: Trung Vo, Viet Nam
VP35 Economic Consequences of a Restricted Dutch STI-Testing Policy Speaker: Anita Suijkerbuijk, Netherlands
121 VIGNETTES
VP36 Cost-Effectiveness of Non-Invasive Prenatal Testing for Down Syndrome Speaker: José Asua, Spain
VP37 Cost-Effectiveness of PET-CT for Primary Aldosteronism Diagnosis Speaker: Jeanette Kusel, UK
VP38 The Impact of Treatment Timing on the Cost-Effectiveness of Tests Speaker: Camille Schubert, Australia
VP39 Health Impacts and Costs: A Prevention Lab in Piemonte, Italy Speaker: Cristiano Piccinelli, Italy
VS.06 Hospital-Based HTA (A) Monday, June 19, 16:30 - 18:00, ARLES (Ground Floor)
VP40 Comprehensive Evaluation of Islet Transplantation for Type 1 Diabetes Speaker: Danni Chen, China
VP41 Introducing New Health Technologies: Making Good Local Decisions Speaker: Tracey Tay, Australia
VP42 Cost-Consequences of Medicine Management in a Cross-Sectorial Setting Speaker: Maja Rasmussen, Denmark
VP43 HB-HTA Stakeholders’ Perspectives in Cipto Mangunkusumo Hospital Speaker: Siti Rizny F. Saldi, Indonesia
122 VIGNETTES
VP44 Rapid HTA: HIFU for Breast Fibroadenomas and Benign Thyroid Nodules Speaker: Keng Ho Pwee, Singapore
VP45 Hospital Efficiency and Utilization of High-Tech Medical Equipment Speaker: Yan Wei, China
VP46 Cost Analysis of Popliteal Aneurysm Management Speaker: Christophe Pinget, Switzerland
VP47 HTA of Intensive Care Ventilators for Pediatric Patients Speaker: Matteo Ritrovato, Italy
VS.07 Economic Evaluation: Devices, Drugs, Treatments (A) Monday, June 19, 16:30 - 18:00, LEPTIS MAGNA II (-2)
VP48 The Costs and Cost-Effectiveness of BCG Vaccination in Estonia Speaker: Triin Võrno, Estonia
VP49 Brazilian Consumer Willingness to Pay for Dengue Vaccine (CYD-TDV) Speaker: Augusto Guerra, Brazil
VP50 Cost Analysis of C-TIPS Versus Paracentesis in Recurrent Ascites Patients Speaker: Francesco Scarpa, Italy
123 VIGNETTES
VP51 Hospitalisations and Costs in Schizophrenia Patients Initiating Long-Acting Injectable Antipsychotics Speaker: Mallik Greene, US
VP52 Cost-Effectiveness of Percutaneous Closure of Patent Foramen Ovale Speaker: Ning Yan Gu, US
VP53 Cost-Utility Analysis: Adalimumab Verus Etanercept in RA, Brazil Speaker: Francisco Acurcio, Brazil
VP54 Costs and Benefits of Intensive In-Patient Rehabilitation After Stroke Speaker: Youshin Suh, Korea, Republic of
VP55 HTA of Orphan Drugs: The Case of Hereditary Angioedema in Italy Speaker: Carlo Federici, Italy
VS.08a Stakeholder Involvement: Patient Focus (A) Monday, June 19, 18:00 - 19:00, LEPTIS MAGNA I (-2)
VP56 HTA of a System for Patient Traceability and Safety Speaker: Giuseppe Banfi, Italy
VP57 Test–Retest Reliability Analysis of the PROBE Study Questionnaire Speaker: Mark Skinner, US
VP58 PREFER: Patient Preferences to Support Decision-Making
124 VIGNETTES
Speaker: Irina Cleemput, Belgium
VP59 Patients Views on Providing Evidence; Feeding Into the HTA Ecosystem Speaker: Heidi Livingstone, UK
VS.08b Stakeholder Involvement: Patient Focus (B) Monday, June 19, 18:00 - 19:00, CESAREA (-1)
VP60 The Importance of Patient Organisation Involvement in HTA Speaker: Kathi Apostolidis, Belgium
VP61 Patient Views of HTA at NICE: Enhancing Involvement Opportunities Speaker: Lizzie Thomas, UK
VP62 Deciding on the Right Innovations: The Future of the Patient Centric a Speaker: Ole Moland, Norway
VP63 NICE Technology Appraisal Patient Expert Feedback: 15-Month Analysis Speaker: Chloe Kastoryano, UK
VS.09 Capacity Building in HTA (Policy) Monday, June 19, 18:00 - 19:00, POLA (-1)
VP64 Post-Graduation Selection Using Multi-Criteria Decision Analysis
125 VIGNETTES
Speaker: Marisa Santos, Brazil
VP65 A Clearinghouse for African Health Technologies Speaker: Vince Thomas, Ethiopia
VP66 Perception of Decision-Makers and Researchers Towards HTA in Ghana Speaker: Rebecca Addo, Australia
VP67 The Value of EUnetHTA Outputs for National HTA: The French Experience Speaker: Irena Guzina, France
VS.10 Country-Specific and Regional HTA (B) Monday, June 19, 18:00 - 19:00, MASSALIA I (-1)
VP68 Five Years of Collaboration by REBRATS: A Social Network Analysis Speaker: Juliana Girardi, Brazil
VP69 Mapping Brazilian Nuclear Medicine Installed Capacity and Perspectives Speaker: Lorena Pozzo, Brazil
VP70 Structuring the Process of Innovation Uptake in Tunisia Speaker: Iñaki Gutiérrez-Ibarluzea, Spain
VP71 Health Technology Assessment in Japan: Current Issues and Challenges Speaker: Kaori Kido, Japan
126 VIGNETTES
VP72 Development Trend Analysis on New Health Technology Based on EuroScan Speaker: Chongyang Jiang, China
VP73 Primary Health Care Structure Evaluation for Prenatal Care in Brazil Speaker: Gisele Alexandre, Brazil
VS.11 Country-Specific and Regional HTA (C) Monday, June 19, 18:00 - 19:00, MASSALIA II (-1)
VP74 Russian System of Medicines Provision: Status and Future Aspects Speaker: Roza Yagudina, Russia
VP75 CEA of Pneumococcal Vaccination in Immuno-Compromised Adults in Taiwan Speaker: Chee Jen Chang, Chinese Taipei
VP76 European Collaboration in HTA: Experiences and Possible Benefits Speaker: Sabine Ettinger, Austria
VP77 Listen, Learn, and Adapt: Engagement of EUnetHTA’s Stakeholders Speaker: Michelle Mujoomdar, Netherlands
VP78 Cross-Country Variation in HTA Preferences: An International Survey Speaker: Olina Efthymiadou, UK
VP79 Primary Health Care Assessment With PCATOOL in Brazil Speaker: Gisele Alexandre, Brazil
127 VIGNETTES
VS.12 Developing Methods for HTA (B) Monday, June 19, 18:00 - 19:00, MERIDA (-1)
VP80 Mapping FACT-B to EQ-5D Utility Scores of Breast Cancer in China Speaker: Cheng Xuan, China
VP81 HTA and Rare Disease Decision-Making: Focus on Orphan Drugs Speaker: Ralitsa Raycheva, Bulgaria
VP82 Economic Evaluation of Dementia: Diagnosis and Disease Progression Speaker: Praveen Thokala, UK
VP83 How to Identify Technologies Eligible for HTA: A Bottom-Up Approach Speaker: Susanna Maltoni, Italy
VP84 A Synthetic Index to Assess the Quality of Care of Acute Hospitals Speaker: Mireia Espallargues, Spain
VP85 Multiple Surrogate End Points in Advanced Colorectal Cancer Speaker: Eleni Elia, UK
VS.13 Developing Methods for HTA (C) Monday, June 19, 18:00 - 19:00, SPALATO (-1)
VP86 Early Warning to Ensure Timely Evidence-Based Decision-Making Speaker: Vigdis Lauvrak, Norway
128 VIGNETTES
VP87 Extrapolation From Progression-Free Survival to Overall Survival in on Speaker: Karla Hernandez-Villafuerte, UK
VP88 Transient Ischaemic Attack Referral (TIER) Intervention Development Speaker: Chelsey Hampton, UK
VP89 Assessing mHealth: Proposal of a New Framework Speaker: Elisa Puigdomenech Puig, Spain
VP90 Uniform Assessment Methods to Assess New Genomic Tests Speaker: Fueloep Scheibler, Germany
VS.14 Economic Evaluation and Decision-Making (A) Monday, June 19, 18:00 - 19:00, ORANGE I (-1)
VP91 Analysis of Paper and Electronic-Based Medical Claims Review in Ghana Speaker: Eric Nsiah-Boateng, Ghana
VP92 Quantifying Health Need to Inform Funding Decisions Speaker: James Harris, New Zealand
VP93 Budget Impact Analysis of Non-Invasive Prenatal Testing for Down Syndrome Speaker: Yan Xu, China
VP94 Framework of High-Quality Value Assessment Criteria in Health Care Speaker: Ralitsa Raycheva, Bulgaria
129 VIGNETTES
VP95 The Monetary Value of a Statistical Life-Year: A Systematic Review Speaker: Michael Schlander, Germany
VP96 Information Flow as Basis for Planning Biomedical Technologies in Italy Speaker: Mario Fregonara Medici, Italy
VS.15 Economic Evaluation: Devices, Drugs, Treatments (B) Monday, June 19, 18:00 - 19:00, ORANGE II (-1)
VP97 The Economic and Fiscal Impact of Vaccination in Italy Speaker: Matteo Ruggeri, Italy
VP98 Cost-Effectiveness of Public Access Defibrillation in Japan Speaker: Mie Sasaki, Japan
VP99 Economic Impact of rpFVIII in the Management of Acquired Haemophilia A Speaker: Valentina Lorenzoni, Italy
VP100 Disease-Modelling Approaches in Multiple Sclerosis Speaker: Matteo Ferrario, Italy
VP101 Medical Devices for Treatment-Resistant Hypertension: HTA Report Speaker: Marina Cerbo, Italy
130 VIGNETTES
VS.16 Other Vignette Presentations (A) Monday, June 19, 18:00 - 19:00, SABRATHA (-1)
VP102 The Determinants of Diffusion of New Technologies Across Life Cycle Speaker: Giuditta Callea, Italy
VP103 HTA of Genetic Tests for Cystic Fibrosis Carrier Screening in Italy Speaker: Vladimir Vukovic, Italy
VP104 The Economic Impact of SSB Taxes in Brazil: An Input–Output Analysis Speaker: Larissa Cardoso, Brazil
VP105 The Impact of Community-Acquired Pneumonia on Health-Related Quality of Life Speaker: Marie-Josee J. Mangen, Netherlands
VP106 Biotechnology and Biosimilar Landscape in Turkey Speaker: Aysen Senturk, Turkey
131 VIGNETTES
VS.17 Stakeholder Involvement (A) Monday, June 19, 18:00 - 19:00, LEPTIS MAGNA IV (-2)
VP107 Pharmaceutical Industry Experiences With German HTA Scientific Advice Speaker: Charalabos-Markos Dintsios, Germany
VP108 Environmental Sustainability in Hospitals HTA: A Survey Speaker: Orna Tal, Israel
VP109 Identifying Priorities for a National Health Research Funder Speaker: Sheila Turner, UK
VP110 Building Capacity in HTA Through Plain Language Speaker: Kinneret Globerman, Canada
VP111 Referral Centre for Multiple Myeloma Patient Care Speaker: Paulo Picon, Brazil
132 VIGNETTES
VS.18 Big Data for Better HTA (B) Tuesday, June 20, 16:30 - 18:00, POLA (-1)
VP112 Can We Use Administrative Data to Estimate the Costs of an ICU Stay? Speaker: Oriana Ciani, Italy
VP113 Reframing “Disinvestment”: Appropriateness and Real-Time Data Capture Speaker: Charlene Ronquillo, UK
VP114 Nationwide Registries to Inform on Economic Burden of a Rare Disease Speaker: Florence Marteau, France
VP115 Practical Issues of Using Real-World Data in Effectiveness Research Speaker: Amr Makady, Netherlands
VP116 Comparison Between TTOT and AIFA Registries’ Treatment Duration Speaker: Gabriele Vittoria, Italy
VP117 Analysis of Mortality of Ectopic Pregnancy in Shanghai, 1979–2010 Speaker: Li Du, China
VP118 Using Medicine-Insight Data to Improve Clinical Care in Australia Speaker: Karen Kaye, Australia
VP119 Improve Emergency Ambulance Care for People With Mental Health Speaker: Helen Snooks, UK
133 VIGNETTES
VS.19 Clinical Practice Guidelines, Effectiveness, and Safety (B) Tuesday, June 20, 16:30 - 18:00, SIRMIUM (Ground Floor)
VP120 A UK Research-Commissioning Framework for Devices and Diagnostics Speaker: Susan Peirce, UK
VP121 Network Meta-Analysis for Managing Biosimilars Speaker: Sabrina Trippoli, Italy
VP122 Cryoballoon Versus Radiofrequency Ablation for Atrial Fibrillation Speaker: Gongru Wang, China
VP123 Erlotinib Versus Docetacel in Advanced NSCLC: A Meta-Analysis Speaker: Hui Sun, China
VP124 The End of French Medical Dogma for Hepatitis B and C Diagnosis Speaker: Jean-Charles Lafarge, France
VP125 A Systematic Review of PD-1/PD-L1 Inhibitors in Advanced NSCLC Speaker: David Tamblyn, Australia
VP126 The Effectiveness and Safety of Barbed Sutures in Bariatric Surgery Speaker: Yifei Lin, China
134 VIGNETTES
VP127 Comparison of Efficacy, Safety, and Cost of RFA With SR for HCC Speaker: Kun Xiong, China
VP128 Cost-Effectiveness of E-Cigarettes for Smoking Cessation Speaker: Patricia Harrington, Ireland
VS.20 Economic Evaluation and Decision-Making (B) Tuesday, June 20, 16:30 - 18:00, MASSALIA II (-1)
VP129 Social Cost–Benefit Analysis (SCBA) of Three Alcohol Policy Measures Speaker: Ardine de Wit, Netherlands
VP130 Burden of Illness for Urothelial Bladder Cancer (UBC) in Italy Speaker: Alessandra Recchia, Italy
VP131 Comparison of Variation Methods for One-Way Sensitivity Analyses Speaker: Robert McQueen, US
VP132 Cost-Effectiveness of a Predictive Risk Model in Primary Care Speaker: Helen Snooks, UK
VP133 Patient-Reported Health-State Utilities in Neuroendocrine Tumours Speaker: Jerome Dinet, France
VP134 When Might Evidence From a Trial Become More Useful Than Modelling? Speaker: Neill Booth, Finland
135 VIGNETTES
VP135 Clustering Surgical Indicators and Predictors of Catastrophic Expenses Speaker: Songul Cinaroglu, Turkey
VP136 The Impact of Hospital-Costing Methods on Economic Evaluations Speaker: Stefania Manetti, Italy
VS.21 Ethical, Social, and Legal Issues in HTA Tuesday, June 20, 16:30 - 18:00, SPALATO (-1)
VP137 Why We Should Not Meet Unmet Needs! Speaker: Lars Sandman, Sweden
VP138 Integration of Ethics in Health Technology Assessment Speaker: Pierre Dagenais, Canada
VP139 Broadening the Scope: Assessment of Methods Used in Social Services Speaker: Pernilla Östlund, Sweden
VP140 Methods for Ethical Analysis in Health Technology Assessment Speaker: Flavia Elias, Brazil
VP141 Ask the Internet: Analysis of Online Discussions on Value Frameworks Speaker: Katie Noon, UK
136 VIGNETTES
VP142 Assessing Human Enhancements: Exposing and Elucidating Ethical Issues Speaker: Bjørn Hofmann, Norway
VP143 An Adaptation of MCDA in HTA of Orphan Drugs Speaker: Kamilla Gaitova, Kazakhstan
VS.22 Hospital-Based HTA (B) Tuesday, June 20, 16:30 - 18:00, ARLES (Ground Floor)
VP149 Sustained Low-Efficiency Dialysis (SLED): A Rapid Review Speaker: Khin Chaw Yu Aung, Singapore
VP144 Health Technology Assessment in Hospitals: Determinants of Performance Speaker: Roberta Pagani, Italy
VP145 Web-Based Cardiac Rehabilitation for Decliners: HTA Feasibility Trial Speaker: Ala Szczepura, UK
VP146 A Comparative Assessment of 3D/2D Laparoscopic Display Systems Speaker: Martina Andellini, Italy
VP147 Implementing Electronic Health Records in a Children’s Hospital Speaker: Matteo Ritrovato, Italy
137 VIGNETTES
VP148 HTA of Femtosecond Laser: A New Frontier in Cataract Surgery Speaker: Martina Andellini, Italy
VP150 HTA as a Tool for Hospital Innovation Speaker: Kari Kvaerner, Norway
VP151 Endovenous Iron Deficiency Anemia Treatment in IBD: Hospital-Based HTA Speaker: Jovana Stojanovic, Italy
VS.23 Integrating Regulation and HTA (Policy) Tuesday, June 20, 16:30 - 18:00, TARRAGONA (-1)
VP152 The Systems Archetypes Analysis on Development of Primary Health Care Speaker: Lili Zhu, China
VP153 HTA Reports in Gene and Cellular Therapy Products: A Scoping Review Speaker: Peter Kolominsky-Rabas, Germany
VP154 School-Based Interventions For Smoking Prevention Speaker: Youjin Jung, Republic of Korea
VP155 Synchronisation of Regulatory Approval and HTA Recommendation Timing Speaker: Neil McAuslane, UK
138 VIGNETTES
VP156 Early HTA Dialogue: Trends and Evolution Towards Integrated Advice Speaker: Amina Udechuku, UK
VP157 What Is the Response to Immuno-Oncology by HTA Agencies? Speaker: Judith Rubinstein, US
VS.24 Stakeholder Involvement: Patient Focus (B) Tuesday, June 20, 16:30 - 18:00, LEPTIS MAGNA II (-2)
VP158 Reflective MCDA to Identify Decision Drivers for Patients With GEP-NET Speaker: Mireille Goetghebeur, Canada
VP159 Strengthening Primary Health Care in Nigeria by Patient Involvement Speaker: Sylvester Adeyemi, Nigeria
VP160 Can the Patient Perspective in HTA Be Truly Independent? Speaker: Simone Leyden, Australia
VP161 Identification of Needs of PVNS Patients Using Online Bulletin Board Speaker: Nigel Cook, Switzerland
VP162 SMC: Strengthening Patient and Public Involvement in HTA Speaker: Lindsay Lockhart, UK
VP163 Patient Involvement in the Development of Multi-Criteria Decision Tool Speaker: Marie-Pierre Gagnon, Canada
139 VIGNETTES
VP164 Applying HTA to Pharmacy: The Italian-Medicine-Use-Review-HTA Speaker: Michela Tinelli, UK
VP165 Landscape Assessment: Patient Engagement in HTA Speaker: Elisabeth Oehrlein US
VS.25 Clinical Practice Guidelines, Effectiveness and Safety (C) Tuesday, June 20, 18:00 - 19:00, MASSALIA I (-1)
VP166 Selecting Rapid Review Methods for HTA Speaker: Eva Kaltenthaler, UK
VP167 Comparison of Methodology in MTCs of Treatments for Multiple Sclerosis Speaker: Joseph Kleijnen, UK
VP168 Assessment of Plasmapheresis for the Systematic Review of Alzheimer’s Disease Speaker: Luis María Sánches-Gómez, Spain
VP169 Grouping Treat-to-Target Studies in Systematic Reviews Speaker: Marrissa Martyn-St James, UK
VP171 The Safety of Barbed Sutures in Cosmetic Surgery Speaker: Yifei Lin, China
140 VIGNETTES
VS.26 Clinical Practice Guidelines, Effectiveness and Safety (D) Tuesday, June 20, 18:00 - 19:00, MASSALIA II (-1)
VP172 Clinical Effectiveness of a Predictive Risk Model in Primary Care Speaker: Helen Snooks, UK
VP173 Determinants of BHS Efficiency in OECD Countries Speaker: Songul Cinaroglu, Turkey
VP174 Atlases of Quality: Assessing Integrated Care in Chronic Diseases Speaker: Mireia Espallargues, Spain
VP175 Validating Outcome Assessments for HTA in CLN2, an Ultra-Rare Disease Speaker: Thomas Butt, UK
VP176 Effectiveness of Anti-TNF in Patients With Psoriatic Arthritis Speaker: Francisco Acurcio, Brazil
VP177 Older People With Cancer: To Treat or Not to Treat With Chemotherapy? Speaker: Gerlinde Pilkington, UK
141 VIGNETTES
VS.27 Country-Specific and Regional HTA (D) Tuesday, June 20, 18:00 - 19:00, ARLES (Ground Floor)
VP178 Allocation and Utilization of CT in China: Panel Data Analysis Speaker: Luyang He, China
VP179 HTA of Tolvaptan in the Treatment of ADPKD Speaker: Silvia Coretti, Italy
VP180 Effect of Two-Invoice System on Drug Distribution and Price in China Speaker: Yingfeng Ye, China
VP181 From National to European Assessment: The German Case Speaker: Tommaso Panni, Germany
VP182 Network Amongst the HTA Ecosystem Speaker: Songul Cinaroglu, Turkey
VP183 National Policy: Impact on Antipsychotic Prescribing in Care Homes Speaker: Ala Szczepura, UK
142 VIGNETTES
VS.28 Economic Evaluation: Devices, Drugs, Treatments (C) Tuesday, June 20, 18:00 - 19:00, ORANGE I (-1)
VP184 A Cost Analysis of Flash Glucose Monitoring Systems in Veneto Region Speaker: Anna Cavazzana, Italy
VP185 Coronary Disease Preferences: A Systematic Review Speaker: Carlos Magliano, Brazil
VP186 The Importance of Therapeutic Adherence in Chronic Diseases Speaker: Michele Basile, Italy
VP187 Budgetary Impact Analysis: Real-World Evidence Versus Theoretical Results Speaker: Francisco Acurcio, Brazil
VP188 Cost-Effectiveness of Outpatient Treatment of Febrile Neutropenia Speaker: Alfonos Reyes-Lopez, Mexico
VS.29 Hospital-Based HTA (C) Tuesday, June 20, 18:00 - 19:00, SPALATO (-1)
VP189 Haemolysis Induced by Modern Infusion Pumps During Blood Transfusion Speaker: Thomas Poder, Canada
VP190 A Review of Best Practices in Five Mental Disorders in Youth
143 VIGNETTES
Speaker: Alain Lesage, Canada
VP191 Peripheral Nerve-Field Stimulation for Chronic Low Back Pain Speaker: Marc Rhainds, Canada
VP192 Importance of Contextual Data in Producing HTA Recommendations Speaker: Thomas Poder, Canada
VP193 Criteria for Opting for Either Hospital (Local) HTA or National HTA Speaker: Helene Arentz-Hansen, Norway
VP194 HTA Applied to Nurse Retention and Development: A Sickle Cell Example Speaker: Matthew Mitchell, US
VS.30 Information Search and Knowledge Transfer Tuesday, June 20, 18:00 - 19:00, MERIDA (-1)
VP195 Using the ISSG Search Filter Resource in Health Technology Assessment Speaker: Kath Wright, UK
VP196 Impact of Trial Registry Search Features on Searches in CT.gov/ICTRP Speaker: Kelke Hausner, Germany
VP197 Sustainable Production of Rapid HTAs and Clinical Guidelines Speaker: Susan Myles, UK
144 VIGNETTES
VP198 Efficient Retrieval of Trial Protocols: An Empirical Study Speaker: Anthea Sutton, UK
VP199 Limitations of Studies on Oxygen Therapy in Acute Care Settings Speaker: Carmen Moga, Canada
VP200 Untangling What Information Specialists Should Document and Report Speaker: Lisa Tjosvold, Canada
VS.31 Other Vignette Presentations (B) Tuesday, June 20, 18:00 - 19:00, CESAREA (-1)
VP201 From a Systematic Review to Adressing Evidence Gaps Speaker: Marie Österberg, Sweden
VP202 EVIPNet Brazil and the Experience of Knowledge-Translation Projects Speaker: Eliana Carlan, Brazil
VP203 Performance Evaluation of Eye-Tracking Devices Speaker: Luciano Recalde, Paraguay
VP204 Patient-Safety Climate in General Public Hospitals in China Speaker: Ping Zhou, China
VP205 Implementing Electronic Records in Ambulances Speaker: Alison Porter, UK
145 VIGNETTES
VS.32 Stakeholder Involvement (B) Tuesday, June 20, 18:00 - 19:00, LEPTIS MAGNA II (-2)
VP206 Health Technology Assessment and Health Literacy Speaker: Shin-hee Kang, Korea, Republic of
VP207 The Adoption of Non-Invasive Prenatal Testing Technology in China Speaker: Lizheng Shi, US
VP208 Informing an Economic Model for Hyperhidrosis: A Clinical Survey Speaker: Julija Stoniute, UK
VP209 Two-Way SMS for Better Engagement and a Quality Bio-Surveillance System Speaker: Cuong Nguyen, Viet Nam
VP210 Establishing an Advisory Group for Patient and Public Involvement in HTA Speaker: Lindsay Lockhart, UK
146 VIGNETTES
VS.33 Value-Based Health Policy and Management Tuesday, June 20, 18:00 - 19:00, ORANGE II (-1)
VP211 Willingness to Pay for Anti-HCV Drugs From the Kazakhstan Perspective Speaker: Alexandr Kostyuk, Kazakhstan
VP212 Value of Comparing Real-World Outcomes to HTA Speaker: Mary Warner, Australia
VP213 Satisfaction Survey of National Essential Medicines System in China Speaker: Ren Jianping, China
VP214 Criteria That Influence Brazilian Public Decision-Making Speaker: Marisa Santos, Brazil
VP215 Time to Public Reimbursement for Innovative Medicines in Canada Speaker: Chander Sehgal, Canada
VP216 HTA’s Balance Between Additional Data, Adoption, and Patient Access Speaker: Parashar Patel, US
147 VIGNETTES
Making drug developMent work How R&D can provide the answers HTA assessment bodies need Tuesday 20 June 2017, 1.00pm – 2.30pm 14th HTAi Annual Meeting Ergife Palace Hotel, Rome
The session will look to: Engage different perspectives on the challenges of misalignment between data collection and HTA requirements
Provide insights into the therapy development process, with a view to identifying points for alignment between industry and HTA bodies
Introduce the BEACON framework as an aid for shaping therapy development data collection
Gather views on the BEACON framework and new ideas on how to enhance the therapy development programme to improve HTA submissions to save time and resources MINT/UNAL-17008f May 2017
148 VIGNETTES
GOING GoBoldly.com AFTER CURES ISN’T FOR THE FAINT OF HEART.
PhRMA is pleased to support the HTAi 2017 Annual Meeting. Welcome to the future of medicine. For all of us.
149 HTAI INTEREST GROUP MEETINGS
HTAi Interest Group Meetings Sunday, June 18, 2017 IG.01 HTAi Early Career Network
17:00 – 18:30, SPALATO (-1)
Monday, June 19, 2017 IG.02 Interest Groups Steering Committee Meeting (Invitation Only)
7:00 – 08:30, TREVIRI (-1)
IG.03 Impact of Public Health Interventions (INPHORM)
13:00 – 14:30, POLA (1)
IG.04 HTAi Assessment of Vaccination Programs
13:00 – 14:30, SPALATO (-1)
IG.05 Patient and Citizen Involvement in HTA
16:30 – 18:00, LEPTIS MAGNA I (-2)
IG.06 HTA in Developing Countries
16:30 – 18:00, MYLASA (-1)
150 HTAI INTEREST GROUP MEETINGS
Tuesday, June 20, 2017 IG.07 Regulatory Interactions and Conditional Coverage (RICC)
7:00 – 08:30, MERIDA (-1)
IG.08 Information Retrieval
13:00 – 14:30, MERIDA (-1)
IG.09 Disinvestment and Early Awareness
13:00 – 14:30, POLA (1)
IG.10 Ethical Issues in HTA
13:00 – 14:30, SPALATO (-1)
IG.11 Hospital-Based HTA
16:30 – 18:00, ORANGE II (-1)
151 HTAI AND ASSOCIATED MEETINGS
HTAi and Associated Meetings Saturday, June 17, 2017 HTAi Board of Directors Meeting (Invitation Only)
8:30 – 16:30, HAMA (-1)
Chair: Guy Maddern, Australia
HTAi Policy Forum Coordinating Committee (Invitation Only)
17:00 – 18:30, HAMA (-1)
Chair: Karen Facey, UK
Sunday, June 18, 2017 HTAi Policy Forum: Business and Topic-Scoping Meeting (Invitation Only) 8:00 – 12:00, MASSALIA II (-1)
Chair: Laura Sampietro-Colom, Spain
HTAi Global Policy Forum: Committee Meeting (Invitation Only)
12:30 – 13:30, TREVIRI (-1)
Chair: Laura Sampietro-Colom, Spain
152 HTAI AND ASSOCIATED MEETINGS
HTAi Asia Policy Forum: Committee Meeting (Invitation Only)
14:00 – 15:30, TREVIRI (-1)
Chair: Brendon Kearney, Australia
Monday, June 19, 2017 International Journal of Technology Assessment in Health Care: Editors’ Meeting (Invitation Only) 7:00 – 08:30, ALCANTARA (-1)
Chair: Wendy Babidge, Australia
International Scientific Programme Committee Meeting 2018 Vancouver (Invitation Only) 13:00 – 14:30, TREVIRI (-1)
Co-Chairs: Tammy Clifford, Canada Alric Rüther, Germany
HTAi Annual General Meeting (Open to All HTAi Members)
19:00 – 20:00, LEPTIS MAGNA IV (-2)
Chair: Guy Maddern, Australia
153 HTAI AND ASSOCIATED MEETINGS
Tuesday, June 20, 2017 HTAi Business Development Committee (Invitation Only)
7:00 – 08:30, TREVIRI (-1)
Chair: David Grainger, Australia
International Journal of Technology Assessment in Health Care: Editorial Board Meeting (Invitation Only) 13:00 – 14:30, ALCANTARA (-1)
Chair: Wendy Babidge, Australia
HTAi – WHO Business Meeting (Invitation Only)
13:00 – 14:30, TREVIRI (-1)
Chair: Guy Maddern, Australia
154 SPONSOR EVENTS AND SYMPOSIA
Sponsor Events and Symposia Monday, June 19, 2017
SY.01 Resistance to Antimicrobials: A Call for Multi- Disciplinary Action: How Can HTA Help? Angelini Spa 13:00 – 14:30, LEPTIS MAGNA I (-2)
Moderators: Prof. Americo Cicchetti, Graduate School of Health Economics and Management, Catholic University of the Sacred Heart (ALTEMS), Italy Dr. Iñaki Gutiérrez-Ibarluzea, Ministry of Health, Basque Government (OSTEBA), Spain Panellists: Dr. Paola Testori Coggi, President, P&R Committee, AIFA, Italy Dr. Krzysztof Landa, Board of the National Center for Research & Development, Poland Prof. Roman S. Kozlov, Chief Specialist for Clinical Microbiology and AMR Program, Ministry of Health, Russia Dr. Mercedes Palomar Martínez, Head, Intensive Care Unit, Hospital Universitari Arnau de Vilanova, Spain Prof. Adrian Towse, Director, Office of Health Economics, UK
Resistance to antimicrobials and a lack of new effective drugs is a wide-spreading medical threat. Challenges include finding a balance between newly discovered and costly effective therapies; providing patient access to new antibiotics; and health care sustainability. HTA may help by scrutinizing not only drug costs, but also organisational adjustments, hospital length of stay, and redirection to outpatient care.
155 SPONSOR EVENTS AND SYMPOSIA
SY.02 Building HTA Processes for Good HTA Decisions: Findings of a Research Project and Implications for a Complex Area (AD) Eli Lilly and Company 13:00 – 14:30, LEPTIS MAGNA II (-2)
Moderator: David Grainger, Eli Lilly and Company, HTAi Board Member, Australia Panellists: Dr. Wija Oortwijn, Ecorys Consulting, Netherlands Dr Nick Crabb, Centre for Health Technology Evaluation, National Institute for Health and Care Excellence, UK Jean Georges, Alzheimer Europe, Luxembourg
How do the overall processes for conducting assessments and appraisals feed into making good HTA decisions? In 2016, Lilly commissioned a study of HTA processes in 10 countries that compared their practices against two important benchmarks: the European Integrate HTA framework, and the Accountability for Reasonableness framework of Norman Daniels. We will report findings and invite interpretation from several perspectives.
156 SPONSOR EVENTS AND SYMPOSIA
SY.03 Using Real-World Data to Make Flexible Payment Models Work for Everyone: Learnings and Challenges F. Hoffmann-La Roche 16:30 – 18:00, ORANGE II (-1)
Moderator: Clifford Goodman, PhD, Center for Comparative Effectiveness Research, Lewin Group, US Panellists: Dominique Polton, President, Institut des données de santé Charenton-le-Pont, France Martina Weiss, MBA, Helsana-Gruppe, Switzerland Dr. Walter Van Dyck, Vlerick Business School, Belgium Dr. Jens Grueger, Roche, Switzerland
Over the last decade, Italy has used the AIFA registry to support flexible payment models and ensure patient access to the latest medicines. Until now, other countries have been slow to replicate this approach, but the panel will show how smart use of real-world data is now resulting in progress elsewhere in Europe.
157 SPONSOR EVENTS AND SYMPOSIA
SY.04 Enlarging the Value Framework in the Assessment of Immunization Plans MSD 16:30 – 18:00, ORANGE I (-1)
Moderator: Prof. Americo Cicchetti, Graduate School of Health Economics and Management, Catholic University of the Sacred Heart (ALTEMS), Italy Panellists: Prof. Francesco S. Mennini, University of Tor Vergata; President, ISPOR Rome Chapter, Italy Ranieri Guerra, Director of Prevention and CMO, Ministry of Health, Italy Michael Gmeinder, Directorate for Employment, Labour, and Social Affairs, OECD, Austria Mondher Toumi, Chair, HTAi Interest Group for Assessment of Vaccination Programmes, France Panos Kanavos, Department of Social Policy, London School of Economics (LSE); Medical Technology Research Group (MTRG) at LSE Health, UK Matteo Ruggeri, Catholic University of the Sacred Heart (ALTEMS), Italy
The European Vaccine Action Plan 2015–2020 was enacted to provide member states with a guide to support the objective of a European region free from vaccine- preventable diseases. This symposium aims to analyze and discuss the main aspects of the Vaccine Action Plan, as well as results from national plans and studies designed to test public-health investments in immunization strategies.
158 SPONSOR EVENTS AND SYMPOSIA
Tuesday, June 20, 2017
SY.05 Making Drug Development Work: How R&D Can Provide the Answers HTA Assessment Bodies Need Mundipharma International Limited 13:00 – 14:30, LEPTIS MAGNA I (-2)
Moderator: Will Dunlop, Mundipharma International Limited Panellists: Professor Ron Goeree, Department of Health Research Methods, Evidence, and Impact at McMaster University Andrew Walker, Salus Alba, a specialist pharmacoeconomics and HTA consultancy, UK Panos Tsintis, NDA Regulatory Science Ltd.
This symposium will explore how data collected through the clinical development process can be better aligned with the evidence required by HTA bodies and other decision-makers. The symposium will consider how the BEACON framework can be used to better guide pharmaceutical research investment and produce the right data for HTA submissions.
159 SPONSOR EVENTS AND SYMPOSIA
SY.06 Global Lessons on Value Assessment Frameworks PhRMA 13:00 – 14:30, LEPTIS MAGNA II (-2)
Moderator: David Grainger, Eli Lilly, Australia Panellists: Julia Gaebler, PhD, Health Advances, US Elizabeth Cobbs, PhD, Merck & Co., US Stefan Weber, Novartis, Switzerland Helen Yang, Amgen, Hong Kong
Sound frameworks to assess the value of medical tests, treatments, and services can represent one of many tools to support well-informed, patient-centred health care. Join us for a discussion with global industry experts on comparative experiences with value-assessment frameworks and how value assessment can evolve to better reflect scientific advances and patient needs.
160 SPONSOR EVENTS AND SYMPOSIA
SY.07 Changing the HTA Paradigm: Beyond Clinical and Economic Evaluation for Innovative Drugs Takeda Pharmaceuticals International AG 16:30 – 18:00, ORANGE I (-1)
Moderator: Dr. Mark Ratcliffe, PhD, Managing Director, PHMR, UK Panellists: Dr Andrew Walker, PhD, Senior researcher, University of Glasgow; Former assessor at the Scottish Medical Consortium, Scotland, United Kingdom Hanim Edoo, MSc, Early Engagement & Patient Access Consultant at Medi-Qualite Omega, Paris, France Prof Claudio Jommi, MSc, Associate Professor of Management, Università del Piemonte Orientale, Novara, Italy Dr J. Jaime Caro, MDCM, FCRPC, FACP, McGill University, Canada; Evidera, USA
This Takeda-sponsored symposium is aimed at examining the impact of the use of clinical and economic criteria and different value frameworks in HTA, resulting in patient access for innovative drugs, especially combination oncology drugs. The international faculty will articulate key challenges around existing HTA approaches, and how these approaches could be improved to ensure better patient access for innovative health technologies.
161 SPONSOR EVENTS AND SYMPOSIA
162 Posters
POSTERS
Posters Poster Session 1 PS01 Clinical Practice Guidelines, Effectiveness, and Safety (CPGEF) PP01 Ultrasound to Guide Treatment Decisions in Rheumatoid Arthritis Monday, June 19, 11:00 - 11:15, Presentation Column Number: 1 Presenter: Matt Stevenson, UK
PS01 Clinical Practice Guidelines, Effectiveness, and Safety (CPGEF) PP02 Sudden Cardiac Arrest: Wearable Cardioverter-Defibrillator Therapy Monday, June 19, 11:00 - 11:15, Presentation Column Number: 2 Presenter: Sabine Ettinger, Austria
PS01 Clinical Practice Guidelines, Effectiveness, and Safety (CPGEF) PP03 Theoretical Model for Influencing Mechanism of Clinical Pathway Use Monday, June 19, 11:00 - 11:15, Presentation Column Number: 3 Presenter: Wenbin Liu, China
PS01 Country-Specific and Regional HTA (CSR) PP04 HTA as a Driver for Innovative Public Funding Arrangements Monday, June 19, 11:00 - 11:15, Presentation Column Number: 4 Presenter: Mary Warner, Australia
165 POSTERS
PS01 Economic Evaluation and Decision-Making (EEDM) PP05 Micro-Costing of Colorectal Cancer in China Monday, June 19, 11:00 - 11:15, Presentation Column Number: 5 Presenter: Ju-Fang Shi, China
PS01 Economic Evaluation: Devices, Drugs, Treatments (EEDDT) PP06 Ebola in the Netherlands: Costs of Preparedness and Response Monday, June 19, 11:00 - 11:15, Presentation Column Number: 6 Presenter: Anita Suijkerbuijk, Netherlands
PS01 Hospital-Based HTA (HB) PP07 Technology Adoption in Hospitals: Balancing Incentives — A Survey Monday, June 19, 11:00 - 11:15, Presentation Column Number: 7 Presenter: Orna Tal, Israel
PS01 Hospital-Based HTA (HB) PP08 HTA Analysis of New Biological Drugs in Chronic Inflammatory Diseases Monday, June 19, 11:00 - 11:15, Presentation Column Number: 8 Presenter: Francesco Ferrara, Italy
PS01 Other (O) PP09 Quality Assessment in a Clinical Setting: A Look Upstream From HTA Monday, June 19, 11:00 - 11:15, Presentation Column Number: 9 Presenter: Julie Fattal, Canada
166 POSTERS
PS01 Stakeholder Involvement (SI) PP10 Promoting Access to Improved Quality Health Care Monday, June 19, 11:00 - 11:15, Presentation Column Number: 10 Presenter: John Vianney Amanya, Uganda
PS01 Value-Based Health Policy and Management (VBHPM) PP11 Covering New Medical Devices With Low Cost-Effectiveness Evidence Monday, June 19, 11:00 - 11:15, Presentation Column Number: 11 Presenter: Su-Jin Cho, Korea, Republic of
Poster Session 2 PS02 Clinical Practice Guidelines, Effectiveness, and Safety (CPGEF) PP12 Efficacy and Safety of the ELIPSE Gastric Balloon for Weight Loss Monday, June 19, 13:00 - 13:15, Presentation Column Number: 1 Presenter: Luis María Sánches-Gómez, Spain
PS02 Clinical Practice Guidelines, Effectiveness, and Safety (CPGEF) PP13 Pain Management and Substance Abuse in Sickle Cell Disease Patients Monday, June 19, 13:00 - 13:15, Presentation Column Number: 2 Presenter: Paulo Picon, Brazil
167 POSTERS
PS02 Country-Specific and Regional HTA (CSR) PP14 Will a Proposed Policy in Japan, Health Gold License, Work? Monday, June 19, 13:00 - 13:15, Presentation Column Number: 3 Presenter: Kosuke Iwasaki, Japan
PS02 Developing Methods for HTA (DM) PP15 Methodological Quality of HTA Reports Monday, June 19, 13:00 - 13:15, Presentation Column Number: 4 Presenter: Elke Hausner, Germany
PS02 Economic Evaluation and Decision-Making (EEDM) PP16 Hepatitis C Cost Study in Brazil, 2014 Monday, June 19, 13:00 - 13:15, Presentation Column Number: 5 Presenter: Alexander Itria, Brazil
PS02 Economic Evaluation: Devices, Drugs, Treatments (EEDDT) PP17 Social Cost–Benefit Analysis of CBT for Alcohol and Cannabis Addiction Monday, June 19, 13:00 - 13:15, Presentation Column Number: 6 Presenter: Paul van Gils, Netherlands
PS02 Hospital-Based HTA (HB) PP18 Clinical Risk Prediction Scores for VTE in Hospitalised Patients Monday, June 19, 13:00 - 13:15, Presentation Column Number: 7 Presenter: Matthew Mitchell, US
168 POSTERS
PS02 Hospital-Based HTA (HB) PP19 Clostridium Difficile Infection Diagnosis: Hospital-Based HTA Monday, June 19, 13:00 - 13:15, Presentation Column Number: 8 Presenter: Kátia Senna, Brazil
PS02 Integrating Regulation and HTA (Policy) (IR) PP20 Decision-Making Beyond Evidence Alone: Topic Prioritisation for HTA Monday, June 19, 13:00 - 13:15, Presentation Column Number: 9 Presenter: Hong Ju, Singapore
PS02 Stakeholder Involvement (SI) PP21 Peer Review Innovations for Grant Applications: Efficient and Effective? Monday, June 19, 13:00 - 13:15, Presentation Column Number: 10 Presenter: Geoff Frampton, UK
PS02 Value-Based Health Policy and Management (VBHPM) PP22 New Models Are Needed to Optimise the Management of New Medicines Monday, June 19, 13:00 - 13:15, Presentation Column Number: 11 Presenter: Brian Godman, UK
PS02 Developing Methods for HTA (DM) PP23 Applying Oncology Patient Registries as HTA Tool Monday, June 19, 13:15 - 13:30, Presentation Column Number: 11 Presenter: Alexander Kostyuk, Kazakhstan
169 POSTERS
Poster Session 3 PS03 Clinical Practice Guidelines, Effectiveness, and Safety (CPGEF) PP24 Changes in Reporting Characteristics of Systematic Reviews for the UK Monday, June 19, 13:30 - 13:45, Presentation Column Number: 1 Presenter: Eva Kaltenthaler, UK
PS03 Clinical Practice Guidelines, Effectiveness, and Safety (CPGEF) PP25 Thrombopoietin Receptor Agonist for Treatment of Adults With Chronic ITP Monday, June 19, 13:30 - 13:45, Presentation Column Number: 2 Presenter: Grace Li Ying Huang, Chinese Taipei
PS03 Country-Specific and Regional HTA (CSR) PP26 Effects on Decision-Making of HTA Reports: SAGEM Examples Monday, June 19, 13:30 - 13:45, Presentation Column Number: 3 Presenter: Olgun Sener, Turkey
PS03 Developing Methods for HTA (DM) PP27 N-Of-1 Trials: A Good Tool to Evaluate the Effectiveness in Cancers Monday, June 19, 13:30 - 13:45, Presentation Column Number: 4 Presenter: Jiang Li, China
PS03 Economic Evaluation and Decision-Making (EEDM) PP28 Hyperhidrosis Quality-of-Life Measures: Review and Patient Perspective Monday, June 19, 13:30 - 13:45, Presentation Column Number: 5 Presenter: Ros Wade, UK
170 POSTERS
PS03 Economic Evaluation: Devices, Drugs, Treatments (EEDDT) PP29 Hospitalisations and Costs in Bipolar Disorder Patients Initiating Long-Acting Injectable Antipsychotics Monday, June 19, 13:30 - 13:45, Presentation Column Number: 6 Presenter: Mallik Greene, US
PS03 Economic Evaluation: Diagnostics (EED) PP30 Socioeconomics of Cardiac Rehabilitation: A Meta-Analysis Monday, June 19, 13:30 - 13:45, Presentation Column Number: 7 Presenter: Yin Ge, Japan
PS03 Hospital-Based HTA (HB) PP31 iStent® for Open-Angle Glaucoma: Standard or Emerging Care? Monday, June 19, 13:30 - 13:45, Presentation Column Number: 8 Presenter: Marc Rhainds, Canada
PS03 Integrating Regulation and HTA (Policy) (IR) PP32 Holistic Patient-Access Processes of Medical Devices in South Korea Monday, June 19, 13:30 - 13:45, Presentation Column Number: 9 Presenter: Sang-Soo Lee, Korea, Republic of
PS03 Stakeholder Involvement (SI) PP33 Patient and Public Involvement in HTA: The Brazilian Experience Monday, June 19, 13:30 - 13:45, Presentation Column Number: 10 Presenter: Aline Silva, Brazil
171 POSTERS
PS03 Value-Based Health Policy and Management (VBHPM) PP34 Are Financial Incentives Related to Doctor Prescribing Patterns? Monday, June 19, 13:30 - 13:45, Presentation Column Number: 11 Presenter: Sunmee Jang, Korea, Republic of
Poster Session 4 PS04 Clinical Practice Guidelines, Effectiveness, and Safety (CPGEF) PP35 Systematic Review of Diagnosis of C.Difficile Infection Using GDH Monday, June 19, 14:00 - 14:15, Presentation Column Number: 1 Presenter: Jinhee Jung, Korea, Republic of
PS04 Clinical Practice Guidelines, Effectiveness, and Safety (CPGEF) PP36 Systematic Review of Simultaneous Imaging Technology Monday, June 19, 14:15 - 14:30, Presentation Column Number: 1 Presenter: Jinhee Jung, Korea, Republic of
PS04 Country-Specific and Regional HTA (CSR) PP37 Quality Criteria and Good Practices in the HTA Spanish Network Monday, June 19, 14:00 - 14:15, Presentation Column Number: 3 Presenter: Sergio Márquez-Peláez, Spain
172 POSTERS
PS04 Developing Methods for HTA (DM) PP38 EQ-5D-3L Electronic Version Development for the Brazilian Population Monday, June 19, 14:00 - 14:15, Presentation Column Number: 4 Presenter: Sandro Miguel, Brazil
PS04 Economic Evaluation and Decision-Making (EEDM) PP39 Health Utility Values in Renal Cell Carcinoma: A Systematic Review Monday, June 19, 14:00 - 14:15, Presentation Column Number: 5 Presenter: Jerome Dinet, France
PS04 Economic Evaluation: Devices, Drugs, Treatments (EEDDT) PP40 Hospitalisation Costs in Schizophrenia: Long-Acting Injectable Antipsychotics Versus Oral Antipsychotic Use Monday, June 19, 14:00 - 14:15, Presentation Column Number: 6 Presenter: Mallik Greene, US
PS04 Economic Evaluation: Diagnostics (EED) PP41 Universal Coverage Through Innovative Telediagnosis Technology Monday, June 19, 14:00 - 14:15, Presentation Column Number: 7 Presenter: Pedro Galvan, Paraguay
PS04 Hospital-Based HTA (HB) PP42 Rapid HTA: No Flare Reaction With Synolis V-A in Knee Osteoarthritis Monday, June 19, 14:00 - 14:15, Presentation Column Number: 8 Presenter: Keng Ho Pwee, Singapore
173 POSTERS
PS04 Integrating Regulation and HTA (Policy) (IR) PP43 Medical Devices Under the New European Rule: Risks and Opportunities Monday, June 19, 14:00 - 14:15, Presentation Column Number: 9 Presenter: Kurt Neeser, Germany
PS04 Stakeholder Involvement (SI) PP44 Adherence to Enzyme Replacement Therapy in Gaucher Disease Monday, June 19, 14:00 - 14:15, Presentation Column Number: 10 Presenter: Paulo Picon, Brazil
PS04 Value-Based Health Policy and Management (VBHPM) PP45 From HTA Data to National Health Care Service Basket in Finland Monday, June 19, 14:00 - 14:15, Presentation Column Number: 11 Presenter: Sari Koskinen, Finland
Poster Session 5 PS05 Clinical Practice Guidelines, Effectiveness, and Safety (CPGEF) PP46 Screening in Women Vaccinated Against HPV: Governing Innovation Monday, June 19, 16:00 - 16:15, Presentation Column Number: 1 Presenter: Paolo Giorgi Rossi, Italy
174 POSTERS
PS05 Clinical Practice Guidelines, Effectiveness, and Safety (CPGEF) PP47 Intravenous Iron Sucrose Therapy in Real-World Anemic Patients Monday, June 19, 16:00 - 16:15, Presentation Column Number: 2 Presenter: Jorge Félix, Portugal
PS05 Country-Specific and Regional HTA (CSR) PP48 Quality of Health Care Through Integration: Experience of CI Monday, June 19, 16:00 - 16:15, Presentation Column Number: 3 Presenter: Aigul Medeulova, Kazakhstan
PS05 Developing Methods for HTA (DM) PP49 Exploring the Utility of a Validated Quality-Appraisal Tool Monday, June 19, 16:00 - 16:15, Presentation Column Number: 4 Presenter: Carmen Moga, Canada
PS05 Economic Evaluation and Decision-Making (EEDM) PP50 Analysis of Pharmacoeconomic and Clinical Economic Studies Published Monday, June 19, 16:00 - 16:15, Presentation Column Number: 5 Presenter: Roza Yagudina, Russia
PS05 Economic Evaluation: Devices, Drugs, Treatments (EEDDT) PP51 Cost-Effectiveness of Vedolizumab Compared With antiTNF-a Therapies Monday, June 19, 16:00 - 16:15, Presentation Column Number: 6 Presenter: Michele Basile, Italy
175 POSTERS
PS05 Hospital-Based HTA (HB) PP52 Hospital-Based HTA of Prasugrel in Patients With a Stent: Outpatient Use Monday, June 19, 16:00 - 16:15, Presentation Column Number: 7 Presenter: Marisa Santos, Brazil
PS05 Integrating Regulation and HTA (Policy) (IR) PP53 A Case Study: Collective Individual Basis for the Judiciary Debate Monday, June 19, 16:00 - 16:15, Presentation Column Number: 8 Presenter: Evelinda Trindade, Brazil
PS05 Stakeholder Involvement (SI) PP54 The All Wales PROMs, PREMs, and Effectiveness Program Monday, June 19, 16:00 - 16:15, Presentation Column Number: 9 Presenter: Kathleen Withers, UK
PS05 Value-Based Health Policy and Management (VBHPM) PP55 Coverage Under Evidence Development: Proposals From the Italian HPF Monday, June 19, 16:00 - 16:15, Presentation Column Number: 10 Presenter: Americo Cicchetti, Italy
PS05 Clinical Practice Guidelines, Effectiveness, and Safety (CPGEF) PP56 Multi-Component Interventions for Treating Obesity in Children Monday, June 19, 16:00 - 16:15, Presentation Column Number: 11 Presenter: Ida-Kristin Ørjasæter Elvsaas, Norway
176 POSTERS
Poster Session 6
PS06 Clinical Practice Guidelines, Effectiveness, and Safety (CPGEF) PP57 HTA of Trifluridine/Tipiracil for Metastatic Colorectal Cancer Monday, June 19, 18:00 - 18:15, Presentation Column Number: 1 Presenter: Anna Maria Ferriero, Italy
PS06 Country-Specific and Regional HTA (CSR) PP58 Incentives Of Pricing New Drugs Using PE Within The HTA Dossier In Taiwan Monday, June 19, 18:00 - 18:15, Presentation Column Number: 2 Presenter: Chee Jen Chang, Chinese Taipei
PS06 Developing Methods for HTA (DM) PP59 National Survey of Current UK Ambulance Service TIA Referral Pathways Monday, June 19, 18:00 - 18:15, Presentation Column Number: 3 Presenter: Chelsey Hampton, UK
PS06 Economic Evaluation and Decision-Making (EEDM) PP60 Burden of Nervous System Diseases on the Social Security System Monday, June 19, 18:00 - 18:15, Presentation Column Number: 4 Presenter: Simone Russo, Italy
PS06 Economic Evaluation: Devices, Drugs, Treatments (EEDDT) PP61 Direct Cost of Physiotherapeutic Devices Judicialization in Brazil Monday, June 19, 18:00 - 18:15, Presentation Column Number: 5 Presenter: Luciana Tarbes, Brazil
177 POSTERS
PS06 Economic Evaluation: Diagnostics (EED) PP62 Multiple Populations in a Single Economic Evaluation of CFTR Testing Monday, June 19, 18:00 - 18:15, Presentation Column Number: 6 Presenter: Camille Schubert, Australia
PS06 Hospital-Based (HB) HTA PP63 Clinical Pathway of Stroke Therapy: An Approach in HTA Monday, June 19, 18:00 - 18:15, Presentation Column Number: 7 Presenter: Rainer Riedel, Germany
PS06 Integrating Regulation and HTA (Policy) (IR) PP64 Registration of Health Care Mobile Apps in Brazil Monday, June 19, 18:00 - 18:15, Presentation Column Number: 8 Presenter: Benefran Bezerra, Brazil
PS06 Other (O) PP65 Impact of a Population-Based Cervical Cancer Programme Implementation Monday, June 19, 18:00 - 18:15, Presentation Column Number: 9 Presenter: José Asua, Spain
PS06 Stakeholder Involvement (SI) PP66 Disseminating Results Through Social Video and Social Networks Monday, June 19, 18:00 - 18:15, Presentation Column Number: 10 Presenter: Debora Egenvall, Sweden
178 POSTERS
PS06 Value-Based Health Policy and Management (VBHPM) PP67 Tuscany Technological Equipment Centralized Management Procedure Monday, June 19, 18:00 - 18:15, Presentation Column Number: 11 Presenter: Marius Spinu, Italy
Poster Session 7 PS07 Stakeholder Involvement (SI) PP68 Stakeholder Views on Peer Review of NIHR Grant Applications Monday, June 19, 18:30 - 18:45, Presentation Column Number: 1 Presenter: Sheila Turner, UK
PS07 Clinical Practice Guidelines, Effectiveness, and Safety (CPGEF) PP69 HTA of Radium-223 Dichloride in Resistant Metastatic Prostate Cancer Monday, June 19, 18:30 - 18:45, Presentation Column Number: 2 Presenter: Flavia Kheiraoui, Italy
PS07 Clinical Practice Guidelines, Effectiveness, and Safety (CPGEF) PP70 Home Mechanical Ventilation: A Health Technology Assessment Monday, June 19, 18:30 - 18:45, Presentation Column Number: 3 Presenter: Camilla Nielsen, Denmark
179 POSTERS
PS07 Country-Specific and Regional HTA (CSR) PP71 HTA in Bulgaria: A Review of the First 15 Reports Assessed Monday, June 19, 18:30 - 18:45, Presentation Column Number: 4 Presenter: Ralitsa Raycheva, Bulgaria
PS07 Developing Methods for HTA (DM) PP72 Applying Sensitivity Analysis for Robust Choice of Health Technologies Monday, June 19, 18:30 - 18:45, Presentation Column Number: 5 Presenter: Francesco Faggiano, Italy
PS07 Economic Evaluation and Decision-Making (EEDM) PP73 Cost - Effectiveness of E-SUS in the Unified Health System Monday, June 19, 18:30 - 18:45, Presentation Column Number: 6 Presenter: Weverton Rosa, Brazil
PS07 Economic Evaluation: Devices, Drugs, Treatments (EEDDT) PP74 Hormone-Dependent Metastatic Breast Cancer: Pharmacoeconomic Aspects Monday, June 19, 18:30 - 18:45, Presentation Column Number: 7 Presenter: Vasily Ryazhenov, Russia
PS07 Hospital-Based HTA (HB) PP75 Does Drug Replacement Have an Impact on Hospital Teatment? An HTA Debate Monday, June 19, 18:30 - 18:45, Presentation Column Number: 8 Presenter: Rainer Riedel, Germany
180 POSTERS
PS07 Integrating Regulation and HTA (Policy) (IR) PP76 Research on Drug Policy Changes in China Since the 2009 New Medical Reform Monday, June 19, 18:30 - 18:45, Presentation Column Number: 9 Presenter: Yingfeng Ye, China
PS07 Value-Based Health Policy and Management (VBHPM) PP77 Intravitreal Corticosteroids in Macular Edema: Quality of the Evidence Monday, June 19, 18:30 - 18:45, Presentation Column Number: 10 Presenter: Luz Irene Urbina, Italy
PS07 Value-Based Health Policy and Management (VBHPM) PP78 Centralized Approach for Health Technology Management in Tuscany Monday, June 19, 18:30 - 18:45, Presentation Column Number: 11 Presenter: Grazia Campanile, Italy
PS07 Big Data for Better HTA (BD) PP79 The Construction of Database Using Japanese National Claims Database Monday, June 19, 18:45 - 19:00, Presentation Column Number: 11 Presenter: Daisuke Sato, Japan
181 POSTERS
Poster Session 8
PS08 Clinical Practice Guidelines, Effectiveness, and Safety (CPGEF) PP80 Dementia as a Comorbidity of Diabetes in Evaluating Interventions Tuesday, June 20, 10:00 - 10:15, Presentation Column Number: 1 Presenter: Praveen Thokala, UK
PS08 Big Data for Better HTA (BD) PP81 Relation Between Pain and Treatment/Activity Based on Mobile App Data Tuesday, June 20, 10:00 - 10:15, Presentation Column Number: 2 Presenter: Tomomi Takeshima, Japan
PS08 Capacity Building in HTA (Policy) (CB) PP82 Capacity Needs Towards Increased Health Care and Networking Tuesday, June 20, 10:00 - 10:15, Presentation Column Number: 3 Presenter: John Vianney Amanya, Uganda
PS08 Clinical Practice Guidelines, Effectiveness, and Safety (CPGEF) PP83 The Use of Barbed Sutures in Partial Nephrectomy? A Systematic Review Tuesday, June 20, 10:00 - 10:15, Presentation Column Number: 4 Presenter: Yifei Lin, China
182 POSTERS
PS08 Country-Specific and Regional HTA (CSR) PP84 Diabetic Macular Edema: A Comparison Between Treatment Options Tuesday, June 20, 10:00 - 10:15, Presentation Column Number: 5 Presenter: Lucrezia Ferrario, Italy
PS08 Developing Methods for HTA (DM) PP85 A Scoping Review of Emergency Assessment and Referral of Suspected TIA Tuesday, June 20, 10:00 - 10:15, Presentation Column Number: 6 Presenter: Chelsey Hampton, UK
PS08 Developing Methods for HTA (DM) PP86 Horizon Scanning in Multiple Sclerosis Decisions in Brazil Tuesday, June 20, 10:00 - 10:15, Presentation Column Number: 7 Presenter: Pollyanna Gomes, Brazil
PS08 Economic Evaluation and Decision-Making (EEDM) PP87 A Tool of Transferibility of Cost-Utility Analysis of High Cost Drugs Tuesday, June 20, 10:00 - 10:15, Presentation Column Number: 8 Presenter: Alicia Aleman, Uruguay
PS08 Economic Evaluation: Devices, Drugs, Treatments (EEDDT) PP88 CEA of Caspofungin Vs. Voriconazole for Empirical Antifungal Therapy Tuesday, June 20, 10:00 - 10:15, Presentation Column Number: 9 Presenter: Yan Wei, China
183 POSTERS
PS08 Hospital-Based HTA (HB) PP89 HTA of an Automated Compounding of Parenteral Nutrition Tuesday, June 20, 10:00 - 10:15, Presentation Column Number: 10 Presenter: Francesco Faggiano, Italy
PS08 Clinical Practice Guidelines, Effectiveness, and Safety (CPGEF) PP90 Reduccing Low-Value Practices in Catalonia: Essencial Project Tuesday, June 20, 10:00 - 10:15, Presentation Column Number: 11 Presenter: Johanna Caro, Spain
PS08 Developing Methods for HTA (DM) PP91 A Follow-Up Study on Transcatheter Aortic Valve Implantation (TAVI) Tuesday, June 20, 10:15 - 10:30, Presentation Column Number: 11 Presenter: Silvana Marcia Bruschi Kelles, Brazil
Poster Session 9
PS09 Big Data for Better HTA (BD) PP92 Real-World Data: Biologic Treatment for Naive Patients in Lazio Region Tuesday, June 20, 13:00 - 13:15, Presentation Column Number: 1 Presenter: Paolo Sciattella, Italy
184 POSTERS
PS09 Capacity Building in HTA (Policy) (CB) PP93 Bringing Evidence on Prevention Programs Cost-Effectiveness Tuesday, June 20, 13:00 - 13:15, Presentation Column Number: 2 Presenter: Silvie Jerabkova, Czech Republic
PS09 Clinical Practice Guidelines, Effectiveness, and Safety (CPGEF) PP94 Autologous Stem Cell Transplantation for Multiple Sclerosis Tuesday, June 20, 13:00 - 13:15, Presentation Column Number: 3 Presenter: Liv Giske, Norway
PS09 Clinical Practice Guidelines, Effectiveness, and Safety (CPGEF) PP95 Assessment of Magmaris Resorbable Metal Stent in Patients With Angina Tuesday, June 20, 13:00 - 13:15, Presentation Column Number: 4 Presenter: Luis María Sánches-Gómez, Spain
PS09 Country-Specific and Regional HTA (CSR) PP96 EU-HTAs for Medical Devices: How to Overcome Reimbursement Divergence Tuesday, June 20, 13:00 - 13:15, Presentation Column Number: 5 Presenter: Jana Hemmerling, Germany
PS09 Developing Methods for HTA (DM) PP97 Challenges of Rapid Reviews in HTA: Case Study From an Italian Region Tuesday, June 20, 13:00 - 13:15, Presentation Column Number: 6 Presenter: Antonella Negro, Italy
185 POSTERS
PS09 Developing Methods for HTA (DM) PP98 Evaluation of Breast Cancer Diagnosis Process for Decision-Making Tuesday, June 20, 13:00 - 13:15, Presentation Column Number: 7 Presenter: Lizbeth Acuña Merchán, Colombia
PS09 Economic Evaluation and Decision-Making (EEDM) PP99 Development of Interface to Reactivate Old-Generation Gamma Cameras Tuesday, June 20, 13:00 - 13:15, Presentation Column Number: 8 Presenter: César Yegros, Paraguay
PS09 Economic Evaluation: Devices, Drugs, Treatments (EEDDT) PP100 Economic Evaluation of a New Non-Antibiotic First-Line Treatment of rUTI Tuesday, June 20, 13:00 - 13:15, Presentation Column Number: 9 Presenter: Marianna Mauro, Italy
PS09 Hospital-Based HTA (HB) PP101 A Procedural Method for Networking Local and Regional Stakeholders Tuesday, June 20, 13:00 - 13:15, Presentation Column Number: 10 Presenter: Pierre Dagenais, Canada
PS09 Stakeholder Involvement (SI) PP102 Perceived Quality by Patients Hospitalised at Home Undergoing Domicil Tuesday, June 20, 13:00 - 13:15, Presentation Column Number: 11 Presenter: Ottavio Davini, Italy
186 POSTERS
PS09 Other (O) PP103 Characteristics of Systems Applied to Language Rehabilitation Tuesday, June 20, 13:15 - 13:30, Presentation Column Number: 11 Presenter: José Núñez, Paraguay
Poster Session 10 PS10 Big Data for Better HTA (BD) PP104 Brazilian Health Council Monitoring System (SIACS): An Assessment Tuesday, June 20, 13:30 - 13:45, Presentation Column Number: 1 Presenter: Danylo Vilaça, Brazil
PS10 Capacity Building in HTA (Policy) (CB) PP105 National HTA R&D Development for Evidence-Based Health Care Tuesday, June 20, 13:30 - 13:45, Presentation Column Number: 2 Presenter: Sukyeong Kim, Brazil
PS10 Clinical Practice Guidelines, Effectiveness, and Safety (CPGEF) PP106 Regional Guidance on Aids for Ostomy Tuesday, June 20, 13:30 - 13:45, Presentation Column Number: 3 Presenter: Anna Cavazzana, Italy
187 POSTERS
PS10 Clinical Practice Guidelines, Effectiveness, and Safety (CPGEF) PP107 Amiodarone for Arrhythmia in Chagas Patients: A Systematic Review Tuesday, June 20, 13:30 - 13:45, Presentation Column Number: 4 Presenter: Luciane Cruz, Brazil
PS10 Country-Specific and Regional HTA (CSR) PP108 HTA Educational Programs in the Russian Federation Tuesday, June 20, 13:30 - 13:45, Presentation Column Number: 5 Presenter: Roza Yagudina, Russia
PS10 Developing Methods for HTA (DM) PP109 Horizon Scanning for Information-Providing in Brazil Tuesday, June 20, 13:30 - 13:45, Presentation Column Number: 6 Presenter: Pollyanna Gomes, Brazil
PS10 Economic Evaluation: Devices, Drugs, Treatments (EEDDT) PP110 Economic Impact of Therapeutic Regime Reduction in the HCV Infection Tuesday, June 20, 13:30 - 13:45, Presentation Column Number: 7 Presenter: Giulia Valinotti, Italy
PS10 Hospital-Based HTA (HB) PP111 The Use of Long-Acting Injectable Antipsychotics in Schizophrenia Tuesday, June 20, 13:30 - 13:45, Presentation Column Number: 8 Presenter: Chiara Bini, Italy
188 POSTERS
PS10 Information Search and Knowledge Transfer (ISKT) PP112 Cost-Effectiveness Strategies for Homeless Persons With Tuberculosis Tuesday, June 20, 13:30 - 13:45, Presentation Column Number: 9 Presenter: Ana Carolina Pereira, Brazil
PS10 Other (O) PP113 hsCRP Measurements and Burden in Patients With History of MI Tuesday, June 20, 13:30 - 13:45, Presentation Column Number: 10 Presenter: Ramandeep Jindal, India
PS10 Stakeholder Involvement (SI) PP114 MCDA to Explore GEP-NET Decision Criteria With Patients and Clinicians Tuesday, June 20, 13:30 - 13:45, Presentation Column Number: 11 Presenter: Dima Samaha, UK
Poster Session 11
PS11 Stakeholder Involvement (SI) PP115 Patient and Public Involvement in HTA: Update of a Systematic Review Tuesday, June 20, 14:00 - 14:15, Presentation Column Number: 1 Presenter: Marie-Pierre Gagnon, Canada
189 POSTERS
PS11 Big Data for Better HTA (BD) PP116 Data Linkage Across Ambulance Services and Emergency Departments Tuesday, June 20, 14:00 - 14:15, Presentation Column Number: 2 Presenter: Alison Porter, UK
PS11 Clinical Practice Guidelines, Effectiveness, and Safety (CPGEF) PP117 Isosorbide and Nifedipine in Chagas Patients: A Systematic Review Tuesday, June 20, 14:00 - 14:15, Presentation Column Number: 3 Presenter: Luciane Cruz, Brazil
PS11 Clinical Practice Guidelines, Effectiveness, and Safety (CPGEF) PP118 PlasmaJetTM as a Novel Surgical Approach to Ovarian Cancer Debulking Tuesday, June 20, 14:00 - 14:15, Presentation Column Number: 4 Presenter: Mar Polo-Desantos, Spain
PS11 Country-Specific and Regional HTA (CSR) PP119 HTA in the Mandatory Social Health Insurance Conditions Tuesday, June 20, 14:00 - 14:15, Presentation Column Number: 5 Presenter: Kamilla Gaitova, Kazakhstan
PS11 Developing Methods for HTA (DM) PP120 Developing Methods for HTA Tuesday, June 20, 14:00 - 14:15, Presentation Column Number: 6 Presenter: Mondher Toumi, France
190 POSTERS
PS11 Economic Evaluation: Devices, Drugs, Treatments (EEDDT) PP121 Cost Analysis of the Pharmaceutical Care in Type 2 Diabetes Mellitus Tuesday, June 20, 14:00 - 14:15, Presentation Column Number: 7 Presenter: Renato Picoli, Brazil
PS11 Ethical, Social, and Legal Issues in HTA (ESL) PP122 Strengthening Ethics Compliance in a Large Research Program: Uganda Tuesday, June 20, 14:00 - 14:15, Presentation Column Number: 8 Presenter: Sylvia Nabukenya, Uganda
PS11 Hospital-Based HTA (HB) PP123 Medical Devices Exclusivity: The Impact of HB-HTA on Procurement Tuesday, June 20, 14:00 - 14:15, Presentation Column Number: 9 Presenter: Corrado Gemma, Italy
PS11 Other (O) PP124 The HTAi Vortal: A Comparative Analysis Tuesday, June 20, 14:00 - 14:15, Presentation Column Number: 10 Presenter: Patrice Chalon, Belgium
PS11 Stakeholder Involvement (SI) PP125 Evidence-Based Policy-Making: Bottom-Up Heuristic Engagement Process Tuesday, June 20, 14:00 - 14:15, Presentation Column Number: 11 Presenter: Evelinda Trindade, Brazil
191 POSTERS
Roche HTAI 2017 Ad 2017-05-24_v0.4_Print.pdf 1 24/05/2017 14:52
Using Real World Data to make Join our panel of flexible payment experts from across models work Europe for a lively discussion of real-world for everyone: experience in implementing learnings and flexible payment models, challenges moderated by: Clifford GOODMAN Senior Vice President, The Lewin Group Monday June 19th, 16.30-18.00 Ergife Palace Hotel, Rome
192 POSTERS
Poster Session 12
PS12 Big Data for Better HTA (BD) PP126 MEA in Italy: Correlation Between Time to PbR and TTOT Curve Tuesday, June 20, 16:00 - 16:15, Presentation Column Number: 1 Presenter: Gabriele Vittoria, Italy
PS12 Clinical Practice Guidelines, Effectiveness, and Safety (CPGEF) PP127 Organising Home Mechanical Ventilation: Lessons From Denmark Tuesday, June 20, 16:00 - 16:15, Presentation Column Number: 2 Presenter: Camilla Nielsen, Denmark
PS12 Clinical Practice Guidelines, Effectiveness, and Safety (CPGEF) PP128 Regional Guidance on Spinal Cord Stimulation for Chronic Pain Tuesday, June 20, 16:00 - 16:15, Presentation Column Number: 3 Presenter: Anna Cavazzana, Italy
PS12 Developing Methods for HTA (DM) PP129 Methodological Issues With Assessing Newborn Screening Tests Tuesday, June 20, 16:00 - 16:15, Presentation Column Number: 4 Presenter: Bing Guo, Canada
PS12 Ethical, Social, and Legal Issues in HTA (ESL) PP130 Nudging in Public Health: Accountability for Practical Wisdom Tuesday, June 20, 16:00 - 16:15, Presentation Column Number: 5 Presenter: Michal Stanak, Austria
193 POSTERS
PS12 Hospital-Based HTA (HB) PP131 A Process for Rational Use of Vitamin D Testing in a Training and Rese Tuesday, June 20, 16:00 - 16:15, Presentation Column Number: 6 Presenter: Nadi Yüksek, Turkey
PS12 Information Search and Knowledge Transfer (ISKT) PP132 Using HTA for Managing Health Care Information Systems Tuesday, June 20, 16:00 - 16:15, Presentation Column Number: 7 Presenter: Fabrizio Massimo Ferrara, Italy
PS12 Stakeholder Involvement (SI) PP134 Does SDM Influence Upon the Adoption of New Health Technologies Tuesday, June 20, 16:00 - 16:15, Presentation Column Number: 9 Presenter: Yan Wei, China
PS12 Stakeholder Involvement (SI) PP135 Stakeholder Involvement in an HTA Assessment of Hyperhidrosis Tuesday, June 20, 16:00 - 16:15, Presentation Column Number: 10 Presenter: Ros Wade, UK
PS12 Other (O) PP136 The Effect of the Rational Medical Devices Management on Sustainability Tuesday, June 20, 16:00 - 16:15, Presentation Column Number: 11 Presenter: Gulcan Tecirli, Turkey
194 POSTERS
PS12 Country-Specific and Regional HTA (CSR) PP137 Regional Process for Planning Medical Equipment Procurement in Italy Tuesday, June 20, 16:00-16:15, Presentation Column Number: 8 Presenter: Mario Fregonara Medici, Italy
Poster Session 13
PS13 Big Data for Better HTA (BD) PP138 AIFA Registries Distribution by MEA and by Therapeutic Area Tuesday, June 20, 18:00 - 18:15, Presentation Column Number: 1 Presenter: Gabriele Vittoria, Italy
PS13 Clinical Practice Guidelines, Effectiveness, and Safety (CPGEF) PP140 Effectiveness of Tele-Monitoring Interventions for Asthma Tuesday, June 20, 18:00 - 18:15, Presentation Column Number: 3 Presenter: Youjin Jung, Korea, Republic of
PS13 Ethical, Social, and Legal Issues in HTA (ESL) PP141 Legal Governance: How Does Law Circumscribe the Social Role of HTA? Tuesday, June 20, 18:00 - 18:15, Presentation Column Number: 4 Presenter: Louise Bernier, Canada
195 POSTERS
PS13 Hospital-Based HTA (HB) PP142 A Mental Health HB-HTA in Quebec, Canada: Structure and Products Tuesday, June 20, 18:00 - 18:15, Presentation Column Number: 5 Presenter: Ionela Gheorghiu, Canada
PS13 Information Search and Knowledge Transfer (ISKT) PP143 Investigating the Transferability of Test Accuracy for Decision-Making Tuesday, June 20, 18:00 - 18:15, Presentation Column Number: 6 Presenter: Karoline Freeman, UK
PS13 Integrating Regulation and HTA (Policy) (IR) PP144 Challenge for Health Technology Assessment and the Coverage Decision Tuesday, June 20, 18:00 - 18:15, Presentation Column Number: 7 Presenter: Su-Jin Cho, Korea, Republic of
PS13 Other (O) PP145 SIR-Spheres Y-90 Resin Microspheres in Patients With mCRCi Tuesday, June 20, 18:00 - 18:15, Presentation Column Number: 8 Presenter: Silvia Coretti, Italy
PS13 Stakeholder Involvement (SI) PP146 Patient-Perceived Quality in Week Multi-Specialty Surgery Tuesday, June 20, 18:00 - 18:15, Presentation Column Number: 9 Presenter: Giovanna Mulloni, Italy
196 POSTERS
PS13 Stakeholder Involvement (SI) PP147 Physician and Patient-Reported Anxiety and Depression in Haemophilia Tuesday, June 20, 18:00 - 18:15, Presentation Column Number: 10 Presenter: Mark Skinner, US
PS13 Stakeholder Involvement (SI) PP148 Development and Evaluation of a Tool Supporting Prescription Behaviour Tuesday, June 20, 18:00 - 18:15, Presentation Column Number: 11 Presenter: Valentina Lorenzoni, Italy
Poster Session 14
PS14 Big Data for Better HTA (BD) PP149 Assessment of New Medical Devices With Administrative Databases Tuesday, June 20, 18:30 - 18:45, Presentation Column Number: 1 Presenter: Giuditta Callea, Italy
PS14 Capacity Building in HTA (Policy) (CB) PP150 Rapid Analgesia for Pre-Hospital Hip Disruption: A Feasibility Study Tuesday, June 20, 18:30 - 18:45, Presentation Column Number: 2 Presenter: Jenna Bulger, UK
197 POSTERS
PS14 Capacity Building in HTA (Policy) (CB) PP151 Strategy for Decision-Making of Health Technology Assessment Tuesday, June 20, 18:30 - 18:45, Presentation Column Number: 3 Presenter: Su-Jin Cho, Korea, Republic of
PS14 Clinical Practice Guidelines, Effectiveness, and Safety (CPGEF) PP152 HTA of the Combination of Elbasvir/Grazoprevir Tuesday, June 20, 18:30 - 18:45, Presentation Column Number: 4 Presenter: Andrea Poscia, Italy
PS14 Clinical Practice Guidelines, Effectiveness, and Safety (CPGEF) PP153 Loxapine Inhalation Powder for Agitation Control in Mental Illnesses Tuesday, June 20, 18:30 - 18:45, Presentation Column Number: 5 Presenter: Marta Marino, Italy
PS14 Developing Methods for HTA (DM) PP154 Developing HTA Designs for E-Health: A Systematic Review of Reviews Tuesday, June 20, 18:30 - 18:45, Presentation Column Number: 6 Presenter: Anne Ekeland, Norway
PS14 Ethical, Social, and Legal Issues in HTA (ESL) PP155 The Impact of Lawsuits in the Brazilian Public Health System Tuesday, June 20, 18:30 - 18:45, Presentation Column Number: 7 Presenter: Carla Biella, Brazil
198 POSTERS
PS14 Hospital-Based HTA (HB) PP156 New Information and Communication Technologies and Hospital Design Tuesday, June 20, 18:30 - 18:45, Presentation Column Number: 8 Presenter: Eduardo Alves, Brazil
PS14 Information Search and Knowledge Transfer (ISKT) PP157 The Value-Based Model: Which Lessons From Multiple Myeloma Tuesday, June 20, 18:30 - 18:45, Presentation Column Number: 9 Presenter: Marco Rizzo, Italy
PS14 Stakeholder Involvement (SI) PP158 Monitoring the HAS Initiative on Patient Contribution to Rapid HTA Tuesday, June 20, 18:30 - 18:45, Presentation Column Number: 10 Presenter: Hervé Nabarette, France
PS14 Stakeholder Involvement (SI) PP159 Children With Rare Chromosome Disorders: Families’ Experiences Tuesday, June 20, 18:30 - 18:45, Presentation Column Number: 11 Presenter: Ala Szczepura, UK
PS14 Country-Specific and Regional HTA (CSR) PP160 The Pilot Implementation and Future Challenges of Japan-Specific HTA Tuesday, June 20, 18:45 - 19:00, Presentation Column Number: 11 Presenter: Isao Kamae, Japan
199 POSTERS
Poster Sessions 15
PS15 Big Data for Better HTA (BD) PP161 Prevalence and Characteristics of Drug-Induced Parkinsonism (DIP) Wednesday, June 21, 10:00 - 10:15, Presentation Column Number: 1 Presenter: Sunmee Jang, Korea, Republic of
PS15 Clinical Practice Guidelines, Effectiveness, and Safety (CPGEF) PP162 Hydroxyurea Adherence Among Patients With Sickle Cell Disease Wednesday, June 21, 10:00 - 10:15, Presentation Column Number: 2 Presenter: Camila Ribeiro, Brazil
PS15 Clinical Practice Guidelines, Effectiveness, and Safety (CPGEF) PP163 Long-Term Outcomes of ESD for EGC in Korea Wednesday, June 21, 10:00 - 10:15, Presentation Column Number: 3 Presenter: Chanmi Park, Korea, Republic of
PS15 Country-Specific and Regional HTA (CSR) PP164 SSB Consumption and Price Sensitivity Among Brazilians Wednesday, June 21, 10:00 - 10:15, Presentation Column Number: 4 Presenter: Larissa Cardoso, Brazil
PS15 Ethical, Social, and Legal Issues in HTA (ESL) PP165 A Strategy to Face Judicialization of the Right of Health Wednesday, June 21, 10:00 - 10:15, Presentation Column Number: 5 Presenter: Alicia Aleman, Uruguay
200 POSTERS
PS15 Hospital-Based HTA (HB) PP166 From an Institutional Strategic Plan to a KT Tool for HTA: Case of DES Wednesday, June 21, 10:00 - 10:15, Presentation Column Number: 6 Presenter: Thomas Poder, Canada
PS15 Hospital-Based HTA (HB) PP167 Health Technology Assessment Nucleus in a Reference Hospital in Brazil Wednesday, June 21, 10:00 - 10:15, Presentation Column Number: 7 Presenter: Maria Angélica Ferreira, Brazil
PS15 Information Search and Knowledge Transfer (ISKT) PP168 Combination Therapy Versus Intensification of Statin Monotherapy Wednesday, June 21, 10:00 - 10:15, Presentation Column Number: 8 Presenter: Hela Grati, Tunisia
PS15 Other (O) PP169 Risks and Barriers For Adopting Internet of People In Healthcare Wednesday, June 21, 10:00 - 10: 15, Presentation Column Number: 9 Presenter: Eva Turk, Tunisia
PS15 Stakeholder Involvement (SI) PP170 Health Impact Assessment of Teleradiology Programs in Disadvantaged Areas Wednesday, June 21, 10:00 - 10: 15, Presentation Column Number: 10 Presenter: Ottavio Davini, Italy
201 POSTERS
PS15 Stakeholder Involvement (SI) PP171 Immuno-Oncology: A Patient Perspective Wednesday, June 21, 10:00 - 10:15, Presentation Column Number: 11 Presenter: Judith Rubinstein, US
PS15 Stakeholder Involvement (SI) PP172 Recruiting Academic Physicians Without Financial Conflict of Interest Wednesday, June 21, 10:15 - 10:30, Presentation Column Number: 11 Presenter: Stéphanie Luzio, France
Integrated reimbursement, regulatory and pricing data to inform pricing decisions.
202 POSTERS
CHANGING THE HTA PARADIGM: BEYOND CLINICAL AND ECONOMIC EVALUATION FOR INNOVATIVE DRUGS A symposium sponsored by Takeda Pharmaceuticals International
Ergife Palace Hotel, Rome, Italy Tuesday, June 20th 4:30 PM to 6 PM
Invited speakers: Focus on: Dr Andrew Walker The impact of insisting on a singlecost-effectiveness PhD, Former assessor at the Scottish Medical threshold or the use of multiple criteria for the Consortium, Scotland, UK. reimbursement of innovative drugs, in particular combination oncology therapies. Hanim Edoo MSc, Early Engagement & Patient Access • Does the use of a single cost-effectiveness Consultant at Medi-Qualite Omega, Paris, threshold facilitate patient access to France. innovative drugs? • Is there a better approach which would Prof Claudio Jommi respect budgets and provide access? MSc, Associate Professor of Management, • Should HTA agencies find other ways to assess Università del Piemonte Orientale, Novara, Italy. combination therapies in oncology? Prof J. Jaime Caro • Is it acceptable from a societal perspective to MDCM, FCRPC, FACP, Chief Scientist at Evidera, set different rules for innovative drugs? Boston, MA, USA. • What can be learned from different countries and experiences? Moderator: Dr Mark Ratcliffe PhD, Managing Director, PHMR Ltd. UK.
203 POSTERS
204 Sponsors / Exhibitors
PLATINUM SPONSORS
Platinum Sponsors
Italian Medicines Agency (AIFA) Angelini Contact name: Simona Montilla Contact name: Marco Soro Contact email: [email protected] Contact email: [email protected] Contact phone: 39 06 597 8401 Contact phone: 39 06 78 0531 www.aifa.gov.it www.angelinipharma.com
The Italian Medicines Agency (AIFA) is the Angelini is a private international national authority responsible for regulation, company and a leader in both health pricing, and reimbursement decisions care and wellness solutions. The group for medicinal products. AIFA guarantees employs about 5,000 people with an access to medicines and their safe and annual turnover of more than 1.6 billion appropriate use; ensures the unity of the euros. Angelini is strongly committed national pharmaceutical system; and the to helping patients and their caregivers innovation, efficiency, and simplification fight illnesses with continuous efforts of marketing authorization procedures in the areas of inflammation, chronic to grant rapid access to innovative drugs and acute pain, infectious diseases, and orphan drugs for rare diseases. AIFA neuro-science, supportive onco, and is also responsible for the governance of disinfection. pharmaceutical expenditures, encourages investment in R&D, funds independent Exhibit Location: research programmes, interacts with civil Lower Level -2, Booth 1 society, and promotes an independent pharmaceutical culture.
Exhibit Location: Lower Level -2, Booth 6
207 PLATINUM SPONSORS
CADTH ECRI Institute Contact name: Josee Nugent Contact name: Michael Stewart Contact email: [email protected] Contact email: [email protected] Contact phone: 1 613 226 4969 ext. 1545 Contact phone: 44 (0)1707 831001 www.cadth.ca www.ecri.org.uk
CADTH is an independent, not-for-profit ECRI is a not-for-profit and independent organisation responsible for providing institution with a clear objective: to Canada’s health care decision-makers advance patient care by improving the with objective evidence to help make effectiveness, safety, and economy of informed decisions about the optimal health services. use of drugs and medical devices. CADTH receives funding from Canada’s Over 5,000 customers benefit from our federal, provincial, and territorial advice, nearly 50 years of experience, governments, with the exception and comprehensive online tools offering of Quebec. unbiased, expert support and guidance.
Exhibit Location: Our expert HTA team provides Lower Level -1, Booth 18 comprehensive custom research support and information tools for evidence-based decision-making on new, emerging, and existing medical devices and procedures.
Exhibit Location: Lower Level -1, Booth 11
208 PLATINUM SPONSORS
Eli Lilly and Company Istituto Superiore di Contact name: David Grainger Sanità (ISS) Contact email: [email protected] Contact name: Marco Marchetti Contact phone: 61(2) 93254544 Contact email: [email protected] www.lilly.com Contact phone: 39 06 49901 Eli Lilly and Company is a global www.iss.it pharmaceutical corporation The Italian National Institute of Health headquartered in the US in Indianapolis, (Istituto Superiore di Sanità [ISS]) is the Indiana. Lilly unites caring with discovery main Italian research institute in the to make life better for people around biomedical and public health fields. It is the world. We make medicines that help the technical and scientific body of the people live longer, healthier, and more Italian National Health Service (Servizio active lives. Sanitario Nazionale [SSN]).
Exhibit Location: Lower Level -1, Booth 19
209 PLATINUM SPONSORS
MSD Italian Ministry of Health Contact name: Kathleen Grilli Contact name: Alfredo Dari Contact email: [email protected] Contact email: [email protected] Contact phone: 1 267 305 8921 Contact phone: 39 06 5994 3423 www.merck.com www.salute.gov.it
For more than a century, MSD, a leading Health is a fundamental right of each global biopharmaceutical company, has been individual in the interest of society. In inventing for life, bringing forward medicines and vaccines for the world’s most challenging accordance with this principle, Italian diseases. MSD is a trade name of Merck & health care system is based on the Co., Inc., with headquarters in the United National Health Service, founded on States in Kenilworth, New Jersey. Through the principles of universal coverage our prescription medicines, vaccines, biologic and organised in three levels: national, therapies and animal health products, we work with customers and operate in more regional, and local. The national level than 140 countries to deliver innovative is responsible for ensuring the general health solutions. We also demonstrate objectives and fundamental principles our commitment to increasing access to of the national health care system. The health care through far-reaching policies, main central institution is the Ministry programmes and partnerships. Today, MSD continues to be at the forefront of research of Health. to advance the prevention and treatment of diseases that threaten people and communities Exhibit Location: around the world, including cancer, cardio- Lower Level -2, Booth 5 metabolic diseases, emerging animal diseases, Alzheimer’s disease and infectious diseases, including HIV and Ebola.
Exhibit Location: Lower Level -1, Booth 20
210 PLATINUM SPONSORS
Mundipharma PhRMA International Limited Contact name: Kevin Haninger Contact email: [email protected] Contact name: Tirzah Webb Contact phone: 1 202 835 3519 Contact email: [email protected] www.phrma.org Contact phone: 44 (0) 1223 397470 PhRMA represents the country’s leading www.mundipharma.com innovative biopharmaceutical research Mundipharma International Limited companies, which are devoted to is a privately owned company that discovering and developing medicines forges successful partnerships to bring that enable patients to live longer, pharmaceutical products to market, healthier and more productive lives. ensuring patients are able to access Since 2000, PhRMA member companies them when this is clinically appropriate. have invested more than half a trillion A key area of expertise is in managing dollars in the search for new treatments health technology assessment (HTA) and cures, including an estimated and market access by ensuring the right $58.8 billion in 2015 alone. evidence is available for health services to make informed decisions. Exhibit Location: Lower Level -1, Booth 14 Exhibit Location: Lower Level -1, Booth 21
211 PLATINUM SPONSORS
UNIVERSITÀ CATTOLICA del Sacro Cuore
ALTA SCUOLA DI ECONOMIA E MANAGEMENT DEI SISTEMI SANITARI
SIHTA ALTEMS Contact name: Americo Cicchetti Contact name: Alessandra Gioia Contact email: [email protected] Contact email: [email protected] Contact phone: 39 06 3105 2392 Contact phone: 39 06 30155863 www.sihta.it www.altems.unicatt.it
The Italian Society of Health Technology ALTEMS is the result of a common Assessment (SIHTA) was founded in scientific collaboration that involves the 2006 to support and promote the HTA faculty of Economics and the A. Gemelli approach within the Italian National Faculty of Medicine and Surgery at the Health Service (NHS). In particular, it Catholic University of Rome (Italy), explores relevant issues related to the in cooperation with the Hospital implementation or disinvestment of Foundation Policlinico Agostino Gemelli. health technologies in Italian health It provides graduate, post-graduate, care organisations through a multi- dimensional and multi-stakeholder and executive programmes in the fields process. Since 2010, SIHTA has been of health economics and health care running the Italian Health Policy Forum, management in both Italian and English. which gathers payers, health care The educational programmes are managers, patient groups, and industry innovative and constantly updated, in a strategic and structured discussion thanks to the participation of ALTEMS on the role of HTA in the Italian National researchers in national, European, and Healthcare Service. international research projects.
Exhibit Location: Lower Level -2, Booth 3
212 GOLD SPONSORS
Gold Sponsors
Boston Scientific Edwards Lifesciences Contact name: Mary Gerrans Contact name: Kim Salata Contact email: [email protected] Contact email: [email protected] Contact phone: 1 508 683 5628 Contact phone: 1 949 250 5826 www.bostonscientific.com www.edwards.com
Boston Scientific (NYSE: BSX) transforms Edwards Lifesciences is the global leader lives through innovative medical in patient-focused medical innovations solutions that improve the health of for structural heart disease, as well as patients around the world. As a global critical care and surgical monitoring. medical technology leader for more Driven by a passion to help patients, the than 35 years, we advance science for company collaborates with the world’s life by providing a broad range of high leading clinicians and researchers to performance solutions that address address unmet health care needs, unmet patient needs and reduce the working to improve patient outcomes cost of health care. and enhance lives.
213 GOLD SPONSORS
Pfizer Sanofi Genzyme Contact name: Joe Cook Contact name: Marie-Laure Prud’homme Contact email: [email protected] Contact email: Contact phone: 1 212 733 2323 [email protected] www.pfizer.com Contact phone: 33 (0) 1 53 77 88 44 www.sanofigenzyme.com
Genzyme has pioneered the development and delivery of transformative therapies for patients affected by rare and debilitating diseases for over 30 years. With a focus on rare diseases and multiple sclerosis, we are dedicated to making a positive impact on the lives of the patients and families we serve.
214 SILVER SPONSORS
Silver Sponsors
Context Matters Data-driven insights to create consistency and accelerate Contact name: Joan Gaffney technology assessments. Contact email: [email protected] • Agency benchmarking Contact number: 1 646 863 3688 • Policy analysis contextmatters.com • Internal process and decision tracking Context Matters modernizes and improves the process of valuing drug therapies, empowering life sciences DOWNLOAD OUR organisations to achieve optimal reimbursement for their innovation. INDUSTRY REPORT The Context Matters Market Access Platform (MAP) is a disruptive innovation RESEARCHED AND that provides pharmaceutical and DEVELOPED FOR biotechnology companies direct access to the insights they need to inform key HTAi 2017 product development decisions and gain optimal reimbursement value.
Exhibit Location: Lower Level -1, Booth 13 contextmatters.com/htai2017
Visit us at Booth 13 on Level -1
215 SYMPOSIA SPONSORS
Symposia Sponsors
Roche Takeda Pharmaceutical Contact name: Michael Schröter Company Limited Contact email: [email protected] Contact name: Marina Kern Contact phone: 41 61 688 72 03 Contact email: [email protected] www.roche.com Contact phone: 41 (0)44 555 1148 Roche is a global pioneer in www.takeda.com pharmaceuticals and diagnostics Takeda Pharmaceutical Company focused on advancing science to Limited is a global research- and improve people’s lives. Roche is the development-driven pharmaceutical world’s largest biotech company, company committed to bringing better with truly differentiated medicines in health and a brighter future to patients oncology, immunology, infectious by translating science into life-changing diseases, ophthalmology and diseases medicines. Takeda focuses its R&D of the central nervous system. efforts on oncology, gastroenterology, and central nervous system therapeutic areas, plus vaccines. Takeda conducts R&D both internally and with partners to stay at the leading edge of innovation. New innovative products, especially in oncology and gastroenterology, as well as our presence in emerging markets, fuel the growth of Takeda. More than 30,000 Takeda employees are committed to improving quality of life for patients, working with our partners in health care in more than 70 countries.
216 EXHIBITORS
Exhibitors
INAHTA Cochrane
Contact name: Tara Schuller Contact name: Charlotte Pestridge Contact email: [email protected] Contact email: [email protected] Contact phone: 1 780 401 1770 Contact phone: 44 (0) 207 183 7503 www.inahta.org www.cochrane.org
The International Network of Agencies Cochrane is a global independent for Health Technology Assessment network of researchers, professionals, (INAHTA) is a network of 51 publicly patients, carergivers, and people funded HTA agencies that support interested in health. Cochrane produces health system decision-making that reviews that study all of the best affects over one billion people in 31 countries around the globe. INAHTA available evidence generated through brings HTA agencies together to share research and make it easier to inform knowledge and tools to strengthen decisions about health. We offer a range their role as essential contributors to of systematic review services tailored to health outcomes and health system the needs of commissioners. sustainability. Exhibit Location: Exhibit Location: Lower Level -1, Booth 12 Lower Level -1, Booth 16
217 EXHIBITORS
Decision Resources Galbraith Wight Group (DRG) Contact name: Fiona Warren Contact email: [email protected] Contact name: Ivanka Vankova Contact phone: 39 02 5755 41 Contact email: [email protected] Contact phone: 01869 241281 www.galbraithwight.com www.decisionresourcesgroup.com/ Galbraith Wight is a global strategic Abacus market access consultancy with 20 years of thought leadership partnering with Decision Resources Group (DRG) pharmaceutical and biotechnology is a global provider of health care clients. We are experts in value analytics, data and insight products, strategy based on in-depth customer and consulting services to the world’s insights, creating value through leading pharmaceutical, biotechnology, clinical and HEOR evidence; achieving and medical technology companies. successful pricing, reimbursement, and funding approval; and brand launch The DRG Abacus team provides and commercialisation. We have integrated health economics and unparalleled expertise in building market outcomes research, and market-access access and commercial capabilities for solutions throughout the product life global, regional, and country teams. cycle. We have extensive experience in developing successful and supported evidence dossiers for submission to Exhibit Location: HTA bodies around the globe. Lower Level -2, Booth 7
Exhibit Location: Lower Level -2, Booth 9
218 EXHIBITORS
MA Provider QuintilesIMS Contact name: Silvia Mascoli Contact name: Angelika Boucsein Contact email: [email protected] Contact email: Contact phone: 39 02 36597962 [email protected] www.maprovider.com Contact phone: 49 69 66044332 www.quintilesims.com Since 2010, MA Provider has been one of the major consulting companies in QuintilesIMS helps customers drive health care. We are located in Italy, with health care forward by combining data, a focus on market access and public technology, and services in new ways. affairs. With iso 9001:2015 certification, From clinical to commercial to real- we combine our expertise in pricing, world insights, we help improve clinical HE, national and regional market access, trials, patient outcomes, economic and public affairs and communication, modelling, and market access. offering excellence in quality and speed, putting our customers’ needs Exhibit Location: at the centre of our activity. We are Lower Level -2, Booth 8 focused mainly on specialty care drugs (oncology, rare diseases, infections, biotechnology), medical devices and, most recently, on ATMPs.
Exhibit Location: Lower Level -2, Booth 2
219 OTHER CONTRIBUTIONS Other Contributions
Swedish Agency for Health European Federation of Technology Assessemt Pharmaceutical Industries and Assessment of Social and Associations (EFPIA) Services (SBU) Contact name: Fabienne Muylle Contact name: Jessica Tell Contact email: [email protected] Contact email: [email protected] Contact phone: 32 2 626 25 55 Contact phone: 08 412 32 90 www.efpia.eu www.sbu.se The European Federation of SBU evaluates methods used by Pharmaceutical Industries and medical and social services. SBU is an Associations (EFPIA) represents the independent national authority, tasked pharmaceutical industry operating in by the government with assessing health Europe. Through its direct membership care and social service interventions of 33 national associations and from a broad perspective, covering 39 leading pharmaceutical companies, medical, economic, ethical and social EFPIA is the voice on the EU scene aspects. SBU assessments are based on of 2,000 companies committed to “systematic literature reviews” of published researching, developing, and bringing research. The review method developed to patients new medicines that will by SBU is thorough and rigorous. SBU was improve health and quality of life founded in 1987. We are one of the oldest around the world. HTA organisations in the world.
Exhibit Location: Lower Level -1, Booth 15
220 EXHIBIT FLOOR PLANS
ROOM NIMES ROOM ROOM Exhibit Floor Plans ORANGE 2 MASSALIA II
ROOM Lower Level -1 ORANGE 1
ROOM Intexo s.r.l.: 10MYLASA INAHTA: 16 ECRI Institute: 11 HTAi: 17 ROOM MASSALIA I Cochrane: 12 CADTH: 18 ROOM Context Matters: 13 ISS: 19 ALCANTARA Lower Level -1 ROOM PhRMA: 14 MSD: 20 TREVIRI SBU: 15 Mundipharma International Limited: 21
ROOM STAIRS FROM THE POLA GROUND FLOOR COFFEE BREAK AREAS STAIRS FROM THE GROUND
FLOOR ROOM EXHIBITION AREA SPALATO
ROOM MERIDA ROOM 19 20 21 EFESO
ROOM TARRAGONA ELEVATORS 10 11 12 13 14 15 16 17 18
HOSPITALITY ROOM
COFFEE BREAK AREA ROOM CESAREA ROOM ROOM STAIRS FROM HAMA THE GROUND SABRATHA FLOOR AND TO LOWER LEVEL -2
221 EXHIBIT FLOOR PLANS
Lower Level -2 Angelini: 1 AIFA: 6 MA Provider: 2 Galbraith Wight: 7 SIHTA: 3 QuintilesIMS: 8 Catholic University of the Sacred Heart: 4 Decision Resources Group: 9 Italian Ministry of Health: 5 Lower Level -2
COFFEE BREAK POSTERS AREA
ELEVATORS
9 1 8 2 7 3 6 4
5 ROOM GERASA I IV LEPTIS MAGNA
STAIRS FROM II THE GROUND FLOOR AND LOWER LEVEL -1
SPEAKERS’ READY-ROOM
222 EXHIBIT FLOOR PLANS Istituto Superiore di Sanità ITALIAN NATIONAL INSTITUTE OF HEALTH
Mission Promotion and safeguard of national and international public health through research, surveillance, regulation, control, prevention, communication, counseling and training activities. Vision The ISS produces knowledge through research and trials and disseminates scientific knowledge and evidence to decision-makers, professional workers and citizens in order to protect and promote public health. The new Regulation for the organization and operation of the Institute, published on the Official Gazette of Italian Republic no. 88 of April 15, 2016 establishes its organizational structure into two main operational areas: administrative and technical-scientific. Technical-scientific operational area
Departments Cardiovascular, dysmetabolic and aging-associated diseases Environment and health Food safety, nutrition and veterinary public health Infectious diseases Neurosciences Oncology and molecular medicine
National Centres Animal testing and welfare Chemical substances, cosmetics and consumer protection Clinical excellence, care quality and safety Disease prevention and health promotion Drug dependence and doping Global health Health technology assessment HIV/AIDS research Innovative technologies in public health Medicines control and evaluation Medicines research and clinical/preclinical evaluation Radiation protection and computational physics Rare diseases Telemedicine and new health care technologies
Blood Transplants
Reference Centres Behavioural sciences and mental health Gender medicine
Technical-scientific services Biology Grant office and technology transfer Major equipments and core facilities Research coordination and support Statistics
Notified body Notified body for activities under 93/42/CEE, 90/385/CEE and 98/79/CE Directives President Offices Personal secretary Bioethics unit Press office Service for external relations and centre for international affairs Service for knowledge and scientific communication (documentation, library and publishing ) Realizzato dal Settore Attività Editoriali, ISS, 20 aprile 2016
223 NOTES
Notes
224 NOTES
225 NOTES
226 Thank You to All Our Sponsors, Exhibitors, and Partners
SYMPOSIA SPONSORS
OTHER CONTRIBUTORS / LOCAL GRANTS
EXHIBITORS